

**DUKE UNIVERSITY MEDICAL CENTER
CURRICULUM VITAE**

for the Permanent Record
and the
Appointment, Promotions and Promotions Committee

Date CV Prepared: February 25, 2026

Name: Stephen John Greene, MD, FACC, FHFSa

Preferred familiar name: Steve

Primary academic rank: Associate Professor of Medicine

Primary academic department: Department of Medicine

Other titles: Co-director of the Duke Guideline-Directed Medical Therapy Clinic

Rank and date of first Duke faculty appointment: Assistant Professor of Medicine – July 1, 2020

NC Medical Board license certificate number: North Carolina #2017-01297
Next renewal date: 03/16/2027

Specialty certification and dates: American Board of Internal Medicine, #357223

Internal Medicine	08/18/2015
Cardiovascular Disease	10/09/2018
Advanced Heart Failure and Transplant Cardiology	10/21/2020

Education:

	<u>Institution</u>	<u>Year</u>	<u>Degree</u>
High School	Litchfield High School Litchfield, CT	2004	Diploma
College	Brown University Providence, RI	2008	BA, Biology and Economics Magna Cum Laude
Medical School	Northwestern University Feinberg School of Medicine Chicago, IL	2012	MD

Professional Training and Academic Career:

<u>Institution</u>	<u>Position/Title</u>	<u>Dates</u>
McGaw Medical Center of Northwestern University	Internship, Internal Medicine	2012 – 2013
McGaw Medical Center of Northwestern University	Residency, Internal Medicine	2013 – 2015
Duke University Medical Center	Clinical Cardiology Fellow	2015 – 2017
Duke Clinical Research Institute	Clinical Research Fellow	2017 – 2019
Duke University Medical Center	Advanced Heart Failure Fellow	2019 – 2020
Duke University Medical Center	Assistant Professor of Medicine	2020 – Present
Duke Clinical Research Institute	Faculty Member	2020 – Present

Scholarship

A. Original Research Publications:

1. Gheorghiade M, **Greene SJ**, Filippatos G, Erdmann E, Ferrari R, Levy PD, Maggioni A, Nowack C, Mebazaa A; COMPOSE Investigators and Coordinators. Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. *Eur J Heart Fail.* 2012 Sep;14(9):1056-66. doi: 10.1093/eurjhf/hfs093. Epub 2012 Jun 19. PMID: 22713287.
2. **Greene SJ**, Harinstein ME, Vaduganathan M, Subačius H, Konstam MA, Zannad F, Maggioni AP, Swedberg K, Butler J, Gheorghiade M; EVEREST Trial Investigators. Prognostic value of monocyte count in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). *Am J Cardiol.* 2012 Dec 1;110(11):1657-62. doi: 10.1016/j.amjcard.2012.07.035. Epub 2012 Aug 21. PMID: 22917555.
3. Vaduganathan M, Ambrosy AP, **Greene SJ**, Mentz RJ, Subacius HP, Maggioni AP, Swedberg K, Nodari S, Zannad F, Konstam MA, Butler J, Gheorghiade M; EVEREST trial investigators. Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. *Circ Heart Fail.* 2012 Nov;5(6):750-8. doi: 10.1161/CIRCHEARTFAILURE.112.970525. Epub 2012 Oct 9. PMID: 23051949.
4. **Greene SJ**, Vaduganathan M, Lupi L, Ambrosy AP, Mentz RJ, Konstam MA, Nodari S, Subacius HP, Fonarow GC, Bonow RO, Gheorghiade M; EVEREST Trial Investigators. Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). *Am J Cardiol.* 2013 Feb 15;111(4):574-81. doi: 10.1016/j.amjcard.2012.10.042. Epub 2012 Dec 1. PMID: 23206923.
5. Lanfear DE, Sabbah HN, Goldsmith SR, **Greene SJ**, Ambrosy AP, Fought AJ, Kwasny MJ, Swedberg K, Yancy CW, Konstam MA, Maggioni AP, Zannad F, Gheorghiade M; EVEREST

- trial investigators. Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. *Circ Heart Fail.* 2013 Jan;6(1):47-52. doi: 10.1161/CIRCHEARTFAILURE.112.970012. Epub 2012 Dec 12. PMID: 23239836; PMCID: PMC3790140.
6. Ambrosy AP, Vaduganathan M, Mentz RJ, **Greene SJ**, Subačius H, Konstam MA, Maggioni AP, Swedberg K, Gheorghiade M. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. *Am Heart J.* 2013 Feb;165(2):216-25. doi: 10.1016/j.ahj.2012.11.004. Epub 2012 Dec 29. PMID: 23351825.
 7. Gheorghiade M, Patel K, Filippatos G, Anker SD, van Veldhuisen DJ, Cleland JG, Metra M, Aban IB, **Greene SJ**, Adams KF, McMurray JJ, Ahmed A. Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. *Eur J Heart Fail.* 2013 May;15(5):551-9. doi: 10.1093/eurjhf/hft010. Epub 2013 Jan 25. PMID: 23355060; PMCID: PMC3707428.
 8. Gheorghiade M, **Greene SJ**, Ponikowski P, Maggioni AP, Korewicki J, Macarie C, Metra M, Grzybowski J, Bubenek-Turconi SI, Radziszewski W, Olson A, Bueno OF, Ghosh A, Deckelbaum LI, Li LY, Patel AR, Koester A, Konstam MA. Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction. *Eur J Heart Fail.* 2013 Jun;15(6):679-89. doi: 10.1093/eurjhf/hft023. Epub 2013 Mar 6. PMID: 23471413.
 9. Gheorghiade M, Böhm M, **Greene SJ**, Fonarow GC, Lewis EF, Zannad F, Solomon SD, Baschiera F, Botha J, Hua TA, Gimpelewicz CR, Jaumont X, Lesogor A, Maggioni AP; ASTRONAUT Investigators and Coordinators. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. *JAMA.* 2013 Mar 20;309(11):1125-35. doi: 10.1001/jama.2013.1954. Erratum in: *JAMA.* 2013 Apr 10;309(14):1461. PMID: 23478743.
 10. **Greene SJ**, Gheorghiade M, Vaduganathan M, Ambrosy AP, Mentz RJ, Subacius H, Maggioni AP, Nodari S, Konstam MA, Butler J, Filippatos G; EVEREST Trial investigators. Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. *Eur J Heart Fail.* 2013 Dec;15(12):1401-11. doi: 10.1093/eurjhf/hft110. Epub 2013 Jul 11. PMID: 23845795; PMCID: PMC4199468.
 11. Maggioni AP, **Greene SJ**, Fonarow GC, Böhm M, Zannad F, Solomon SD, Lewis EF, Baschiera F, Hua TA, Gimpelewicz CR, Lesogor A, Gheorghiade M; ASTRONAUT Investigators and Coordinators. Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. *Eur Heart J.* 2013 Oct;34(40):3117-27. doi: 10.1093/eurheartj/ehf342. Epub 2013 Sep 2. PMID: 23999456; PMCID: PMC3800848.
 12. Vaduganathan M, **Greene SJ**, Ambrosy AP, Mentz RJ, Fonarow GC, Zannad F, Maggioni AP, Konstam MA, Subacius HP, Nodari S, Butler J, Gheorghiade M; EVEREST Trial Investigators. Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial). *Am J Cardiol.* 2013 Dec

1;112(11):1763-9. doi: 10.1016/j.amjcard.2013.07.020. Epub 2013 Oct 4. PMID: 24095030; PMCID: PMC4158384.

13. **Greene SJ**, Vaduganathan M, Wilcox JE, Harinstein ME, Maggioni AP, Subacius H, Zannad F, Konstam MA, Chioncel O, Yancy CW, Swedberg K, Butler J, Bonow RO, Gheorghiade M; EVEREST Trial Investigators. The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial. *JACC Heart Fail.* 2013 Dec;1(6):488-96. doi: 10.1016/j.jchf.2013.08.005. Epub 2013 Dec 2. PMID: 24622000.
14. Mentz RJ, **Greene SJ**, Ambrosy AP, Vaduganathan M, Subacius HP, Swedberg K, Maggioni AP, Nodari S, Ponikowski P, Anker SD, Butler J, Gheorghiade M. Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial. *Circ Heart Fail.* 2014 May;7(3):401-8. doi: 10.1161/CIRCHEARTFAILURE.113.000840. Epub 2014 Apr 15. PMID: 24737459; PMCID: PMC4151504.
15. Vaduganathan M, Dei Cas A, Mentz RJ, **Greene SJ**, Khan S, Subacius HP, Chioncel O, Maggioni AP, Konstam MA, Senni M, Fonarow GC, Butler J, Gheorghiade M; EVEREST Trial Investigators. Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial). *Am J Cardiol.* 2014 Sep 1;114(5):743-50. doi: 10.1016/j.amjcard.2014.05.064. Epub 2014 Jun 24. PMID: 25060414; PMCID: PMC4160659.
16. Vaduganathan M, **Greene SJ**, Ambrosy AP, Mentz RJ, Subacius HP, Chioncel O, Maggioni AP, Swedberg K, Zannad F, Konstam MA, Senni M, Givertz MM, Butler J, Gheorghiade M; EVEREST trial investigators. Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). *Am J Cardiol.* 2014 Dec 1;114(11):1713-21. doi: 10.1016/j.amjcard.2014.09.008. Epub 2014 Sep 16. PMID: 25312638.
17. **Greene SJ**, Maggioni AP, Fonarow GC, Solomon SD, Böhm M, Kandra A, Prescott MF, Reimund B, Hua TA, Lesogor A, Zannad F, Gheorghiade M; ASTRONAUT Investigators and Coordinators. Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial. *Eur J Heart Fail.* 2015 Jan;17(1):98-108. doi: 10.1002/ejhf.201. PMID: 25597870.
18. **Greene SJ**, Fonarow GC, Solomon SD, Subacius H, Maggioni AP, Böhm M, Lewis EF, Zannad F, Gheorghiade M; ASTRONAUT Investigators and Coordinators. Global variation in clinical profile, management, and post-discharge outcomes among patients hospitalized for worsening chronic heart failure: findings from the ASTRONAUT trial. *Eur J Heart Fail.* 2015 Jun;17(6):591-600. doi: 10.1002/ejhf.280. Epub 2015 Apr 30. PMID: 25930208.
19. Khan H, **Greene SJ**, Fonarow GC, Kalogeropoulos AP, Ambrosy AP, Maggioni AP, Zannad F, Konstam MA, Swedberg K, Yancy CW, Gheorghiade M, Butler J; EVEREST Trial Investigators. Length of hospital stay and 30-day readmission following heart failure hospitalization: insights from the EVEREST trial. *Eur J Heart Fail.* 2015 Oct;17(10):1022-31. doi: 10.1002/ejhf.282. Epub 2015 May 9. PMID: 25960401.

20. Vaduganathan M, Tahhan AS, **Greene SJ**, Kelkar AA, Georgiopoulou VV, Kalogeropoulos AP, Fonarow GC, Gheorghiade M, Butler J. Contemporary cardiovascular device clinical trials (trends and patterns 2001 to 2012). *Am J Cardiol*. 2015 Jul 15;116(2):307-12. doi: 10.1016/j.amjcard.2015.03.062. Epub 2015 Apr 18. PMID: 25963222.
21. Samman Tahhan A, Vaduganathan M, Kelkar A, Georgiopoulou VV, Kalogeropoulos AP, **Greene SJ**, Fonarow GC, Gheorghiade M, Butler J. Trends in Heart Failure Clinical Trials From 2001-2012. *J Card Fail*. 2016 Mar;22(3):171-9. doi: 10.1016/j.cardfail.2015.06.014. Epub 2015 Jun 21. PMID: 26106806.
22. Ambrosy AP, Hernandez AF, Armstrong PW, Butler J, Dunning A, Ezekowitz JA, Felker GM, **Greene SJ**, Kaul P, McMurray JJ, Metra M, O'Connor CM, Reed SD, Schulte PJ, Starling RC, Tang WH, Voors AA, Mentz RJ. The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF. *Eur J Heart Fail*. 2016 Mar;18(3):306-13. doi: 10.1002/ejhf.420. Epub 2015 Oct 14. PMID: 26467269; PMCID: PMC4801656.
23. Gheorghiade M, **Greene SJ**, Butler J, Filippatos G, Lam CS, Maggioni AP, Ponikowski P, Shah SJ, Solomon SD, Kraigher-Krainer E, Samano ET, Müller K, Roessig L, Pieske B; SOCRATES-REDUCED Investigators and Coordinators. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. *JAMA*. 2015 Dec 1;314(21):2251-62. doi: 10.1001/jama.2015.15734. PMID: 26547357.
24. **Greene SJ**, Temporelli PL, Campia U, Vaduganathan M, Degli Esposti L, Buda S, Veronesi C, Butler J, Nodari S. Effects of Polyunsaturated Fatty Acid Treatment on Postdischarge Outcomes After Acute Myocardial Infarction. *Am J Cardiol*. 2016 Feb 1;117(3):340-6. doi: 10.1016/j.amjcard.2015.10.050. Epub 2015 Nov 18. PMID: 26708689.
25. Cook TD, **Greene SJ**, Kalogeropoulos AP, Fonarow GC, Zea R, Swedberg K, Zannad F, Maggioni AP, Konstam MA, Gheorghiade M, Butler J. Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the EVEREST Trial). *Am J Cardiol*. 2016 Feb 15;117(4):611-616. doi: 10.1016/j.amjcard.2015.11.050. Epub 2015 Dec 8. PMID: 26742474.
26. Vaduganathan M, Marti CN, Mentz RJ, **Greene SJ**, Ambrosy AP, Subacius HP, Fonarow GC, Chioncel O, Bazari H, Maggioni AP, Zannad F, Konstam MA, Sato N, Gheorghiade M, Butler J; EVEREST trial investigators. Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. *Am J Cardiol*. 2016 Apr 1;117(7):1144-50. doi: 10.1016/j.amjcard.2015.12.059. Epub 2016 Jan 14. PMID: 26851146.
27. Ambrosy AP, Khan H, Udelson JE, Mentz RJ, Chioncel O, **Greene SJ**, Vaduganathan M, Subacuis HP, Konstam MA, Swedberg K, Zannad F, Maggioni AP, Gheorghiade M, Butler J. Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial. *Circ Heart Fail*. 2016 May;9(5):e002458. doi: 10.1161/CIRCHEARTFAILURE.115.002458. PMID: 27140204.
28. **Greene SJ**, Hernandez AF, Sun JL, Metra M, Butler J, Ambrosy AP, Ezekowitz JA, Starling RC, Teerlink JR, Schulte PJ, Voors AA, Armstrong PW, O'Connor CM, Mentz RJ. Influence

- of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). *Circ Heart Fail*. 2016 Sep;9(9):e002986. doi: 10.1161/CIRCHEARTFAILURE.116.002986. PMID: 27623769.
29. **Greene SJ**, Fonarow GC, Solomon SD, Subacius HP, Ambrosy AP, Vaduganathan M, Maggioni AP, Böhm M, Lewis EF, Zannad F, Butler J, Gheorghiade M; ASTRONAUT Investigators and Coordinators. Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial. *Eur J Heart Fail*. 2017 Apr;19(4):552-562. doi: 10.1002/ejhf.674. Epub 2016 Oct 17. PMID: 27748006; PMCID: PMC5892441.
 30. Barroso MC, Kramer F, **Greene SJ**, Scheyer D, Köhler T, Karoff M, Seyfarth M, Gheorghiade M, Dinh W. Serum insulin-like growth factor-1 and its binding protein-7: potential novel biomarkers for heart failure with preserved ejection fraction. *BMC Cardiovasc Disord*. 2016 Oct 21;16(1):199. doi: 10.1186/s12872-016-0376-2. PMID: 27769173; PMCID: PMC5073807.
 31. Butler J, Epstein SE, **Greene SJ**, Quyyumi AA, Sikora S, Kim RJ, Anderson AS, Wilcox JE, Tankovich NI, Lipinski MJ, Ko YA, Margulies KB, Cole RT, Skopicki HA, Gheorghiade M. Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy: Safety and Efficacy Results of a Phase II-A Randomized Trial. *Circ Res*. 2017 Jan 20;120(2):332-340. doi: 10.1161/CIRCRESAHA.116.309717. Epub 2016 Nov 16. PMID: 27856497.
 32. Ambrosy AP, Cerbin LP, Armstrong PW, Butler J, Coles A, DeVore AD, Dunlap ME, Ezekowitz JA, Felker GM, Fudim M, **Greene SJ**, Hernandez AF, O'Connor CM, Schulte P, Starling RC, Teerlink JR, Voors AA, Mentz RJ. Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF Trial. *JACC Heart Fail*. 2017 Jan;5(1):1-13. doi: 10.1016/j.jchf.2016.09.012. PMID: 28034373; PMCID: PMC5218831.
 33. Ambrosy AP, Cerbin LP, DeVore AD, **Greene SJ**, Kraus WE, O'Connor CM, Piña IL, Whellan DJ, Wojdyla D, Wu A, Mentz RJ. Aerobic exercise training and general health status in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) trial. *Am Heart J*. 2017 Apr;186:130-138. doi: 10.1016/j.ahj.2016.12.017. Epub 2017 Jan 19. PMID: 28454828.
 34. Ambrosy AP, Bhatt AS, Gallup D, Anstrom KJ, Butler J, DeVore AD, Felker GM, Fudim M, **Greene SJ**, Hernandez AF, Kelly JP, Samsky MD, Mentz RJ. Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Heart Failure Network). *Am J Cardiol*. 2017 Jul 1;120(1):98-105. doi: 10.1016/j.amjcard.2017.03.249. Epub 2017 Apr 12. PMID: 28479167; PMCID: PMC5471496.
 35. Alkhwam L, **Greene SJ**. Bulletproof heart: Gunshot wound to the ventricular septum without pericardial effusion or hemodynamic collapse. *CJEM*. 2018 Oct;20(S2):S40. doi: 10.1017/cem.2017.340. Epub 2017 Jun 20. PMID: 28631580.
 36. **Greene SJ**, Hernandez AF, Dunning A, Ambrosy AP, Armstrong PW, Butler J, Cerbin LP, Coles A, Ezekowitz JA, Metra M, Starling RC, Teerlink JR, Voors AA, O'Connor CM, Mentz

- RJ. Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial. *J Am Coll Cardiol.* 2017 Jun 27;69(25):3029-3039. doi: 10.1016/j.jacc.2017.04.043. PMID: 28641792.
37. Gori M, Canova P, Calabrese A, Cioffi G, Trevisan R, De Maria R, Grosu A, Iacovoni A, Fontana A, Ferrari P, **Greene SJ**, Gheorghide M, Parati G, Gavazzi A, Senni M. Strategy to identify subjects with diabetes mellitus more suitable for selective echocardiographic screening: The DAVID-Berg study. *Int J Cardiol.* 2017 Dec 1;248:414-420. doi: 10.1016/j.ijcard.2017.06.101. Epub 2017 Jun 28. PMID: 28709699.
 38. Khan MS, Fonarow GC, Ahmed A, **Greene SJ**, Vaduganathan M, Khan H, Marti C, Gheorghide M, Butler J. Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta-Analysis. *Circ Heart Fail.* 2017 Aug;10(8):e003956. doi: 10.1161/CIRCHEARTFAILURE.117.003956. PMID: 28790052.
 39. Khan MS, Fonarow GC, Khan H, **Greene SJ**, Anker SD, Gheorghide M, Butler J. Renin-angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta-analysis. *ESC Heart Fail.* 2017 Nov;4(4):402-408. doi: 10.1002/ehf2.12204. Epub 2017 Sep 4. PMID: 28869332; PMCID: PMC5695183.
 40. **Greene SJ**, Butler J, Fonarow GC, Subacius HP, Ambrosy AP, Vaduganathan M, Triggiani M, Solomon SD, Lewis EF, Maggioni AP, Böhm M, Chioncel O, Nodari S, Senni M, Zannad F, Gheorghide M; ASTRONAUT Investigators and Coordinators. Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. *Eur J Heart Fail.* 2018 Feb;20(2):281-291. doi: 10.1002/ejhf.1019. Epub 2017 Oct 17. PMID: 29044915; PMCID: PMC6429915.
 41. Fudim M, O'Connor CM, Dunning A, Ambrosy AP, Armstrong PW, Coles A, Ezekowitz JA, **Greene SJ**, Metra M, Starling RC, Voors AA, Hernandez AF, Michael Felker G, Mentz RJ. Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF. *Eur J Heart Fail.* 2018 Feb;20(2):304-314. doi: 10.1002/ejhf.1020. Epub 2017 Oct 29. PMID: 29082629; PMCID: PMC5826892.
 42. Vaduganathan M, Cheema B, Cleveland E, Sankar K, Subacius H, Fonarow GC, Solomon SD, Lewis EF, **Greene SJ**, Maggioni AP, Böhm M, Zannad F, Butler J, Gheorghide M. Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial. *Eur J Heart Fail.* 2018 Apr;20(4):677-686. doi: 10.1002/ejhf.973. Epub 2017 Nov 16. PMID: 29143416; PMCID: PMC6676477.
 43. Vaduganathan M, Samman Tahhan A, **Greene SJ**, Okafor M, Kumar S, Butler J. Globalization of heart failure clinical trials: a systematic review of 305 trials conducted over 16 years. *Eur J Heart Fail.* 2018 Jun;20(6):1068-1071. doi: 10.1002/ejhf.1130. Epub 2018 Jan 4. PMID: 29314445; PMCID: PMC6676479.
 44. Cerbin LP, Ambrosy AP, **Greene SJ**, Armstrong PW, Butler J, Coles A, DeVore AD, Ezekowitz JA, Hernandez AF, Metra M, Starling RC, Tang W, Teerlink JR, Voors AA, Wu A, O'Connor CM, Mentz RJ. Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure: Insights From ASCEND-HF Trial. *JACC Heart Fail.* 2018

Apr;6(4):298-307. doi: 10.1016/j.jchf.2018.01.018. Epub 2018 Mar 7. PMID: 29525328; PMCID: PMC7445462.

45. Vaduganathan M, Patel RB, Mentz RJ, Subacius H, Chatterjee NA, **Greene SJ**, Ambrosy AP, Maggioni AP, Udelson JE, Swedberg K, Konstam MA, O'Connor CM, Butler J, Gheorghide M, Zannad F. Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial). *Am J Cardiol*. 2018 Jul 15;122(2):255-260. doi: 10.1016/j.amjcard.2018.03.362. Epub 2018 Apr 11. PMID: 29731121; PMCID: PMC6028287.
46. Ambrosy AP, Bhatt AS, Stebbins AL, Wruck LM, Fudim M, **Greene SJ**, Kraus WE, O'Connor CM, Piña IL, Whellan DJ, Mentz RJ. Prevalent digoxin use and subsequent risk of death or hospitalization in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) randomized controlled trial. *Am Heart J*. 2018 May;199:97-104. doi: 10.1016/j.ahj.2018.02.004. Epub 2018 Feb 11. PMID: 29754673; PMCID: PMC7050977.
47. **Greene SJ**, O'Brien EC, Mentz RJ, Luo N, Hardy NC, Laskey WK, Heidenreich PA, Chang CL, Turner SJ, Yancy CW, Hernandez AF, Curtis LH, Peterson PN, Fonarow GC, Hammill BG. Home-Time After Discharge Among Patients Hospitalized With Heart Failure. *J Am Coll Cardiol*. 2018 Jun 12;71(23):2643-2652. doi: 10.1016/j.jacc.2018.03.517. PMID: 29880124; PMCID: PMC6742493.
48. Iorio A, Senni M, Barbati G, **Greene SJ**, Poli S, Zambon E, Di Nora C, Cioffi G, Tarantini L, Gavazzi A, Sinagra G, Di Lenarda A. Prevalence and prognostic impact of non-cardiac comorbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study. *Eur J Heart Fail*. 2018 Sep;20(9):1257-1266. doi: 10.1002/ejhf.1202. Epub 2018 Jun 19. PMID: 29917301.
49. **Greene SJ**, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI, Hill CL, McCague K, Mi X, Patterson JH, Spertus JA, Thomas L, Williams FB, Hernandez AF, Fonarow GC. Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. *J Am Coll Cardiol*. 2018 Jul 24;72(4):351-366. doi: 10.1016/j.jacc.2018.04.070. PMID: 30025570.
50. Fudim M, Loungani R, Doerfler SM, Coles A, **Greene SJ**, Cooper LB, Fiuzat M, O'Connor CM, Rogers JG, Mentz RJ. Worsening renal function during decongestion among patients hospitalized for heart failure: Findings from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) trial. *Am Heart J*. 2018 Oct;204:163-173. doi: 10.1016/j.ahj.2018.07.019. Epub 2018 Jul 29. PMID: 30121018.
51. **Greene SJ**, Hernandez AF, Sun JL, Butler J, Armstrong PW, Ezekowitz JA, Zannad F, Ferreira JP, Coles A, Metra M, Voors AA, Califf RM, O'Connor CM, Mentz RJ. Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points. *Circ Cardiovasc Qual Outcomes*. 2018 Oct;11(10):e004783. doi: 10.1161/CIRCOUTCOMES.118.004783. PMID: 30354576; PMCID: PMC6208149.
52. Patel RB, Vaduganathan M, Rikhi A, Chakraborty H, **Greene SJ**, Hernandez AF, Felker GM, Redfield MM, Butler J, Shah SJ. History of Atrial Fibrillation and Trajectory of Decongestion in Acute Heart Failure. *JACC Heart Fail*. 2019 Jan;7(1):47-55. doi: 10.1016/j.jchf.2018.09.008. Epub 2018 Nov 5. PMID: 30409707; PMCID: PMC6320310.

53. **Greene SJ**, Fonarow GC, Solomon SD, Subacius HP, Vaduganathan M, Ambrosy AP, Fudim M, Böhm M, Maggioni AP, Lewis EF, Zannad F, Butler J. Relationship between timing of trial randomization, protocol completion, and clinical outcomes among patients hospitalized for heart failure: from the ASTRONAUT trial. *Eur J Heart Fail*. 2018 Dec;20(12):1760-1763. doi: 10.1002/ejhf.1310. Epub 2018 Nov 11. PMID: 30415473; PMCID: PMC6298803.
54. Ambrosy AP, Lewis GD, Malhotra R, Jones AD, **Greene SJ**, Fudim M, Coles A, Butler J, Sharma A, Hernandez AF, Mentz RJ. Identifying responders to oral iron supplementation in heart failure with a reduced ejection fraction: a post-hoc analysis of the IRONOUT-HF trial. *J Cardiovasc Med (Hagerstown)*. 2019 Apr;20(4):223-225. doi: 10.2459/JCM.0000000000000736. PMID: 30540649.
55. Fudim M, Ambrosy AP, Sun JL, Anstrom KJ, Bart BA, Butler J, AbouEzzeddine O, **Greene SJ**, Mentz RJ, Redfield MM, Reddy YNV, Vaduganathan M, Braunwald E, Hernandez AF, Borlaug BA, Felker GM. High-Sensitivity Troponin I in Hospitalized and Ambulatory Patients With Heart Failure With Preserved Ejection Fraction: Insights From the Heart Failure Clinical Research Network. *J Am Heart Assoc*. 2018 Dec 18;7(24):e010364. doi: 10.1161/JAHA.118.010364. PMID: 30561266; PMCID: PMC6405612.
56. Vaduganathan M, Tahhan AS, Alrohaibani A, **Greene SJ**, Fonarow GC, Vardeny O, Lindenfeld J, Jessup M, Fiuzat M, O'Connor CM, Butler J. Do Women and Men Respond Similarly to Therapies in Contemporary Heart Failure Clinical Trials? *JACC Heart Fail*. 2019 Mar;7(3):267-271. doi: 10.1016/j.jchf.2018.12.016. PMID: 30819383; PMCID: PMC7437364.
57. **Greene SJ**, Fonarow GC, DeVore AD, Sharma PP, Vaduganathan M, Albert NM, Duffy CI, Hill CL, McCague K, Patterson JH, Spertus JA, Thomas L, Williams FB, Hernandez AF, Butler J. Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. *J Am Coll Cardiol*. 2019 May 21;73(19):2365-2383. doi: 10.1016/j.jacc.2019.02.015. Epub 2019 Mar 4. PMID: 30844480; PMCID: PMC7197490.
58. **Greene SJ**, Wilson LE, Abbasi SA, Yusuf AA, Hammill BG. Outpatient Intravenous Diuretic Therapy for Heart Failure in the United States. *J Am Coll Cardiol*. 2019 Mar 12;73(9):1101-1103. doi: 10.1016/j.jacc.2018.12.034. PMID: 30846106; PMCID: PMC7085417.
59. Psotka MA, Ammon SE, Fiuzat M, Bozkurt B, Chung ES, Cole RT, **Greene SJ**, Kraus D, Ky B, McIlvennan CK, Shah P, Teerlink JR, Walsh MN, Jessup M, O'Connor CM. Heart Failure Site-Based Research in the United States: Results of the Heart Failure Society of America Research Network Survey. *JACC Heart Fail*. 2019 May;7(5):431-438. doi: 10.1016/j.jchf.2019.02.008. Epub 2019 Apr 10. PMID: 30981742; PMCID: PMC7437361.
60. Friedman DJ, **Greene SJ**, Piccini JP, Vemulapalli S, Jackson KP. Watchman implantation in a patient with left atrial appendage thrombus. *J Cardiovasc Electrophysiol*. 2019 Sep;30(9):1694-1695. doi: 10.1111/jce.14031. Epub 2019 Jul 2. PMID: 31192503.
61. **Greene SJ**, Felker GM, Giczewska A, Kalogeropoulos AP, Ambrosy AP, Chakraborty H, DeVore AD, Fudim M, McNulty SE, Mentz RJ, Vaduganathan M, Hernandez AF, Butler J. Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial. *Can J Cardiol*. 2019 Sep;35(9):1097-1105. doi: 10.1016/j.cjca.2019.01.022. Epub 2019 Feb 7. PMID: 31230825; PMCID: PMC6685766.

62. Blumer V, **Greene SJ**, Sun JL, Bart BA, Ambrosy AP, Butler J, DeVore AD, Fudim M, Hernandez AF, McNulty SE, Felker GM, Mentz RJ. Haemoconcentration during treatment of acute heart failure with cardiorenal syndrome: from the CARRESS-HF trial. *Eur J Heart Fail*. 2019 Nov;21(11):1472-1476. doi: 10.1002/ejhf.1592. Epub 2019 Aug 27. PMID: 31452311.
63. **Greene SJ**, DeVore AD, Sheng S, Fonarow GC, Butler J, Califf RM, Hernandez AF, Matsouaka RA, Samman Tahhan A, Thomas KL, Vaduganathan M, Yancy CW, Peterson ED, O'Connor CM, Mentz RJ. Representativeness of a Heart Failure Trial by Race and Sex: Results From ASCEND-HF and GWTG-HF. *JACC Heart Fail*. 2019 Nov;7(11):980-992. doi: 10.1016/j.jchf.2019.07.011. Epub 2019 Oct 9. PMID: 31606362; PMCID: PMC7362664.
64. Butler J, **Greene SJ**, Shah SH, Shah SJ, Anstrom KJ, Kim RJ, Kalogeropoulos AP, Velazquez EJ, Hernandez AF, Desvigne-Nickens P, Scherzer R, Hsue PY, Braunwald E. Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study. *J Card Fail*. 2020 May;26(5):371-380. doi: 10.1016/j.cardfail.2019.10.011. Epub 2019 Nov 2. PMID: 31682908; PMCID: PMC7195219.
65. Vaduganathan M, Fonarow GC, **Greene SJ**, DeVore AD, Albert NM, Duffy CI, Hill CL, Spertus JA, Thomas LE, Butler J. Health-Related Quality of Life in Comorbid Heart Failure With Reduced Ejection Fraction and Diabetes Mellitus. *J Am Coll Cardiol*. 2019 Dec 24;74(25):3176-3178. doi: 10.1016/j.jacc.2019.10.020. Epub 2019 Nov 11. PMID: 31727426; PMCID: PMC7961327.
66. Samsky MD, Lin L, **Greene SJ**, Lippmann SJ, Peterson PN, Heidenreich PA, Laskey WK, Yancy CW, Greiner MA, Hardy NC, Kavati A, Park S, Mentz RJ, Fonarow GC, O'Brien EC. Patient Perceptions and Familiarity With Medical Therapy for Heart Failure. *JAMA Cardiol*. 2020 Mar 1;5(3):292-299. doi: 10.1001/jamacardio.2019.4987. PMID: 31734700; PMCID: PMC6865328.
67. Bhatt AS, Vaduganathan M, Patel RB, Fonarow GC, Subacius HP, Konstam MA, Zannad F, Butler J, **Greene SJ**. Post-discharge haemodilution, congestion, and clinical outcomes among patients hospitalized for heart failure with reduced ejection fraction: results from the EVEREST trial. *Eur J Heart Fail*. 2020 Jan;22(1):164-167. doi: 10.1002/ejhf.1651. Epub 2019 Dec 3. PMID: 31797490; PMCID: PMC6995413.
68. Fudim M, Kelly JP, Jones AD, AbouEzzeddine OF, Ambrosy AP, **Greene SJ**, Reddy YNV, Anstrom KJ, Alhanti B, Lewis GD, Hernandez AF, Felker GM. Are existing and emerging biomarkers associated with cardiorespiratory fitness in patients with chronic heart failure? *Am Heart J*. 2020 Feb;220:97-107. doi: 10.1016/j.ahj.2019.11.006. Epub 2019 Nov 16. PMID: 31805424; PMCID: PMC7008085.
69. Khan MS, Memon MM, Murad MH, Vaduganathan M, **Greene SJ**, Hall M, Triposkiadis F, Lam CSP, Shah AM, Butler J, Shah SJ. Left atrial function in heart failure with preserved ejection fraction: a systematic review and meta-analysis. *Eur J Heart Fail*. 2020 Mar;22(3):472-485. doi: 10.1002/ejhf.1643. Epub 2020 Jan 9. PMID: 31919960.
70. Blumer V, Ortiz Bezara M, Kittipibul V, **Greene SJ**, Fudim M, Hernandez GA, Chaparro S, Joyce E. Impact of Atrial Fibrillation on In-Hospital Mortality and Thromboembolic Complications after Left Ventricular Assist Device Implantation. *J Cardiovasc Transl Res*.

2021 Feb;14(1):120-124. doi: 10.1007/s12265-020-09968-5. Epub 2020 Feb 19. PMID: 32076994.

71. Khan MS, Samman Tahhan A, Vaduganathan M, **Greene SJ**, Alrohaibani A, Anker SD, Vardeny O, Fonarow GC, Butler J. Trends in prevalence of comorbidities in heart failure clinical trials. *Eur J Heart Fail*. 2020 Jun;22(6):1032-1042. doi: 10.1002/ejhf.1818. Epub 2020 Apr 15. PMID: 32293090; PMCID: PMC7906002.
72. Redouane B, **Greene SJ**, Fudim M, Vaduganathan M, Ambrosy AP, Sun JL, DeVore AD, McNulty SE, Mentz RJ, Hernandez AF, Felker GM, Cooper LB, Borlaug BA, Velazquez EJ, Margulies KB, Sharma A. Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction: Insights From the FIGHT Trial. *Circ Heart Fail*. 2020 May;13(5):e006758. doi: 10.1161/CIRCHEARTFAILURE.119.006758. Epub 2020 May 4. PMID: 32362166; PMCID: PMC7906045.
73. Vaduganathan M, Fonarow GC, **Greene SJ**, DeVore AD, Kavati A, Sikirica S, Albert NM, Duffy CI, Hill CL, Patterson JH, Spertus JA, Thomas LE, Williams FB, Hernandez AF, Butler J. Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF Registry. *JACC Heart Fail*. 2020 Jun;8(6):469-480. doi: 10.1016/j.jchf.2019.12.015. Epub 2020 May 6. PMID: 32387066.
74. Khan MS, Shahid I, Siddiqi TJ, Khan SU, Warraich HJ, **Greene SJ**, Butler J, Michos ED. Ten-Year Trends in Enrollment of Women and Minorities in Pivotal Trials Supporting Recent US Food and Drug Administration Approval of Novel Cardiometabolic Drugs. *J Am Heart Assoc*. 2020 Jun 2;9(11):e015594. doi: 10.1161/JAHA.119.015594. Epub 2020 May 19. PMID: 32427023; PMCID: PMC7428976.
75. Usman MS, Siddiqi TJ, Khan MS, Ahmed A, Ali SS, Michos ED, Hall ME, Krasuski RA, **Greene SJ**, Butler J, Alkhouli M. A Meta-analysis of the Relationship Between Renin-Angiotensin-Aldosterone System Inhibitors and COVID-19. *Am J Cardiol*. 2020 Sep 1;130:159-161. doi: 10.1016/j.amjcard.2020.05.038. Epub 2020 Jun 2. PMID: 32624189; PMCID: PMC7266568.
76. Selvaraj S, **Greene SJ**, Khatana SAM, Nathan AS, Solomon SD, Bhatt DL. The Landscape of Cardiovascular Clinical Trials in the United States Initiated Before and During COVID-19. *J Am Heart Assoc*. 2020 Sep 15;9(18):e018274. doi: 10.1161/JAHA.120.018274. Epub 2020 Jul 27. PMID: 32713281; PMCID: PMC7726978.
77. Reza N, Tahhan AS, Mahmud N, DeFilippis EM, Alrohaibani A, Vaduganathan M, **Greene SJ**, Ho AH, Fonarow GC, Butler J, O'Connor C, Fiuzat M, Vardeny O, Piña IL, Lindenfeld J, Jessup M. Representation of Women Authors in International Heart Failure Guidelines and Contemporary Clinical Trials. *Circ Heart Fail*. 2020 Aug;13(8):e006605. doi: 10.1161/CIRCHEARTFAILURE.119.006605. Epub 2020 Aug 6. PMID: 32757645; PMCID: PMC7719050.
78. **Greene SJ**, Triana TS, Ionescu-Iltu R, Burne RM, Guérin A, Borentain M, Kessler PD, Tugcu A, DeSouza MM, Felker GM, Chen L. In-Hospital Therapy for Heart Failure With Reduced Ejection Fraction in the United States. *JACC Heart Fail*. 2020 Nov;8(11):943-953. doi: 10.1016/j.jchf.2020.05.013. Epub 2020 Aug 12. PMID: 32800512.

79. Grubb AF, Pumill CA, **Greene SJ**, Wu A, Chiswell K, Mentz RJ. Tobacco smoking in patients with heart failure and coronary artery disease: A 20-year experience at Duke University Medical Center. *Am Heart J.* 2020 Dec;230:25-34. doi: 10.1016/j.ahj.2020.09.011. Epub 2020 Sep 25. PMID: 32980363.
80. Blumer V, **Greene SJ**, Ortiz M, Kittipibul V, Hernandez GA, Fudim M, Lemor A, Mentz RJ, Vest AR. In-hospital outcomes after bariatric surgery in patients with heart failure. *Am Heart J.* 2020 Dec;230:59-62. doi: 10.1016/j.ahj.2020.09.007. Epub 2020 Sep 28. PMID: 32991845.
81. **Greene SJ**, Mentz RJ, Limkakeng AT, Irons T, Truong T, Green CL, Nowak C, Blumer V, Pang PS. Comparison of Dyspnea Measurement Instruments in Acute Heart Failure: The DYSPNEA-AHF Pilot Study. *J Card Fail.* 2021 May;27(5):607-609. doi: 10.1016/j.cardfail.2020.10.004. Epub 2020 Oct 20. PMID: 33091609.
82. Vaduganathan M, **Greene SJ**, Zhang S, Grau-Sepulveda M, DeVore AD, Butler J, Heidenreich PA, Huang JC, Kittleson MM, Joynt Maddox KE, McDermott JJ, Owens AT, Peterson PN, Solomon SD, Vardeny O, Yancy CW, Fonarow GC. Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice: The Get With the Guidelines-Heart Failure (GWTG-HF) Registry. *JAMA Cardiol.* 2020 Nov 13;6(3):1-10. doi: 10.1001/jamacardio.2020.5864. Epub ahead of print. PMID: 33185662; PMCID: PMC7666432.
83. Khan MS, Shahid I, Asad N, **Greene SJ**, Khan SU, Doukky R, Metra M, Anker SD, Filippatos GS, Fonarow GC, Butler J. Discontinuation and non-publication of heart failure randomized controlled trials: a call to publish all trial results. *ESC Heart Fail.* 2021 Feb;8(1):16-25. doi: 10.1002/ehf2.13099. Epub 2020 Nov 15. PMID: 33191637; PMCID: PMC7835587.
84. Salah HM, Al'Aref SJ, Khan MS, Al-Hawwas M, Vallurupalli S, Mehta JL, Mounsey JP, **Greene SJ**, McGuire DK, Lopes RD, Fudim M. Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials. *Am Heart J.* 2021 Feb;232:10-22. doi: 10.1016/j.ahj.2020.10.064. Epub 2020 Oct 24. PMID: 33214130.
85. Brooksbank JA, **Greene SJ**, Harris HM, Stebbins A, Fiuzat M, Whellan DJ, Alhanti B, Kraus WE, Piña IL, O'Connor CM, Mentz RJ. Beta-blocker and ACE-inhibitor dosing as a function of body surface area: From the HF-ACTION trial. *Am Heart J.* 2021 Mar;233:1-4. doi: 10.1016/j.ahj.2020.11.003. Epub 2020 Nov 24. PMID: 33245905.
86. Khan MS, Khan MAA, Irfan S, Siddiqi TJ, **Greene SJ**, Anker SD, Sreenivasan J, Friede T, Tahhan AS, Vaduganathan M, Fonarow GC, Butler J. Reporting and interpretation of subgroup analyses in heart failure randomized controlled trials. *ESC Heart Fail.* 2021 Feb;8(1):26-36. doi: 10.1002/ehf2.13122. Epub 2020 Nov 30. PMID: 33254286; PMCID: PMC7835611.
87. Hamo CE, Fonarow GC, **Greene SJ**, Vaduganathan M, Yancy CW, Heidenreich P, Lu D, Matsouaka RA, DeVore AD, Butler J. Temporal trends in risk profiles among patients hospitalized for heart failure. *Am Heart J.* 2021 Feb;232:154-163. doi: 10.1016/j.ahj.2020.11.015. Epub 2020 Nov 29. PMID: 33264607; PMCID: PMC8120737.

88. Fudim M, Brooksbank J, Giczewska A, **Greene SJ**, Grodin JL, Martens P, Ter Maaten JM, Sharma A, Verbrugge FH, Chakraborty H, Bart BA, Butler J, Hernandez AF, Felker GM, Mentz RJ. Ultrafiltration in Acute Heart Failure: Implications of Ejection Fraction and Early Response to Treatment From CARRESS-HF. *J Am Heart Assoc.* 2020 Dec 15;9(24):e015752. doi: 10.1161/JAHA.119.015752. Epub 2020 Dec 8. PMID: 33289458; PMCID: PMC7955382.
89. Fudim M, Ashur N, Jones AD, Ambrosy AP, Bart BA, Butler J, Chen HH, **Greene SJ**, Reddy Y, Redfield MM, Sharma A, Hernandez AF, Felker GM, Borlaug BA, Mentz RJ. Implications of peripheral oedema in heart failure with preserved ejection fraction: a heart failure network analysis. *ESC Heart Fail.* 2021 Feb;8(1):662-669. doi: 10.1002/ehf2.13159. Epub 2020 Dec 9. PMID: 33300277; PMCID: PMC7835593.
90. Salah HM, Al'Aref SJ, Khan MS, Al-Hawwas M, Vallurupalli S, Mehta JL, Mounsey JP, **Greene SJ**, McGuire DK, Lopes RD, Fudim M. Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update. *Am Heart J.* 2021 Mar;233:86-91. doi: 10.1016/j.ahj.2020.12.007. Epub 2020 Dec 29. PMID: 33385359.
91. **Greene SJ**, Tan X, Yeh YC, Bernauer M, Zaidi O, Yang M, Butler J. Factors associated with non-use and sub-target dosing of medical therapy for heart failure with reduced ejection fraction. *Heart Fail Rev.* 2022 May;27(3):741-753. doi: 10.1007/s10741-021-10077-x. Epub 2021 Jan 20. PMID: 33471236.
92. Salah HM, Fudim M, Al'Aref SJ, Khan MS, Almarzooq ZI, Devabhaktuni SR, Mentz RJ, Butler J, **Greene SJ**. Meta-Analysis of Efficacy of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction. *Am J Cardiol.* 2021 Apr 15;145:165-168. doi: 10.1016/j.amjcard.2021.01.013. Epub 2021 Jan 30. PMID: 33529619.
93. Butler J, Usman MS, Khan MS, **Greene SJ**, Friede T, Vaduganathan M, Filippatos G, Coats AJS, Anker SD. Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis. *ESC Heart Fail.* 2020 Dec;7(6):3298-3309. doi: 10.1002/ehf2.13169. Erratum in: *ESC Heart Fail.* 2021 Jun;8(3):2362. PMID: 33586910; PMCID: PMC7755023.
94. **Greene SJ**, Triana TS, Ionescu-Iltu R, Shi S, Guérin A, DeSouza MM, Kessler PD, Tugcu A, Borentain M, Felker GM. Patients Hospitalized for De Novo Versus Worsening Chronic Heart Failure in the United States. *J Am Coll Cardiol.* 2021 Feb 23;77(7):1023-1025. doi: 10.1016/j.jacc.2020.12.026. PMID: 33602461.
95. Blumer V, **Greene SJ**, Wu A, Butler J, Ezekowitz JA, Lindenfeld J, Alhanti B, Hernandez AF, O'Connor CM, Mentz RJ. Sex Differences in Clinical Course and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure. *JACC Heart Fail.* 2021 May;9(5):336-345. doi: 10.1016/j.jchf.2020.12.011. Epub 2021 Mar 10. PMID: 33714746.
96. **Greene SJ**, Butler J, Spertus JA, Hellkamp AS, Vaduganathan M, DeVore AD, Albert NM, Duffy CI, Patterson JH, Thomas L, Williams FB, Hernandez AF, Fonarow GC. Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction. *JAMA Cardiol.* 2021 May 1;6(5):522-531. doi: 10.1001/jamacardio.2021.0372. PMID: 33760037; PMCID: PMC7992023.

97. Blumer V, Mentz RJ, Sun JL, Butler J, Metra M, Voors AA, Hernandez AF, O'Connor CM, **Greene SJ**. Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure. *Circ Heart Fail*. 2021 Apr;14(4):e007871. doi: 10.1161/CIRCHEARTFAILURE.120.007871. Epub 2021 Mar 29. PMID: 33775110; PMCID: PMC9990499.
98. Khan MS, Sreenivasan J, Lateef N, Abougergi MS, **Greene SJ**, Ahmad T, Anker SD, Fonarow GC, Butler J. Trends in 30- and 90-Day Readmission Rates for Heart Failure. *Circ Heart Fail*. 2021 Apr;14(4):e008335. doi: 10.1161/CIRCHEARTFAILURE.121.008335. Epub 2021 Apr 19. PMID: 33866827.
99. Hein AM, Scialla JJ, Sun JL, **Greene SJ**, Shaw LK, Chiswell K, Pun PH, Mentz RJ. Estimated Glomerular Filtration Rate Variability in Patients With Heart Failure and Chronic Kidney Disease. *J Card Fail*. 2021 Nov;27(11):1175-1184. doi: 10.1016/j.cardfail.2021.04.016. Epub 2021 May 10. PMID: 33971291; PMCID: PMC9258722.
100. Patel RB, Fonarow GC, **Greene SJ**, Zhang S, Alhanti B, DeVore AD, Butler J, Heidenreich PA, Huang JC, Kittleson MM, Joynt Maddox KE, McDermott JJ, Owens AT, Peterson PN, Solomon SD, Vardeny O, Yancy CW, Vaduganathan M. Kidney Function and Outcomes in Patients Hospitalized With Heart Failure. *J Am Coll Cardiol*. 2021 Jul 27;78(4):330-343. doi: 10.1016/j.jacc.2021.05.002. Epub 2021 May 11. PMID: 33989713; PMCID: PMC8994871.
101. Khan MS, Sreenivasan J, Shahid I, Bhinder J, Fudim M, **Greene SJ**, Butler J. Trends in Substance Abuse Disorders Among Patients Hospitalized for Heart Failure in the United States. *Circ Heart Fail*. 2021 Jul;14(7):e008147. doi: 10.1161/CIRCHEARTFAILURE.120.008147. Epub 2021 Jul 8. PMID: 34233481.
102. Chow C, **Greene SJ**, North R, Blumer V, Truby LK, Alhanti B, Butler J, Ezekowitz JA, Starling RC, Mentz RJ. Sex-Differences in Cause of Death for Patients Hospitalized for Heart Failure With Reduced Versus Preserved Ejection Fraction (from the ASCEND-HF Trial). *Am J Cardiol*. 2021 Sep 1;154:123-126. doi: 10.1016/j.amjcard.2021.06.006. Epub 2021 Jul 18. PMID: 34284862.
103. Blumer V, Gayowsky A, Xie F, **Greene SJ**, Graham MM, Ezekowitz JA, Perez R, Ko DT, Thabane L, Zannad F, Van Spall HGC. Effect of patient-centered transitional care services on patient-reported outcomes in heart failure: sex-specific analysis of the PACT-HF randomized controlled trial. *Eur J Heart Fail*. 2021 Sep;23(9):1488-1498. doi: 10.1002/ejhf.2312. Epub 2021 Aug 16. PMID: 34302417.
104. **Greene SJ**, Choi S, Lippmann SJ, Mentz RJ, Greiner MA, Hardy NC, Hammill BG, Luo N, Samsky MD, Heidenreich PA, Laskey WK, Yancy CW, Peterson PN, Curtis LH, Hernandez AF, Fonarow GC, O'Brien EC. Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. *J Am Heart Assoc*. 2021 Aug 17;10(16):e021459. doi: 10.1161/JAHA.121.021459. Epub 2021 Aug 5. PMID: 34350772; PMCID: PMC8475054.
105. Carnicelli AP, Lippmann SJ, **Greene SJ**, Mentz RJ, Greiner MA, Hardy NC, Hammill BG, Shen X, Yancy CW, Peterson PN, Allen LA, Fonarow GC, O'Brien EC. Sacubitril/Valsartan Initiation and Postdischarge Adherence Among Patients Hospitalized for Heart Failure. *J Card Fail*. 2021 Aug;27(8):826-836. doi: 10.1016/j.cardfail.2021.03.012. PMID: 34364659.

106. Ezekowitz J, Mentz RJ, Westerhout CM, Sweitzer NK, Givertz MM, Piña IL, O'Connor CM, **Greene SJ**, McMullan C, Roessig L, Hernandez AF, Armstrong PW. Participation in a Heart Failure Clinical Trial: Perspectives and Opportunities From the VICTORIA Trial and VICTORIA Simultaneous Registry. *Circ Heart Fail.* 2021 Sep;14(9):e008242. doi: 10.1161/CIRCHEARTFAILURE.120.008242. Epub 2021 Aug 19. PMID: 34407626.
107. Vaduganathan M, Fonarow GC, **Greene SJ**, Devore AD, Albert NM, Duffy CI, Hill CL, Patterson JH, Spertus JA, Thomas LE, Williams FB, Hernandez AF, Butler J. Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection Fraction. *J Card Fail.* 2022 Feb;28(2):191-201. doi: 10.1016/j.cardfail.2021.08.008. Epub 2021 Aug 21. PMID: 34428591.
108. Carnicelli AP, Li Z, Greiner MA, Lippmann SJ, **Greene SJ**, Mentz RJ, Hardy NC, Blumer V, Shen X, Yancy CW, Peterson PN, Allen LA, Fonarow GC, O'Brien EC. Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. *JACC Heart Fail.* 2021 Dec;9(12):876-886. doi: 10.1016/j.jchf.2021.06.018. Epub 2021 Sep 8. PMID: 34509408.
109. Vaduganathan M, Claggett BL, **Greene SJ**, Aggarwal R, Bhatt AS, McMurray JJV, Fonarow GC, Solomon SD. Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US. *JAMA Cardiol.* 2021 Dec 1;6(12):1415-1423. doi: 10.1001/jamacardio.2021.3651. PMID: 34524394; PMCID: PMC8444065.
110. Salah HM, Minhas AMK, Khan MS, Khan SU, Ambrosy AP, Blumer V, Vaduganathan M, **Greene SJ**, Pandey A, Fudim M. Trends in hospitalizations for heart failure, acute myocardial infarction, and stroke in the United States from 2004 to 2018. *Am Heart J.* 2022 Jan;243:103-109. doi: 10.1016/j.ahj.2021.09.009. Epub 2021 Sep 25. PMID: 34582776.
111. Khan MS, **Greene SJ**, Hellkamp AS, DeVore AD, Shen X, Albert NM, Patterson JH, Spertus JA, Thomas LE, Williams FB, Hernandez AF, Fonarow GC, Butler J. Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry. *Circ Heart Fail.* 2021 Nov;14(11):e008351. doi: 10.1161/CIRCHEARTFAILURE.121.008351. Epub 2021 Oct 22. PMID: 34674536.
112. Vaduganathan M, **Greene SJ**, Zhang S, Solomon N, Chiswell K, Devore AD, Butler J, Heidenreich PA, Huang JC, Kittleson MM, Joynt Maddox KE, Mcdermott JJ, Owens AT, Peterson PN, Solomon SD, Vardeny O, Yancy CW, Fonarow GC. Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure. *J Card Fail.* 2022 Apr;28(4):554-563. doi: 10.1016/j.cardfail.2021.11.010. Epub 2021 Nov 14. PMID: 34785402.
113. **Greene SJ**, Butler J, Hellkamp AS, Spertus JA, Vaduganathan M, Devore AD, Albert NM, Patterson JH, Thomas L, Williams FB, Hernandez AF, Fonarow GC. Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry. *J Card Fail.* 2022 Mar;28(3):370-384. doi: 10.1016/j.cardfail.2021.08.023. Epub 2021 Nov 15. PMID: 34793971.
114. Khan MS, Solomon N, DeVore AD, Sharma A, Felker GM, Hernandez AF, Heidenreich PA, Matsouaka RA, Green JB, Butler J, Yancy CW, Peterson PN, Fonarow GC, **Greene SJ**.

- Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes. *JACC Heart Fail.* 2022 Mar;10(3):198-210. doi: 10.1016/j.jchf.2021.11.001. Epub 2021 Dec 8. PMID: 34895861.
115. Wei S, Le N, Zhu JW, Breathett K, **Greene SJ**, Mamas MA, Zannad F, Van Spall HGC. Factors Associated With Racial and Ethnic Diversity Among Heart Failure Trial Participants: A Systematic Bibliometric Review. *Circ Heart Fail.* 2022 Mar;15(3):e008685. doi: 10.1161/CIRCHEARTFAILURE.121.008685. Epub 2021 Dec 16. PMID: 34911363.
 116. Shah A, Mentz RJ, Sun JL, Rao VN, Alhanti B, Blumer V, Starling R, Butler J, **Greene SJ**. Emergency Department Visits Versus Hospital Readmissions Among Patients Hospitalized for Heart Failure. *J Card Fail.* 2022 Jun;28(6):916-923. doi: 10.1016/j.cardfail.2021.11.025. Epub 2022 Jan 3. PMID: 34987009.
 117. Usman MS, Khan MS, Fonarow GC, **Greene SJ**, Friede T, Vaduganathan M, Filippatos G, Coats AJS, Anker SD, Butler J. Robustness of outcomes in trials evaluating sodium-glucose co-transporter 2 inhibitors for heart failure. *ESC Heart Fail.* 2022 Apr;9(2):885-893. doi: 10.1002/ehf2.13785. Epub 2022 Jan 13. PMID: 35029056; PMCID: PMC8934993.
 118. **Greene SJ**, Fonarow GC, Butler J. Web Exclusive. *Annals for Hospitalists Inpatient Notes - Clinical Pearls-Stopping, Starting, and Optimizing Guideline-Directed Medical Therapy in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.* *Ann Intern Med.* 2022 Jan;175(1):HO2-HO3. doi: 10.7326/M21-4558. PMID: 35038400.
 119. Ijaz SH, Jamal S, Minhas AMK, Sheikh AB, Nazir S, Khan MS, Minhas AS, Hays AG, Warraich HJ, **Greene SJ**, Fudim M, Honigberg MC, Khan SS, Paul TK, Michos ED. Trends in Characteristics and Outcomes of Peripartum Cardiomyopathy Hospitalizations in the United States Between 2004 and 2018. *Am J Cardiol.* 2022 Apr 1;168:142-150. doi: 10.1016/j.amjcard.2021.12.034. Epub 2022 Jan 21. PMID: 35074213; PMCID: PMC9944609.
 120. Minhas AMK, Ijaz SH, Jamal S, Dani SS, Khan MS, **Greene SJ**, Fudim M, Warraich HJ, Shapiro MD, Virani SS, Nasir K, Khan SU. Trends in Characteristics and Outcomes in Primary Heart Failure Hospitalizations Among Older Population in the United States, 2004 to 2018. *Circ Heart Fail.* 2022 May;15(5):e008943. doi: 10.1161/CIRCHEARTFAILURE.121.008943. Epub 2022 Jan 26. PMID: 35078346.
 121. Minhas AMK, Salah HM, Khan MS, Rao VN, Tedford RJ, Reddy YNV, Caughey MC, Savarese G, **Greene SJ**, Michos ED, Fudim M. Most Common Causes of Hospitalization Associated with Inpatient Mortality in the United States Between 2005-2018. *Am J Med Sci.* 2022 May;363(5):459-461. doi: 10.1016/j.amjms.2022.01.009. Epub 2022 Jan 26. PMID: 35090870.
 122. Salah HM, Minhas AMK, Khan MS, Khan SU, Ambrosy AP, Blumer V, Vaduganathan M, **Greene SJ**, Pandey A, Fudim M. Trends and characteristics of hospitalizations for heart failure in the United States from 2004 to 2018. *ESC Heart Fail.* 2022 Apr;9(2):947-952. doi: 10.1002/ehf2.13823. Epub 2022 Jan 30. PMID: 35098700; PMCID: PMC8934991.
 123. Rao S, Jamal Siddiqi T, Khan MS, Michos ED, Navar AM, Wang TJ, **Greene SJ**, Prabhakaran D, Khera A, Pandey A. Association of polypill therapy with cardiovascular outcomes, mortality, and adherence: A systematic review and meta-analysis of randomized

- controlled trials. *Prog Cardiovasc Dis.* 2022 Jul-Aug;73:48-55. doi: 10.1016/j.pcad.2022.01.005. Epub 2022 Feb 1. PMID: 35114251.
124. Salah HM, Al'Aref SJ, Khan MS, Al-Hawwas M, Vallurupalli S, Mehta JL, Mounsey JP, **Greene SJ**, McGuire DK, Lopes RD, Fudim M. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis. *Cardiovasc Diabetol.* 2022 Feb 5;21(1):20. doi: 10.1186/s12933-022-01455-2. PMID: 35123480; PMCID: PMC8817537.
 125. Eisenstein EL, Sapp S, Harding T, Harrington A, Velazquez EJ, Mentz RJ, **Greene SJ**, Sachdev V, Kim DY, Anstrom KJ. Ascertaining Death Events in a Pragmatic Clinical Trial: Insights From the TRANSFORM-HF Trial. *J Card Fail.* 2022 Oct;28(10):1563-1567. doi: 10.1016/j.cardfail.2022.01.020. Epub 2022 Feb 16. PMID: 35181553; PMCID: PMC9378754.
 126. Shahid I, Khan MS, Sohail A, Khan SU, **Greene SJ**, Fudim M, Michos ED. Evaluation of Representation of Women as Authors in Pivotal Trials Supporting US Food and Drug Administration Approval of Novel Cardiovascular Drugs. *JAMA Netw Open.* 2022 Feb 1;5(2):e220035. doi: 10.1001/jamanetworkopen.2022.0035. PMID: 35212753; PMCID: PMC8881772.
 127. Keshvani N, Mehta A, Alger HM, Rutan C, Williams J, Zhang S, Young R, Alhanti B, Chiswell K, **Greene SJ**, DeVore AD, Yancy CW, Fonarow GC, Pandey A. Heart failure quality of care and in-hospital outcomes during the COVID-19 pandemic: findings from the Get With The Guidelines-Heart Failure registry. *Eur J Heart Fail.* 2022 Jun;24(6):1117-1128. doi: 10.1002/ejhf.2484. Epub 2022 Apr 6. PMID: 35289038; PMCID: PMC9087396.
 128. **Greene SJ**, Ezekowitz JA, Anstrom KJ, Demyanenko V, Givertz MM, Piña IL, O'Connor CM, Koglin J, Roessig L, Hernandez AF, Armstrong PW, Mentz RJ. Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry. *J Card Fail.* 2022 Jul;28(7):1063-1077. doi: 10.1016/j.cardfail.2022.02.011. Epub 2022 Mar 14. PMID: 35301107.
 129. Khan MS, Segar MW, Usman MS, Singh S, **Greene SJ**, Fonarow GC, Anker SD, Felker GM, Januzzi JL Jr, Butler J, Pandey A. Frailty, Guideline-Directed Medical Therapy, and Outcomes in HFrEF: From the GUIDE-IT Trial. *JACC Heart Fail.* 2022 Apr;10(4):266-275. doi: 10.1016/j.jchf.2021.12.004. Epub 2022 Mar 9. PMID: 35361446.
 130. Shahid I, Khan MS, Siddiqi TJ, Arshad MS, Saleem A, Van Spall HGC, Reza N, **Greene SJ**, Michos ED. Trends in National Institutes of Health R01 Funding of Principal Investigators in Cardiology by Gender. *J Am Coll Cardiol.* 2022 Apr 19;79(15):1544-1546. doi: 10.1016/j.jacc.2022.02.014. PMID: 35422251; PMCID: PMC9022215.
 131. Jain V, Minhas AMK, Khan SU, **Greene SJ**, Pandey A, Van Spall HGC, Fonarow GC, Mentz RJ, Butler J, Khan MS. Trends in HF Hospitalizations Among Young Adults in the United States From 2004 to 2018. *JACC Heart Fail.* 2022 May;10(5):350-362. doi: 10.1016/j.jchf.2022.01.021. PMID: 35483798.
 132. Razaghizad A, Oulousian E, Randhawa VK, Ferreira JP, Brophy JM, **Greene SJ**, Guida J, Felker GM, Fudim M, Tsoukas M, Peters TM, Mavrakanas TA, Giannetti N, Ezekowitz J, Sharma A. Clinical Prediction Models for Heart Failure Hospitalization in Type 2 Diabetes:

- A Systematic Review and Meta-Analysis. *J Am Heart Assoc.* 2022 May 17;11(10):e024833. doi: 10.1161/JAHA.121.024833. Epub 2022 May 16. PMID: 35574959; PMCID: PMC9238543.
133. **Greene SJ**, Lautsch D, Yang L, Tan XI, Brady JE. Prognostic Interplay Between COVID-19 and Heart Failure With Reduced Ejection Fraction. *J Card Fail.* 2022 Aug;28(8):1287-1297. doi: 10.1016/j.cardfail.2022.05.001. Epub 2022 May 18. PMID: 35597512; PMCID: PMC9116978.
 134. Pierce JB, Mentz RJ, Sun JL, Alhanti B, Whellan DJ, Kraus WE, Piña IL, Fiuzat M, O'Connor CM, **Greene SJ**. Titration of medical therapy and clinical outcomes among patients with heart failure with reduced ejection fraction: Findings from the HF-ACTION trial. *Am Heart J.* 2022 Sep;251:115-126. doi: 10.1016/j.ahj.2022.05.018. Epub 2022 May 29. PMID: 35640729.
 135. Minhas AMK, Ijaz SH, Javed N, Sheikh AB, Jain V, Michos ED, **Greene SJ**, Fudim M, Warraich HJ, Shapiro MD, Al-Kindi SG, Sperling L, Virani SS. National trends and disparities in statin use for ischemic heart disease from 2006 to 2018: Insights from National Ambulatory Medical Care Survey. *Am Heart J.* 2022 Oct;252:60-69. doi: 10.1016/j.ahj.2022.05.015. Epub 2022 May 27. PMID: 35644222.
 136. Peters AE, Mentz RJ, Sun JL, Harrington JL, Fudim M, Alhanti B, Hernandez AF, Butler J, Starling RC, **Greene SJ**. Patient-reported and Clinical Outcomes Among Patients Hospitalized for Heart Failure With Reduced Versus Preserved Ejection Fraction. *J Card Fail.* 2022 Dec;28(12):1652-1660. doi: 10.1016/j.cardfail.2022.05.010. Epub 2022 Jun 7. PMID: 35688408.
 137. Usman MS, Minhas AMK, **Greene SJ**, Van Spall HG, Mentz RJ, Fonarow GC, Al-Khatib SM, Butler J, Khan MS. Utilization of Implantable Cardioverter Defibrillators Among Patients with a Left Ventricular Assist Device: Insights From a National Database. *Curr Probl Cardiol.* 2022 Nov;47(11):101334. doi: 10.1016/j.cpcardiol.2022.101334. Epub 2022 Jul 23. PMID: 35882256.
 138. Jain V, Minhas AMK, Morris AA, **Greene SJ**, Pandey A, Khan SS, Fonarow GC, Mentz RJ, Butler J, Khan MS. Demographic and Regional Trends of Heart Failure-Related Mortality in Young Adults in the US, 1999-2019. *JAMA Cardiol.* 2022 Sep 1;7(9):900-904. doi: 10.1001/jamacardio.2022.2213. PMID: 35895048; PMCID: PMC9330269.
 139. Siddiqi TJ, Ahmed A, **Greene SJ**, Shahid I, Usman MS, Oshunbade A, Alkhouli M, Hall ME, Murad MH, Khera R, Jain V, Van Spall HGC, Khan MS. Performance of current risk stratification models for predicting mortality in patients with heart failure: a systematic review and meta-analysis. *Eur J Prev Cardiol.* 2022 Nov 8;29(15):2027-2048. doi: 10.1093/eurjpc/zwac148. PMID: 35919956.
 140. Murray EM, **Greene SJ**, Rao VN, Sun JL, Alhanti BA, Blumer V, Butler J, Ahmad T, Mentz RJ. Machine learning to define phenotypes and outcomes of patients hospitalized for heart failure with preserved ejection fraction: Findings from ASCEND-HF. *Am Heart J.* 2022 Dec;254:112-121. doi: 10.1016/j.ahj.2022.08.009. Epub 2022 Aug 23. PMID: 36007566.
 141. Minhas AMK, Wyand RA, Ariss RW, Nazir S, Shahzeb Khan M, Jia X, **Greene SJ**, Fudim M, Wang A, Warraich HJ, Kalra A, Alam M, Virani SS. Demographic and Regional Trends

- of Hypertrophic Cardiomyopathy-Related Mortality in the United States, 1999 to 2019. *Circ Heart Fail.* 2022 Sep;15(9):e009292. doi: 10.1161/CIRCHEARTFAILURE.121.009292. Epub 2022 Sep 7. PMID: 36126142.
142. Zhang Y, Gao C, **Greene SJ**, Greenberg BH, Butler J, Yu J, Zheng Z, Ma G, Wang L, Yang P, Ji X, Xu D, Wang J, Zhang Y, Liu Y, Zhao Y, Qi H, Zhai M, Feng J, Huang Y, Zhou Q, Zhang J. Clinical performance and quality measures for heart failure management in China: the China-Heart Failure registry study. *ESC Heart Fail.* 2023 Feb;10(1):342-352. doi: 10.1002/ehf2.14184. Epub 2022 Oct 12. PMID: 36224725; PMCID: PMC9871659.
 143. Cosiano MF, Vista A, Sun JL, Alhanti B, Harrington J, Butler J, Starling RC, Mentz RJ, **Greene SJ**. Comparing New York Heart Association Class and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure. *Circ Heart Fail.* 2023 Jan;16(1):e010107. doi: 10.1161/CIRCHEARTFAILURE.122.010107. Epub 2022 Oct 31. PMID: 36314126.
 144. Rao VN, Shah A, McDermott J, Barnes SG, Murray EM, Kelsey MD, **Greene SJ**, Fudim M, DeVore AD, Patel CB, Blazing MA, O'Brien C, Mentz RJ. In-Hospital Virtual Peer-to-Peer Consultation to Increase Guideline-Directed Medical Therapy for Heart Failure: A Pilot Randomized Trial. *Circ Heart Fail.* 2023 Feb;16(2):e010158. doi: 10.1161/CIRCHEARTFAILURE.122.010158. Epub 2022 Oct 31. PMID: 36314130; PMCID: PMC9974597.
 145. Pierce JB, Li Z, Greiner MA, Lippmann SJ, Hardy NC, Shen X, Stampehl M, Mentz RJ, Allen LA, Peterson PN, Fonarow GC, O'Brien EC, **Greene SJ**. Adoption of Sacubitril/Valsartan Among Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The Get With The Guidelines-Heart Failure Registry. *Circ Heart Fail.* 2023 Jan;16(1):e010176. doi: 10.1161/CIRCHEARTFAILURE.122.010176. Epub 2022 Oct 31. PMID: 36314141.
 146. Siddiqi TJ, Khan Minhas AM, **Greene SJ**, Van Spall HGC, Khan SS, Pandey A, Mentz RJ, Fonarow GC, Butler J, Khan MS. Trends in Heart Failure-Related Mortality Among Older Adults in the United States From 1999-2019. *JACC Heart Fail.* 2022 Nov;10(11):851-859. doi: 10.1016/j.jchf.2022.06.012. Epub 2022 Sep 7. PMID: 36328654.
 147. **Greene SJ**, Goto D, Wang D, Hilkert R, Lautsch D, Fonarow GC. Outpatient versus inpatient intravenous diuretic therapy for heart failure in the United States. *Eur J Heart Fail.* 2022 Nov;24(11):2199-2202. doi: 10.1002/ejhf.2727. Epub 2022 Nov 15. PMID: 36334074.
 148. Talha KM, Butler J, **Greene SJ**, Aggarwal R, Anker SD, Claggett BL, Solomon SD, McMurray JJV, Vaduganathan M, Fonarow GC. Population-Level Implications of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Preserved Ejection Fraction in the US. *JAMA Cardiol.* 2023 Jan 1;8(1):66-73. doi: 10.1001/jamacardio.2022.4348. PMID: 36334258; PMCID: PMC9637275.
 149. Patel RB, **Greene SJ**, Xu H, Alhanti B, Peterson P, Yancy CW, Piccini J, Fonarow GC, Vaduganathan M. Intersection of atrial fibrillation and heart failure with mildly reduced and preserved ejection fraction in >400 000 participants in the Get With The Guidelines-Heart Failure Registry. *Eur J Heart Fail.* 2023 Jan;25(1):63-73. doi: 10.1002/ejhf.2729. Epub 2022 Nov 20. PMID: 36343200.

150. Pierce JB, Maqsood MH, Khan MS, Minhas AMK, Butler J, Felker GM, **Greene SJ**; Durham, North Carolina; New York, New York; Hattiesburg and Jackson, Mississippi; and Dallas, Texas. Duration of Heart Failure, In-hospital Clinical Trajectory, and Postdischarge Outcomes in Patients Hospitalized for Heart Failure. *J Card Fail.* 2023 Feb;29(2):225-228. doi: 10.1016/j.cardfail.2022.10.427. Epub 2022 Nov 6. PMID: 36351495.
151. Aliyev N, Almani MU, Qudrat-Ullah M, Harrington J, Fonarow GC, Butler J, Pandey A, Khan MS, **Greene SJ**. Neighborhood Household Income and Trends in 30-Day Readmission for Patients With Heart Failure. *JACC Heart Fail.* 2023 Jan;11(1):121-123. doi: 10.1016/j.jchf.2022.10.003. Epub 2022 Oct 31. PMID: 36357301.
152. Selvaraj S, **Greene SJ**, Ayodele I, Alhanti B, Allen LA, Lewsey SC, Adusumalli S, Reza N, Hernandez AF, Yancy CW, Jena AB, Fonarow GC, Bhatt DL. Assessing Heuristic Bias During Care for Patients Hospitalized for Heart Failure: Get With The Guidelines-Heart Failure. *Circ Heart Fail.* 2023 Feb;16(2):e010069. doi: 10.1161/CIRCHEARTFAILURE.122.010069. Epub 2022 Dec 2. PMID: 36458538; PMCID: PMC9974743.
153. Siddiqi TJ, Shahid I, Arshad MS, **Greene SJ**, Pandey A, Vaduganathan M, VAN Spall HGC, Mentz RJ, Fonarow GC, Khan MS. Inconsistent Outcome Reporting in Heart Failure Randomized Controlled Trials. *J Card Fail.* 2022 Dec 11:S1071-9164(22)01219-2. doi: 10.1016/j.cardfail.2022.11.008. Epub ahead of print. PMID: 36513272.
154. Sreenivasan J, Malik A, Khan MS, Lloji A, Hooda U, Aronow WS, Lanier GM, Pan S, **Greene SJ**, Murad MH, Michos ED, Cooper HA, Gass A, Gupta R, Desai NR, Mentz RJ, Frishman WH, Panza JA. Pharmacotherapies in Heart Failure With Preserved Ejection Fraction: A Systematic Review and Network Meta-Analysis. *Cardiol Rev.* 2022 Dec 27. doi: 10.1097/CRD.0000000000000484. Epub ahead of print. PMID: 36576372.
155. Jain V, Maqsood MH, Siddiqi TJ, Siddiqi AK, Baloch ZQ, Kittleson MM, Fudim M, Felker GM, **Greene SJ**, Butler J, Khan MS. Trajectory of Decongestion and Mortality in Young Adults with Acute Heart Failure. *Curr Probl Cardiol.* 2023 Apr;48(4):101579. doi: 10.1016/j.cpcardiol.2022.101579. Epub 2022 Dec 30. PMID: 36592843.
156. Mentz RJ, Anstrom KJ, Eisenstein EL, Sapp S, **Greene SJ**, Morgan S, Testani JM, Harrington AH, Sachdev V, Ketema F, Kim DY, Desvigne-Nickens P, Pitt B, Velazquez EJ; TRANSFORM-HF Investigators. Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial. *JAMA.* 2023 Jan 17;329(3):214-223. doi: 10.1001/jama.2022.23924. PMID: 36648467; PMCID: PMC9857435.
157. Teng TK, Tay WT, Ouwerkerk W, Tromp J, Richards AM, Gamble G, **Greene SJ**, Yiu KH, Poppe K, Ling LH, Lund M, Sim D, Devlin G, Loh SY, Troughton R, Ren QW, Jauffeerally F, Lee SGS, Tan RS, Soon DKN, Leong G, Ong HY, Yeo DPS, Lam CSP, Doughty RN. Titration of medications and outcomes in multi-ethnic heart failure cohorts (with reduced ejection fraction) from Singapore and New Zealand. *ESC Heart Fail.* 2023 Feb 1. doi: 10.1002/ehf2.14275. Epub ahead of print. PMID: 36722315.
158. Khan MS, Xu H, Fonarow GC, Lautsch D, Hilker R, Allen LA, DeVore AD, Alhanti B, Yancy CW, Albert NM, Butler J, **Greene SJ**. Applicability of Vericiguat to Patients Hospitalized for

- Heart Failure in the United States. *JACC Heart Fail.* 2023 Feb;11(2):211-223. doi: 10.1016/j.jchf.2022.11.007. PMID: 36754528.
159. Pierce JB, Ikeaba U, Peters AE, DeVore AD, Chiswell K, Allen LA, Albert NM, Yancy CW, Fonarow GC, **Greene SJ**. Quality of Care and Outcomes Among Patients Hospitalized for Heart Failure in Rural vs Urban US Hospitals: The Get With The Guidelines-Heart Failure Registry. *JAMA Cardiol.* 2023 Feb 20:e230241. doi: 10.1001/jamacardio.2023.0241. Epub ahead of print. PMID: 36806447; PMCID: PMC9941973.
 160. Harrington J, Fonarow GC, Khan MS, Hernandez A, Anker S, Böhm M, **Greene SJ**, Felker GM, Vaduganathan M, Butler J. Medication-Attributable Adverse Events in Heart Failure Trials. *JACC Heart Fail.* 2023 Jan 12:S2213-1779(22)00721-1. doi: 10.1016/j.jchf.2022.11.026. Epub ahead of print. PMID: 36881395.
 161. Talha KM, Butler J, **Greene SJ**, Aggarwal R, Anker SD, Claggett BL, Docherty KF, Solomon SD, McMurray JJV, Januzzi JL Jr, Vaduganathan M, Fonarow GC. Potential global impact of sodium-glucose cotransporter-2 inhibitors in heart failure. *Eur J Heart Fail.* 2023 Apr 16. doi: 10.1002/ejhf.2864. Epub ahead of print. PMID: 37062865.
 162. Diamond J, Ayodele I, Fonarow GC, Joynt-Maddox KE, Yeh RW, Hammond G, Allen LA, **Greene SJ**, Chiswell K, DeVore AD, Yancy C, Wadhera RK. Quality of Care and Clinical Outcomes for Patients With Heart Failure at Hospitals Caring for a High Proportion of Black Adults: Get With The Guidelines-Heart Failure Registry. *JAMA Cardiol.* 2023 Jun 1;8(6):545-553. doi: 10.1001/jamacardio.2023.0695. PMID: 37074702; PMCID: PMC10116383.
 163. **Greene SJ**, Spertus JA, Tang W, Kang A, Zhong Y, Myers MC, Shen S, Jiang J, Liu X, Steffen DR, Viola MG, Felker GM. Heart Failure Across the Range of Mildly Reduced and Preserved Ejection Fraction in the United States. *Circ Heart Fail.* 2023 May;16(5):e010430. doi: 10.1161/CIRCHEARTFAILURE.123.010430. Epub 2023 Apr 20. PMID: 37078276; PMCID: PMC10179973.
 164. Harrington J, Sun JL, Fonarow GC, Heitner SB, Divanji PH, Binder G, Allen LA, Alhanti B, Yancy CW, Albert NM, DeVore AD, Felker GM, **Greene SJ**. Clinical Profile, Health Care Costs, and Outcomes of Patients Hospitalized for Heart Failure With Severely Reduced Ejection Fraction. *J Am Heart Assoc.* 2023 May 16;12(10):e028820. doi: 10.1161/JAHA.122.028820. Epub 2023 May 9. PMID: 37158118; PMCID: PMC10227282.
 165. Pierce JB, Vaduganathan M, Fonarow GC, Ikeaba U, Chiswell K, Butler J, DeVore AD, Heidenreich PA, Huang JC, Kittleson MM, Joynt Maddox KE, Langanathan KK, McDermott JJ, Owens AT, Peterson PN, Solomon SD, Vardeny O, Yancy CW, **Greene SJ**. Contemporary Use of Sodium-Glucose Cotransporter-2 Inhibitor Therapy Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in the US: The Get With The Guidelines-Heart Failure Registry. *JAMA Cardiol.* 2023 May 22:e231266. doi: 10.1001/jamacardio.2023.1266. Epub ahead of print. PMID: 37212192; PMCID: PMC10203967.
 166. **Greene SJ**, Velazquez EJ, Anstrom KJ, Clare RM, DeWald TA, Psofka MA, Ambrosy AP, Stevens G, Rommel JJ, Alexy T, Ketema F, Kim DY, Desvigne-Nickens P, Pitt B, Eisenstein EL, Mentz RJ; TRANSFORM-HF Investigators. Effect of Toremide vs Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The

- TRANSFORM-HF Randomized Clinical Trial. *Circulation*. 2023 May 22. doi: 10.1161/CIRCULATIONAHA.123.064842. Epub ahead of print. PMID: 37212600.
167. Aliyev N, Almani MU, Qudrat-Ullah M, Butler J, Khan MS, **Greene SJ**. Comparison of 30-day Readmission Rates and Inpatient Cardiac Procedures for Weekday versus Weekend Hospital Admissions for Heart Failure. *J Card Fail*. 2023 May 25:S1071-9164(23)00188-4. doi: 10.1016/j.cardfail.2023.05.010. Epub ahead of print. PMID: 37244294.
 168. Akhtar KH, Maqsood MH, Ansari SA, Siddiqi TJ, Arshad MS, **Greene SJ**, Butler J, Khan MS. An Individual Patient-Level Meta-Analysis of Ischemic Versus Nonischemic Cardiomyopathy and Trajectory of Decongestion in Patients With Acute Decompensated Heart Failure. *Am J Cardiol*. 2023 Jun 7;200:32-39. doi: 10.1016/j.amjcard.2023.04.043. Epub ahead of print. PMID: 37295177.
 169. Swat SA, Xu H, Allen LA, **Greene SJ**, DeVore AD, Matsouaka RA, Goyal P, Peterson PN, Hernandez AF, Krumholz HM, Yancy CW, Fonarow GC, Hess PL; American Heart Association's Get With the Guidelines–Heart Failure (GWTG-HF) Program. Opportunities and Achievement of Medication Initiation Among Inpatients With Heart Failure With Reduced Ejection Fraction. *JACC Heart Fail*. 2023 Jun 2:S2213-1779(23)00232-9. doi: 10.1016/j.jchf.2023.04.015. Epub ahead of print. PMID: 37318420.
 170. Usman MS, Siddiqi TJ, Anker SD, Bakris GL, Bhatt DL, Filippatos G, Fonarow GC, **Greene SJ**, Januzzi JL Jr, Khan MS, Kosiborod MN, McGuire DK, Piña IL, Rosenstock J, Vaduganathan M, Verma S, Zieroth S, Butler J. Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations. *J Am Coll Cardiol*. 2023 Jun 27;81(25):2377-2387. doi: 10.1016/j.jacc.2023.04.034. PMID: 37344038.
 171. Peters AE, Solomon N, Chiswell K, Fonarow GC, Khouri MG, Baylor L, Alvir J, Bruno M, Huda A, Allen LA, Sharma K, DeVore AD, **Greene SJ**. Transthyretin amyloid cardiomyopathy among patients hospitalized for heart failure and performance of an adapted wild-type ATTR-CM machine learning model: Findings from GWTG-HF. *Am Heart J*. 2023 Jul 1;265:22-30. doi: 10.1016/j.ahj.2023.06.013. Epub ahead of print. PMID: 37400049.
 172. Minhas AMK, Bhopalwala HM, Dewaswala N, Ijaz SH, Khan MS, Khan MZ, Dani SS, Warraich HJ, **Greene SJ**, Edmonston DL, Lopez RD, Virani SS, Bhopalwala A, Fudim M. Association of Chronic Renal Insufficiency with Inhospital Outcomes in Primary Heart Failure Hospitalizations (Insights from the National Inpatient Sample 2004 to 2018). *Am J Cardiol*. 2023 Sep 1;202:41-49. doi: 10.1016/j.amjcard.2023.05.063. Epub 2023 Jul 5. PMID: 37419025.
 173. Keshvani N, Subramanian V, Wrobel CA, Solomon N, Alhanti B, **Greene SJ**, DeVore AD, Yancy CW, Allen LA, Fonarow GC, Pandey A. Patterns of Referral and Postdischarge Utilization of Cardiac Rehabilitation Among Patients Hospitalized With Heart Failure: An Analysis From the GWTG-HF Registry. *Circ Heart Fail*. 2023 Aug;16(8):e010144. doi: 10.1161/CIRCHEARTFAILURE.122.010144. Epub 2023 Jul 11. PMID: 37431671.
 174. Pierce JB, Blumer V, Choi S, Hardy NC, Greiner MA, Carnicelli AP, Shen X, Lippmann SJ, Peterson PN, Allen LA, Fonarow GC, Mentz RJ, **Greene SJ**, O'Brien EC. Comparative Outcomes of Sacubitril/Valsartan Use After Hospitalization for Heart Failure Among Medicare Beneficiaries Naïve to Renin-Angiotensin System Inhibitors. *Am J Cardiol*. 2023

Aug 4;204:151-158. doi: 10.1016/j.amjcard.2023.07.099. Epub ahead of print. PMID: 37544137.

175. Keshvani N, Shah S, Ayodele I, Chiswell K, Alhanti B, Allen L, **Greene SJ**, Yancy C, Alonso W, Van Spall H, Fonarow GC, Heidenreich PA, Pandey A. Sex Differences in long-term outcomes following acute heart failure hospitalization: Findings from the Get with The Guidelines - Heart Failure Registry. *Eur J Heart Fail*. 2023 Aug 26. doi: 10.1002/ejhf.3003. Epub ahead of print. PMID: 37632339.
176. Harrington J, Sun JL, Fonarow GC, Heitner SB, Divanji PH, Allen LA, Alhanti B, Yancy CW, Albert NM, DeVore AD, Felker GM, **Greene SJ**. Potential Applicability of Omecamtiv Mecarbil to Patients Hospitalized for Worsening Heart Failure. *Am J Cardiol*. 2023 Oct 15;205:524-526. doi: 10.1016/j.amjcard.2023.08.013. Epub 2023 Sep 4. PMID: 37666729.
177. Almani MU, Aliyev N, Qudrat-Ullah M, Khan MS, **Greene SJ**. All-Cause and Cause-Specific 30-Day Readmissions After Left Ventricular Assist Device Implantation: Comparing the HeartMate 3 Versus Pre-HeartMate 3 Eras. *Am J Cardiol*. 2023 Nov 15;207:82-83. doi: 10.1016/j.amjcard.2023.08.179. Epub 2023 Sep 19. PMID: 37734304.
178. Bhatt AS, Fonarow GC, **Greene SJ**, Holmes DN, Alhanti B, Devore AD, Butler J, Heidenreich PA, Huang JC, KITTLESOn MM, Linganathan K, Joyntmaddox KE, McDermott JJ, Owens AT, Peterson PN, Solomon SD, Vardeny O, Yancy CW, Vaduganathan M. Medical Therapy Before, During and After Hospitalization in Medicare Beneficiaries With Heart Failure and Diabetes: Get With The Guidelines - Heart Failure Registry. *J Card Fail*. 2023 Sep 25:S1071-9164(23)00344-5. doi: 10.1016/j.cardfail.2023.09.005. Epub ahead of print. PMID: 37757995.
179. Pierce JB, Fonarow GC, **Greene SJ**. Identifying Barriers to Initiation of Sodium-Glucose Cotransporter-2 Inhibitor Therapy in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction-Reply. *JAMA Cardiol*. 2023 Dec 1;8(12):1188-1189. doi: 10.1001/jamacardio.2023.3784. PMID: 37878275.
180. Krim SR, Anand S, **Greene SJ**, Chen A, Wojdyla D, Vilaro J, Haught H, Herre JM, Eisenstein EL, Anstrom KJ, Pitt B, Velazquez EJ, Mentz RJ. Torsemide vs Furosemide Among Patients With New-Onset vs Worsening Chronic Heart Failure: A Substudy of the TRANSFORM-HF Randomized Clinical Trial. *JAMA Cardiol*. 2023 Nov 13:e234776. doi: 10.1001/jamacardio.2023.4776. Epub ahead of print. PMID: 37955908; PMCID: PMC10644243.
181. Oddleifson DA, Holmes DN, Alhanti B, Xu X, Heidenreich PA, Wadhwa RK, Allen LA, **Greene SJ**, Fonarow GC, Spatz ES, Desai NR. Bundled Payments for Care Improvement and Quality of Care and Outcomes in Heart Failure. *JAMA Cardiol*. 2024 Jan 3:e235009. doi: 10.1001/jamacardio.2023.5009. Epub ahead of print. PMID: 38170516.
182. Minhas AMK, Kewcharoen J, Hall ME, Warraich HJ, **Greene SJ**, Shapiro MD, Michos ED, Sauer AJ, Abramov D. Temporal Trends in Substance Use and Cardiovascular Disease-Related Mortality in the United States. *J Am Heart Assoc*. 2024 Jan 16;13(2):e030969. doi: 10.1161/JAHA.123.030969. Epub 2024 Jan 10. PMID: 38197601
183. Talha KM, Januzzi JL Jr, Meng T, **Greene SJ**, Vaduganathan M, Janicijevic TK, John A, Bayes-Genis A, Butler J. Use of natriuretic peptides and echocardiography for diagnosing

- heart failure. *Eur J Heart Fail.* 2024 Feb 20. doi: 10.1002/ejhf.3165. Epub ahead of print. PMID: 38378966.
184. Siddiqi AK, Maniya MT, Alam MT, Ambrosy AP, Fudim M, **Greene SJ**, Khan MS. Acetazolamide as an Adjunctive Diuretic Therapy for Patients with Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis. *Am J Cardiovasc Drugs.* 2024 Mar;24(2):273-284. doi: 10.1007/s40256-024-00633-9. Epub 2024 Feb 28. PMID: 38416359.
 185. Kapelios CJ, **Greene SJ**, Mentz RJ, Ikeaba U, Wojdyla D, Anstrom KJ, Eisenstein EL, Pitt B, Velazquez EJ, Fang JC; TRANSFORM-HF Investigators. Torsemide Versus Furosemide After Discharge in Patients Hospitalized With Heart Failure Across the Spectrum of Ejection Fraction: Findings From TRANSFORM-HF. *Circ Heart Fail.* 2024 Mar;17(3):e011246. doi: 10.1161/CIRCHEARTFAILURE.123.011246. Epub 2024 Mar 4. PMID: 38436075
 186. Martens P, **Greene SJ**, Mentz RJ, Li S, Wojdyla D, Kapelios CJ, Mullens W, Hall ME, Ketema F, Kim DY, Eisenstein EL, Anstrom K, Fang JC, Pitt B, Velazquez EJ, Tang WHW. Impact of baseline kidney dysfunction on oral diuretic efficacy following hospitalization for heart failure - insights from TRANSFORM-HF. *Eur J Heart Fail.* 2024 Apr 1. doi: 10.1002/ejhf.3207. Epub ahead of print. PMID: 38558520.
 187. Haywood HB, Graham AJ, Chermak D, Achanta A, Butler J, Fonarow GC, **Greene SJ**. Estimating the Proportion of Heart Failure Admissions Potentially Eligible for Hospital at Home. *J Card Fail.* 2024 Apr 6:S1071-9164(24)00108-8. doi: 10.1016/j.cardfail.2024.03.004. Epub ahead of print. PMID: 38588859.
 188. **Greene SJ**, Ayodele I, Pierce JB, Khan MS, Lewsey SC, Yancy CW, Alhanti B, Van Spall HGC, Allen LA, Fonarow GC. Eligibility and Projected Benefits of Rapid Initiation of Quadruple Medical Therapy for Newly Diagnosed Heart Failure. *JACC Heart Fail.* 2024 Mar 25:S2213-1779(24)00244-0. doi: 10.1016/j.jchf.2024.03.001. Epub ahead of print. PMID: 38597866.
 189. **Greene SJ**, Gaggin HK, Zhou M, Bash LD, Lautsch D, Djatche L, Song Y, Signorovitch J, Stevenson AS, Blaustein RO, Butler J. Treatment patterns of patients with worsening heart failure with reduced ejection fraction. *ESC Heart Fail.* 2024 Apr 19. doi: 10.1002/ehf2.14805. Epub ahead of print. PMID: 38639469.
 190. Davogustto G, Wells QS, Harrell FE Jr, **Greene SJ**, Roden DM, Stevenson LW. Impact of Insurance Status and Region on Angiotensin Receptor-Nepriylsin Inhibitor Prescription During Heart Failure Hospitalizations. *JACC Heart Fail.* 2024 May;12(5):864-875. doi: 10.1016/j.jchf.2024.02.003. Epub 2024 Apr 17. PMID: 38639698.
 191. Zheng J, Ambrosy AP, Bhatt AS, Collins SP, Flint KM, Fonarow GC, Fudim M, **Greene SJ**, Lala A, Testani JM, Varshney AS, Wi RSK, Sandhu AT. Contemporary Decongestion Strategies in Patients Hospitalized for Heart Failure: A National Community-Based Cohort Study. *JACC Heart Fail.* 2024 Apr 7:S2213-1779(24)00267-1. doi: 10.1016/j.jchf.2024.04.002. Epub ahead of print. PMID: 38678466.
 192. Kittipibul V, Vaduganathan M, Ikeaba U, Chiswell K, Butler J, DeVore AD, Heidenreich PA, Huang JC, Kittleson MM, Joynt Maddox KE, Linganathan KK, McDermott JJ, Owens AT, Peterson PN, Solomon SD, Vardeny O, Yancy CW, Fonarow GC, **Greene SJ**. Cause-

Specific Health Care Costs Following Hospitalization for Heart Failure and Cost Offset With SGLT2i Therapy. *JACC Heart Fail.* 2024 Apr 6;S2213-1779(24)00268-3. doi: 10.1016/j.jchf.2024.04.003. Epub ahead of print. PMID: 38727651.

193. **Greene SJ**, Chambers R, Lerman JB, Harrington J, deFilippi CR, Wendell DC, Kim HW, Green CL, Butler J, Felker GM. Sacubitril/valsartan and cardiovascular biomarkers among patients with recent COVID-19 infection: The PARACOR-19 randomized clinical trial. *Eur J Heart Fail.* 2024 May 11. doi: 10.1002/ejhf.3199. Epub ahead of print. PMID: 38733160.
194. Kittipibul V, Mentz RJ, Clare RM, Wojdyla DM, Anstrom KJ, Eisenstein EL, Ambrosy AP, Goyal P, Skopicki HA, Ketema F, Kim DY, Desvigne-Nickens P, Pitt B, Velazquez EJ, **Greene SJ**. On-treatment analysis of torsemide versus furosemide for patients hospitalized for heart failure: A post-hoc analysis of TRANSFORM-HF. *Eur J Heart Fail.* 2024 May 15. doi: 10.1002/ejhf.3293. Epub ahead of print. PMID: 38745502.
195. Gaggin HK, **Greene SJ**, Zhou M, Lautsch D, Bash LD, Djatche L, Song Y, Signorovitch J, Stevenson AS, Blaustein RO, Butler J. Contemporary outpatient management of patients with worsening heart failure with reduced ejection fraction: Clinical outcome results from the CHART-HF study. *Int J Cardiol Cardiovasc Risk Prev.* 2024 May 6;21:200278. doi: 10.1016/j.ijcrp.2024.200278. PMID: 38766664; PMCID: PMC11101901.
196. Ostrominski JW, **Greene SJ**, Patel RB, Solomon NC, Chiswell K, DeVore AD, Butler J, Heidenreich PA, Huang JC, Kittleson MM, Joynt Maddox KE, Langanathan KK, McDermott JJ, Owens AT, Peterson PN, Solomon SD, Vardeny O, Yancy CW, Fonarow GC, Vaduganathan M. Kidney Outcomes Among Medicare Beneficiaries After Hospitalization for Heart Failure. *JAMA Cardiol.* 2024 Jul 1;9(7):667-672. doi: 10.1001/jamacardio.2024.1108. PMID: 38809567; PMCID: PMC11137656.
197. Mansoor T, Khalid SN, Bilal MI, Ijaz SH, Fudim M, **Greene SJ**, Warraich HJ, Nambi V, Virani SS, Fonarow GC, Abramov D, Minhas AMK. Ongoing and Future Clinical Trials of Pharmacotherapy for Heart Failure. *Am J Cardiovasc Drugs.* 2024 Jul;24(4):481-504. doi: 10.1007/s40256-024-00658-0. Epub 2024 Jun 22. PMID: 38907865.
198. Ali A, Siddiqui AA, Shahid I, Van Spall HGC, **Greene SJ**, Fudim M, Khan MS. Prognostic value of quality of life and functional status in patients with heart failure: a systematic review and meta-analysis. *Egypt Heart J.* 2024 Aug 5;76(1):97. doi: 10.1186/s43044-024-00532-z. PMID: 39101961
199. Khalid SN, Mansoor T, Bilal MI, Ijaz SH, Fudim M, **Greene SJ**, Nambi V, Virani SS, Fonarow GC, Abramov D, Minhas AMK. Ongoing and future clinical trials of device therapies for patients with heart failure. *Curr Probl Cardiol.* 2024 Aug 17;49(11):102805. doi: 10.1016/j.cpcardiol.2024.102805. Epub ahead of print. PMID: 39159710
200. Zheng J, Sandhu AT, Bhatt AS, Collins SP, Flint KM, Fonarow GC, Fudim M, **Greene SJ**, Heidenreich PA, Lala A, Testani JM, Varshney AS, Wi RSK, Ambrosy AP. Inpatient Use of Guideline-Directed Medical Therapy During Heart Failure Hospitalizations Among Community-Based Health Systems. *JACC Heart Fail.* 2024 Aug 30;S2213-1779(24)00603-6. doi: 10.1016/j.jchf.2024.08.004. Epub ahead of print. PMID: 39269395.
201. Sandhu AT, Grau-Sepulveda MV, Witting C, Tisdale RL, Zheng J, Rodriguez F, Edward JA, Ambrosy AP, **Greene SJ**, Alhanti B, Fonarow GC, Joynt Maddox KE, Heidenreich PA.

- Equity in Heart Failure Care: A Get With the Guidelines Analysis of Between- and Within-Hospital Differences in Care by Sex, Race, Ethnicity, and Insurance. *Circ Heart Fail.* 2024 Sep 18:e011177. doi: 10.1161/CIRCHEARTFAILURE.123.011177. Epub ahead of print. PMID: 39291393.
202. **Greene SJ**, Bash LD, Tebbs KW, Hancock LN, Barlow SG, Coyle CR. Physician-Reported Reasons for Not Initiating Guideline-Directed Medical Therapy for Heart Failure. *JACC Heart Fail.* 2024 Sep 3:S2213-1779(24)00601-2. doi: 10.1016/j.jchf.2024.08.002. Epub ahead of print. PMID: 39297863.
203. Polsinelli VB, Sun JL, **Greene SJ**, Chiswell K, Grunwald GK, Allen LA, Peterson P, Pandey A, Fonarow GC, Heidenreich P, Ho PM, Hess PL. Hospital Heart Failure Medical Therapy Score and Associated Clinical Outcomes and Costs. *JAMA Cardiol.* 2024 Sep 25:e242969. doi: 10.1001/jamacardio.2024.2969. Epub ahead of print. PMID: 39320905; PMCID: PMC11425195.
204. Nouhravesh N, **Greene SJ**, Clare R, Wojdyla D, Anstrom KJ, Velazquez E, Pitt B, Mentz RJ, Psotka MA. Diuretic dosing and outcomes with torsemide and furosemide following hospitalization for heart failure: The TRANSFORM-HF trial. *Eur J Heart Fail.* 2024 Oct 4. doi: 10.1002/ejhf.3458. Epub ahead of print. PMID: 39363809.
205. Hameed I, Nusrat K, Jamil A, Fatima K, Minhas AMK, **Greene SJ**, Sauer AJ, Butler J, Khan MS. Demographic and Regional Trends of Cardiovascular Disease and Obesity-Related Mortality in the United States From 1999 to 2021. *Am J Cardiol.* 2024 Dec 15;233:51-54. doi: 10.1016/j.amjcard.2024.09.028. Epub 2024 Oct 5. PMID: 39374685.
206. Tang AB, Solomon N, Chiswell K, **Greene SJ**, Yancy CW, Jessup M, Kittleson M, Butler J, Sweitzer NK, Goldberg LR, Lindenfeld JA, Lewis EF, Peterson PN, Paul S, Serdyński LM, Rutan C, Congdon M, Cherkur S, Fonarow GC. Home-Time, Mortality, and Readmissions Among Patients Hospitalized With Heart Failure: A Baseline Prior to IMPLEMENT-HF. *Circ Heart Fail.* 2024 Oct;17(10):e011795. doi: 10.1161/CIRCHEARTFAILURE.124.011795. Epub 2024 Oct 9. PMID: 39381871; PMCID: PMC11479851.
207. Spahillari A, Cohen LP, Lin C, Liu Y, Tringale A, Sheppard KE, Ko C, Khairnar R, Williamson KM, Wasfy JH, Scott NS, Paquette C, **Greene SJ**, Fonarow GC, Januzzi JL Jr. Efficacy, Safety and Mechanistic Impact of a Heart Failure Guideline-Directed Medical Therapy Clinic. *JACC Heart Fail.* 2024 Oct 9:S2213-1779(24)00623-1. doi: 10.1016/j.jchf.2024.08.017. Epub ahead of print. PMID: 39387769.
208. Jacobs JA, Ayodele I, Bress AP, Sterling MR, Pandey A, Derington CG, Zheutlin AR, Shah KS, **Greene SJ**, Alhanti B, Blanco R, Fonarow GC. Social Determinants of Health and Disparities in Guideline-Directed Medical Therapy Optimization for Heart Failure. *Circ Heart Fail.* 2024 Nov 11:e012357. doi: 10.1161/CIRCHEARTFAILURE.124.012357. Epub ahead of print. PMID: 39527624.
209. Abdel Jawad M, Spertus JA, Ikeaba U, **Greene SJ**, Fonarow GC, Chiswell K, Chan PS. Early Adoption of Sodium-Glucose Cotransporter-2 Inhibitor in Patients Hospitalized With Heart Failure With Mildly Reduced or Preserved Ejection Fraction. *JAMA Cardiol.* 2025 Jan 1;10(1):89-94. doi: 10.1001/jamacardio.2024.4489. PMID: 39556474; PMCID: PMC11574726.

210. Ashley SC, Khan MS, **Greene SJ**. Clinical Course and Outcomes of Acute Heart Failure With Moderate-to-Severe Mitral or Tricuspid Regurgitation. *Am J Cardiol*. 2024 Dec 4:S0002-9149(24)00834-8. doi: 10.1016/j.amjcard.2024.11.034. Epub ahead of print. PMID: 39643254.
211. Srivastava PK, Klomhaus AM, **Greene SJ**, Heidenreich P, Lewsey SC, Yancy CW, Fonarow GC. Angiotensin Receptor-Neprilysin Inhibitor Prescribing Patterns in Patients Hospitalized for Heart Failure. *JAMA Cardiol*. 2024 Dec 11. doi: 10.1001/jamacardio.2024.3815. Epub ahead of print. PMID: 39661383.
212. Averbuch T, Zafari A, Islam S, Lee SF, Sankaranarayanan R, **Greene SJ**, Mamas MA, Pandey A, Van Spall HG. Comparative performance of risk prediction indices for mortality or readmission following heart failure hospitalization. *ESC Heart Fail*. 2025 Apr;12(2):1227-1236. doi: 10.1002/ehf2.15129. Epub 2025 Jan 21. PMID: 39835342; PMCID: PMC11911581.
213. Khan MS, Jamil A, Shakoor M, **Greene SJ**, Fonarow GC, Bhatt DL, DiMaio JM, Mack MJ, Butler J. Patient Enrollment for Cardiovascular Clinical Trials in the United States. *JAMA Cardiol*. 2025 Mar 1;10(3):298-300. doi: 10.1001/jamacardio.2024.5537. PMID: 39937520; PMCID: PMC11822591.
214. Waqas SA, Sohail MU, Saad M, Minhas AMK, **Greene SJ**, Fudim M, Fonarow GC, Abramov D, Khan MS, Ahmed R. Efficacy of GLP-1 Receptor Agonists in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis. *J Card Fail*. 2025 Feb 22:S1071-9164(25)00091-0. doi: 10.1016/j.cardfail.2025.01.022. Epub ahead of print. PMID: 39993464.
215. Shoji S, Solomon N, Chiswell K, Selvaraj S, Khouri MG, Lewsey SC, Baylor L, Bruno M, Fonarow GC, **Greene SJ**. Hospital-Level Variation and Predictive Model for Diagnosis of Transthyretin Amyloid Cardiomyopathy Among Patients Hospitalized Due to Heart Failure. *J Card Fail*. 2025 Mar 29:S1071-9164(25)00150-2. doi: 10.1016/j.cardfail.2025.03.013. Epub ahead of print. PMID: 40164406.
216. Haywood HB, Kaltenbach LA, Ikeaba U, Fonarow GC, Chiswell K, Kittipibul V, Khan MS, Gupta M, Uchehara B, Hammill BG, Butler J, Hernandez AF, Felker GM, **Greene SJ**. Site-Level Variation and Factors Associated With an Outpatient Intravenous Diuretic Strategy for Worsening Heart Failure. *Am J Cardiol*. 2025 Apr 1;247:3-5. doi: 10.1016/j.amjcard.2025.03.041. Epub ahead of print. PMID: 40180143.
217. **Greene SJ**, Gaggin HK, Bash LD, Lautsch D, Song Y, Zhou M, Signorovitch J, Stevenson AS, Blaustein RO, Butler J. Cardiologist-Reported Reasons for Not Titrating Guideline-Directed Medical Therapy for Heart Failure with Reduced Ejection Fraction. *J Card Fail*. 2025 May 11:S1071-9164(25)00206-4. doi: 10.1016/j.cardfail.2025.04.010. Epub ahead of print. PMID: 40360011.
218. **Greene SJ**, Corda S, McMullan CJ, Palombo G, Schooss C, Vlajnic V, Walkamp K, Senni M. Safety and tolerability of a 5 mg starting dose of vericiguat among patients with heart failure: The VELOCITY study. *Eur J Heart Fail*. 2025 May 19. doi: 10.1002/ejhf.3699. Epub ahead of print. PMID: 40389233.

219. Rizvi SK, Dhruve R, Keshvani N, Hendren N, Chadha DS, Ramakrishnan S, Nandekar A, Dasgupta U, Segar MW, Vaduganathan M, Butler J, Bhograj C, Pandey A, **Greene SJ**. Remote Optimization of Guideline-Directed Medical Therapy Using Home Monitoring in Heart Failure: The GOALS-HF Study. *J Card Fail*. 2025 May 20:S1071-9164(25)00208-8. doi: 10.1016/j.cardfail.2025.05.005. Epub ahead of print. PMID: 40403835.
220. **Greene SJ**, Kaltenbach LA, Fonarow GC, Chiswell K, Kittipibul V, Haywood HB, Khan MS, Hammill BG, Butler J, Hernandez AF, Felker GM. Clinical and financial implications of inpatient and outpatient management of worsening heart failure. *Eur J Heart Fail*. 2025 May 26. doi: 10.1002/ejhf.3702. Epub ahead of print. PMID: 40419411.
221. **Greene SJ**, Schilsky S, Roberts AW, Kabadi SM, McKindley DS, Preblich R, Rashkin J, Leeming RC, Sajedian RM, Russo AM. Real-World Health Care Resource Utilization and Costs Associated With First-Line Dronedronone Versus First-Line Ablation in Adults With Atrial Fibrillation. *Clin Cardiol*. 2025 Jun;48(6):e70145. doi: 10.1002/clc.70145. PMID: 40439231; PMCID: PMC12120900.
222. Ahmed M, Zulfiqar E, Shafiq A, Shahzad M, Hashmi TM, Ahmed R, Rana JS, Sidney S, **Greene SJ**, Mentz RJ, Fudim M, Fonarow GC. Type 2 Diabetes Mellitus-Related Mortality in the United States, 1999 to 2023. *JACC Adv*. 2025 Jul;4(7):101882. doi: 10.1016/j.jacadv.2025.101882. Epub 2025 Jun 18. PMID: 40532451; PMCID: PMC12212274.
223. El Rafei A, Gosch K, Manning ES, Ghajar A, Raghavan S, Maddox TM, Peterson PN, Fleming L, Arnold SV, Chan PS, **Greene SJ**, Fonarow GC, Jones PG, Allen LA, Hess PL. Sodium-Glucose Cotransporter 2 Inhibitor Use for Heart Failure in US Ambulatory Cardiovascular Care. *JAMA Cardiol*. 2025 Jul 9:e252145. doi: 10.1001/jamacardio.2025.2145. Epub ahead of print. PMID: 40632519; PMCID: PMC12242822.
224. **Greene SJ**, Sauer AJ, Böhm M, Bozkurt B, Butler J, Cleland JGF, Coats AJS, Desai NR, Grobbee DE, Kelepouris E, Pinto F, Rosano G, Donachie V, Fabien S, Waechter S, Crespo-Leiro MG, Hülsmann M, Kempf T, Pfister O, Pouleur AC, Saxena M, Schulz M, Volterrani M, Anker SD, Kosiborod MN. Management of patients with heart failure at high risk of hyperkalaemia: The CARE-HK in HF registry. *Eur J Heart Fail*. 2025 Aug 11. doi: 10.1002/ejhf.3800. Epub ahead of print. PMID: 40788620.
225. Waqas SA, Ali D, Afridi MK, Siddiqui HF, Nazir A, **Greene SJ**, Khan MS. Efficacy of GLP-1 receptor agonists among older adults: a meta-analysis of cardio-kidney outcome trials. *Arch Gerontol Geriatr*. 2025 Nov;138:105981. doi: 10.1016/j.archger.2025.105981. Epub 2025 Aug 8. PMID: 40812084.
226. Ahmed M, Zulfiqar E, Ashraf H, Hashmi TM, Ahmed R, Rana JS, **Greene SJ**, Mentz RJ, Fudim M, Fonarow GC. Reduced-dose vs full-dose direct oral anticoagulants for extended treatment of venous thromboembolism: a meta-analysis of randomized controlled trials. *Res Pract Thromb Haemost*. 2025 Aug 5;9(5):102996. doi: 10.1016/j.rpth.2025.102996. PMID: 40918033; PMCID: PMC12410526.
227. **Greene SJ**, Coyle CR, Hancock LN, Tebbs KW, Barlow SG, Stevenson AS, Obi EN. Eligible patients with heart failure prescribed vs. not prescribed vericiguat in the United States. *Front*

- Cardiovasc Med. 2025 Aug 26;12:1633435. doi: 10.3389/fcvm.2025.1633435. PMID: 40933314; PMCID: PMC12417153.
228. Waqas SA, Aamir J, Ali D, Imran Z, Salim H, Hassan A, Khan S, **Greene SJ**, Ahmed R. Stroke Mortality in the United States from 1968 to 2023: A CDC WONDER Analysis. *Int J Stroke*. 2025 Sep 21:17474930251384043. doi: 10.1177/17474930251384043. Epub ahead of print. PMID: 40976877.
 229. Siddiqi TJ, Khan MS, Waqas SA, Van Spall HGC, Shapiro MD, Fonarow GC, Januzzi JL, Afzal AM, Pandey A, Butler J, **Greene SJ**. Effect of glucagon-like peptide-1 receptor agonists on heart failure outcomes and cardiovascular death across varying cardiovascular-kidney-metabolic comorbidity. *Eur J Heart Fail*. 2025 Sep 22. doi: 10.1002/ejhf.70048. Epub ahead of print. PMID: 40977256.
 230. Waqas SA, Imran Z, Bilal AR, Ahmed S, Gaba H, Chew NWS, **Greene SJ**, Khan MS. Efficacy of clopidogrel monotherapy versus aspirin monotherapy after percutaneous coronary intervention. *J Thromb Thrombolysis*. 2025 Oct 10. doi: 10.1007/s11239-025-03185-0. Epub ahead of print. PMID: 41071255.
 231. Green MD, Mentz RJ, **Greene SJ**, Hammill BG, Essien UR, Xian Y, Michos ED, Thorpe RJ Jr, Dupre ME, Mac Grory B, Chiu CT, O'Brien EC, Lusk JB. Cardiovascular Multimorbidity in Older Adults in the United States by Race and Sex. *JACC Adv*. 2025 Oct 21;4(11 Pt 1):102103. doi: 10.1016/j.jacadv.2025.102103. Epub ahead of print. PMID: 41124990.
 232. Haywood HB, Ayodele I, Fonarow GC, Alhanti B, Van Spall HG, Pandey A, Lewsey SC, Butler J, **Greene SJ**. Potential Patient Eligibility for Hospital at Home for Management of Worsening Heart Failure in the United States. *J Card Fail*. 2025 Nov 7:S1071-9164(25)00470-1. doi: 10.1016/j.cardfail.2025.09.038. Epub ahead of print. PMID: 41207470.
 233. Shoji S, Ikeaba U, Fonarow GC, Selvaraj S, Lewsey SC, Pandey A, Khouri MG, Alhanti B, McDermott JJ, Wright J, Vaduganathan M, **Greene SJ**. Clinical Outcomes and Health Care Costs in Patients Hospitalized With Heart Failure and Transthyretin Amyloid Cardiomyopathy: Findings From GWTG-HF. *J Card Fail*. 2025 Nov 8:S1071-9164(25)00508-1. doi: 10.1016/j.cardfail.2025.10.007. Epub ahead of print. PMID: 41213322.
 234. Shah A, McDermott J, Rao VN, Gupta M, Barnes SG, Green CL, Caberwal H, Mentz RJ, **Greene SJ**. In-Hospital Virtual Consultation to Implement Guideline-Directed Medical Therapy for Cardiovascular-Kidney-Metabolic Disease: The IMPLEMENT-CRM Randomized Trial. *JACC Heart Fail*. 2025 Nov 11:102755. doi: 10.1016/j.jchf.2025.102755. Epub ahead of print. PMID: 41222533.
 235. Ahmed M, Abbas F, Khan S, Qureshi S, Khan GT, Shafiq SB, Imran W, Waqas SA, Fudim M, Fonarow GC, **Greene SJ**, Khan MS. Trends and Projections in Hypertension-Related Mortality in the United States: A 1979-2050 CDC WONDER Analysis. *High Blood Press Cardiovasc Prev*. 2025 Dec 24. doi: 10.1007/s40292-025-00775-0. Epub ahead of print. PMID: 41442018.
 236. **Greene SJ**, Michel A, Lecomte C, Manca P, Holl K, Senni M. Initiation, titration, and safety of vericiguat for treatment of heart failure in United States clinical practice. *Am Heart J Plus*.

2026 Jan 13;62:100721. doi: 10.1016/j.ahjo.2026.100721. PMID: 41586334; PMCID: PMC12830299.

237. Khan S, Kamil A, Khalid N, Baig M, Hussain M, Hassan M, Qureshi AA, Pirih FNU, Shaikh Z, Waqas SA, **Greene SJ**, Fonarow GC, Chigurupati HD, Łajczak P. Temporal trends and projections in Hypertension with Substance Use-related mortality, 1999-2035: Insights from the CDC WONDER database. *Clin Res Cardiol*. 2026 Jan 26. doi: 10.1007/s00392-026-02847-0. Epub ahead of print. PMID: 41586855.
238. **Greene SJ**, Xu H, Chiswell K, Felker GM, Lewsey SC, Divanji PH, Goertz HP, Heitner SB, Shreay S, Pandey A, Yancy CW, Butler J, Fonarow GC. One-Year Outcomes in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction Prescribed Quadruple Medical Therapy at Discharge. *JAMA Cardiol*. 2026 Jan 28:e255339. doi: 10.1001/jamacardio.2025.5339. Epub ahead of print. PMID: 41604197; PMCID: PMC12853277.
239. **Greene SJ**, Xu H, Chiswell K, Felker GM, Lewsey SC, Divanji PH, Goertz HP, Heitner SB, Butler J, Fonarow GC. Residual Risk Despite Quadruple Medical Therapy for Men vs Women Hospitalized for Heart Failure With Reduced Ejection Fraction. *JACC Heart Fail*. 2026 Feb 2:102939. doi: 10.1016/j.jchf.2026.102939. Epub ahead of print. PMID: 41627274.
240. Ibrahim M, Kashif A, Arfin SMW, Mubeen M, Zafar A, Balach R, Musani MH, **Greene SJ**, Fonarow GC, Sohail MU. Efficacy and Safety of Mavacamten and Aficamten in Obstructive and Non-obstructive Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis. *Crit Pathw Cardiol*. 2026 Jan 30. doi: 10.1097/HPC.0000000000000418. Epub ahead of print. PMID: 41641607.
241. Ibrahim M, Tariq S, Afridi MK, Zafar A, Khamisani FA, Aminpoor H, Arfin SMW, Fonarow GC, **Greene SJ**, Musani MH, Waqas SA. Potent P2Y12 Inhibitor Monotherapy Versus Dual Antiplatelet Therapy After Percutaneous Coronary Intervention for Acute Coronary Syndromes: A Systematic Review and Meta-Analysis. *Clin Appl Thromb Hemost*. 2026 Jan-Dec;32:10760296261422490. doi: 10.1177/10760296261422490. Epub 2026 Feb 11. PMID: 41671172; PMCID: PMC12901862.
242. Ahmed M, Zulfiqar E, Hashmi TM, Zia R, Ashraf H, Naveed MA, Ahmed R, Rana JS, Ahmed F, **Greene SJ**, Fudim M, Mentz RJ, Fonarow GC. Intravenous ferric carboxymaltose in patients with heart failure and iron deficiency: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. *ESC Heart Fail*. 2026 Feb 3;13(1):xvaf018. doi: 10.1093/escfh/xvaf018. PMID: 41711738.
243. Sinha A, Arrington J, Bashi A, **Greene SJ**, Jelovsek JE, Amundsen CL. The Association of Nocturia and Major Cardiovascular Events: A Bayesian Analysis. *Urogynecology (Phila)*. 2026 Mar 1;32(3):289-295. doi: 10.1097/SPV.0000000000001801. PMID: 41712279.

B. Peer-Reviewed Published Scientific Reviews:

1. Gheorghide M, Marti CN, Sabbah HN, Roessig L, **Greene SJ**, Böhm M, Burnett JC, Campia U, Cleland JG, Collins SP, Fonarow GC, Levy PD, Metra M, Pitt B, Ponikowski P, Sato N,

- Voors AA, Stasch JP, Butler J; Academic Research Team in Heart Failure (ART-HF). Soluble guanylate cyclase: a potential therapeutic target for heart failure. *Heart Fail Rev.* 2013 Mar;18(2):123-34. doi: 10.1007/s10741-012-9323-1. PMID: 22622468.
2. Gheorghiade M, Vaduganathan M, Fonarow GC, **Greene SJ**, Greenberg BH, Liu PP, Massie BM, Mehra MR, Metra M, Zannad F, Cleland JG, van Veldhuisen DJ, Shah AN, Butler J. Anticoagulation in heart failure: current status and future direction. *Heart Fail Rev.* 2013 Nov;18(6):797-813. doi: 10.1007/s10741-012-9343-x. PMID: 22987320.
 3. Vaduganathan M, **Greene SJ**, Butler J, Sabbah HN, Shantsila E, Lip GY, Gheorghiade M. The immunological axis in heart failure: importance of the leukocyte differential. *Heart Fail Rev.* 2013 Nov;18(6):835-45. doi: 10.1007/s10741-012-9352-9. PMID: 23054221.
 4. Gheorghiade M, Vaduganathan M, **Greene SJ**, Mentz RJ, Adams KF Jr, Anker SD, Arnold M, Baschiera F, Cleland JG, Cotter G, Fonarow GC, Giordano C, Metra M, Misselwitz F, Mühlhofer E, Nodari S, Frank Peacock W, Pieske BM, Sabbah HN, Sato N, Shah MR, Stockbridge NL, Teerlink JR, van Veldhuisen DJ, Zalewski A, Zannad F, Butler J. Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. *Heart Fail Rev.* 2014 Mar;19(2):135-52. doi: 10.1007/s10741-012-9361-8. PMID: 23099992; PMCID: PMC4161017.
 5. Vaduganathan M, **Greene SJ**, Ambrosy AP, Gheorghiade M, Butler J. The disconnect between phase II and phase III trials of drugs for heart failure. *Nat Rev Cardiol.* 2013 Feb;10(2):85-97. doi: 10.1038/nrcardio.2012.181. Epub 2013 Jan 8. PMID: 23296069.
 6. **Greene SJ**, Gheorghiade M, Borlaug BA, Pieske B, Vaduganathan M, Burnett JC Jr, Roessig L, Stasch JP, Solomon SD, Paulus WJ, Butler J. The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction. *J Am Heart Assoc.* 2013 Dec 11;2(6):e000536. doi: 10.1161/JAHA.113.000536. PMID: 24334823; PMCID: PMC3886746.
 7. Ambrosy AP, Fonarow GC, Butler J, Chioncel O, **Greene SJ**, Vaduganathan M, Nodari S, Lam CSP, Sato N, Shah AN, Gheorghiade M. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. *J Am Coll Cardiol.* 2014 Apr 1;63(12):1123-1133. doi: 10.1016/j.jacc.2013.11.053. Epub 2014 Feb 5. PMID: 24491689.
 8. Parrinello G, **Greene SJ**, Torres D, Alderman M, Bonventre JV, Di Pasquale P, Gargani L, Nohria A, Fonarow GC, Vaduganathan M, Butler J, Paterna S, Stevenson LW, Gheorghiade M. Water and sodium in heart failure: a spotlight on congestion. *Heart Fail Rev.* 2015 Jan;20(1):13-24. doi: 10.1007/s10741-014-9438-7. PMID: 24942806; PMCID: PMC4405162.
 9. Maisel A, Xue Y, **Greene SJ**, Pang PS, Januzzi JL, Piña IL, DeFilippi C, Butler J. The potential role of natriuretic peptide-guided management for patients hospitalized for heart failure. *J Card Fail.* 2015 Mar;21(3):233-9. doi: 10.1016/j.cardfail.2014.11.009. Epub 2014 Nov 26. PMID: 25433362.
 10. Harinstein ME, Butler J, **Greene SJ**, Fonarow GC, Stockbridge NL, O'Connor CM, Pfeffer MA, Mehra MR, Solomon SD, Yancy CW, Fiuzat M, Mentz RJ, Collins SP, McMurray JJ, Vaduganathan M, Dunnmon PM, Rosano GM, Dinh W, Misselwitz F, Bonow RO, Gheorghiade M. Site selection for heart failure clinical trials in the USA. *Heart Fail Rev.* 2015 Jul;20(4):375-83. doi: 10.1007/s10741-015-9473-z. PMID: 25649127.

11. Dei Cas A, Khan SS, Butler J, Mentz RJ, Bonow RO, Avogaro A, Tschoepe D, Doehner W, **Greene SJ**, Senni M, Gheorghiade M, Fonarow GC. Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. *JACC Heart Fail.* 2015 Feb;3(2):136-45. doi: 10.1016/j.jchf.2014.08.004. PMID: 25660838.
12. **Greene SJ**, Fonarow GC, Vaduganathan M, Khan SS, Butler J, Gheorghiade M. The vulnerable phase after hospitalization for heart failure. *Nat Rev Cardiol.* 2015 Apr;12(4):220-9. doi: 10.1038/nrcardio.2015.14. Epub 2015 Feb 10. PMID: 25666406.
13. Echouffo-Tcheugui JB, **Greene SJ**, Papadimitriou L, Zannad F, Yancy CW, Gheorghiade M, Butler J. Population risk prediction models for incident heart failure: a systematic review. *Circ Heart Fail.* 2015 May;8(3):438-47. doi: 10.1161/CIRCHEARTFAILURE.114.001896. Epub 2015 Mar 3. PMID: 25737496.
14. Vaduganathan M, Butler J, Roessig L, Fonarow GC, **Greene SJ**, Metra M, Cotter G, Kupfer S, Zalewski A, Sato N, Filippatos G, Gheorghiade M. Clinical trials in hospitalized heart failure patients: targeting interventions to optimal phenotypic subpopulations. *Heart Fail Rev.* 2015 Jul;20(4):393-400. doi: 10.1007/s10741-015-9485-8. PMID: 25894076.
15. Vaduganathan M, Mentz RJ, **Greene SJ**, Senni M, Sato N, Nodari S, Butler J, Gheorghiade M. Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists. *Expert Rev Cardiovasc Ther.* 2015;13(7):799-809. doi: 10.1586/14779072.2015.1053872. PMID: 26106934.
16. Butler J, Gheorghiade M, Kelkar A, Fonarow GC, Anker S, **Greene SJ**, Papadimitriou L, Collins S, Ruschitzka F, Yancy CW, Teerlink JR, Adams K, Cotter G, Ponikowski P, Felker GM, Metra M, Filippatos G. In-hospital worsening heart failure. *Eur J Heart Fail.* 2015 Nov;17(11):1104-13. doi: 10.1002/ejhf.333. Epub 2015 Aug 3. PMID: 26235192.
17. Kelkar AA, Butler J, Schelbert EB, **Greene SJ**, Quyyumi AA, Bonow RO, Cohen I, Gheorghiade M, Lipinski MJ, Sun W, Luger D, Epstein SE. Mechanisms Contributing to the Progression of Ischemic and Nonischemic Dilated Cardiomyopathy: Possible Modulating Effects of Paracrine Activities of Stem Cells. *J Am Coll Cardiol.* 2015 Nov 3;66(18):2038-2047. doi: 10.1016/j.jacc.2015.09.010. PMID: 26516007.
18. **Greene SJ**, Sabbah HN, Butler J, Voors AA, Albrecht-Küpper BE, Düngen HD, Dinh W, Gheorghiade M. Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure. *Heart Fail Rev.* 2016 Jan;21(1):95-102. doi: 10.1007/s10741-015-9522-7. PMID: 26701329.
19. Chioncel O, Collins SP, **Greene SJ**, Ambrosy AP, Vaduganathan M, Macarie C, Butler J, Gheorghiade M. Natriuretic peptide-guided management in heart failure. *J Cardiovasc Med (Hagerstown).* 2016 Aug;17(8):556-68. doi: 10.2459/JCM.0000000000000329. PMID: 27110656.
20. Mentz RJ, Roessig L, Greenberg BH, Sato N, Shinagawa K, Yeo D, Kwok BW, Reyes EB, Krum H, Pieske B, **Greene SJ**, Ambrosy AP, Kelly JP, Zannad F, Pitt B, Lam CS. Heart Failure Clinical Trials in East and Southeast Asia: Understanding the Importance and Defining the Next Steps. *JACC Heart Fail.* 2016 Jun;4(6):419-27. doi: 10.1016/j.jchf.2016.01.013. PMID: 27256745; PMCID: PMC4893168.

21. Vaduganathan M, Samman-Tahhan A, Patel RB, Kelkar A, Papadimitriou L, Georgiopoulou VV, **Greene SJ**, Kalogeropoulos AP, Peterson E, Fonarow GC, Gheorghiade M, Butler J. Association between funding sources and the scope and outcomes of cardiovascular clinical trials: A systematic review. *Int J Cardiol.* 2017 Mar 1;230:301-303. doi: 10.1016/j.ijcard.2016.12.119. Epub 2016 Dec 22. PMID: 28041703.
22. Senni M, **Greene SJ**, Butler J, Fonarow GC, Gheorghiade M. Drug Development for Heart Failure With Preserved Ejection Fraction: What Pieces Are Missing From the Puzzle? *Can J Cardiol.* 2017 Jun;33(6):768-776. doi: 10.1016/j.cjca.2017.03.013. Epub 2017 Mar 25. PMID: 28545624.
23. Chioncel O, Collins SP, **Greene SJ**, Pang PS, Ambrosy AP, Antohi EL, Vaduganathan M, Butler J, Gheorghiade M. Predictors of Post-discharge Mortality Among Patients Hospitalized for Acute Heart Failure. *Card Fail Rev.* 2017 Nov;3(2):122-129. doi: 10.15420/cfr.2017:12:1. PMID: 29387465; PMCID: PMC5739905.
24. **Greene SJ**, Mentz RJ, Felker GM. Outpatient Worsening Heart Failure as a Target for Therapy: A Review. *JAMA Cardiol.* 2018 Mar 1;3(3):252-259. doi: 10.1001/jamacardio.2017.5250. PMID: 29387880; PMCID: PMC7474527.
25. Ambrosy AP, Mentz RJ, Fiuzat M, Cleland JGF, **Greene SJ**, O'Connor CM, Teerlink JR, Zannad F, Solomon SD. The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions. *Eur J Heart Fail.* 2018 Jun;20(6):963-972. doi: 10.1002/ejhf.1159. Epub 2018 Feb 21. Erratum in: *Eur J Heart Fail.* 2019 Jun;21(6):819. PMID: 29464817.
26. **Greene SJ**, Vaduganathan M, Khan MS, Bakris GL, Weir MR, Seltzer JH, Sattar N, McGuire DK, Januzzi JL, Stockbridge N, Butler J. Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. *J Am Coll Cardiol.* 2018 Mar 27;71(12):1379-1390. doi: 10.1016/j.jacc.2018.01.047. Epub 2018 Mar 10. PMID: 29534825; PMCID: PMC5832063.
27. Njoroge JN, Cheema B, Ambrosy AP, **Greene SJ**, Collins SP, Vaduganathan M, Mebazaa A, Chioncel O, Butler J, Gheorghiade M. Expanded algorithm for managing patients with acute decompensated heart failure. *Heart Fail Rev.* 2018 Jul;23(4):597-607. doi: 10.1007/s10741-018-9697-9. PMID: 29611010; PMCID: PMC6551605.
28. Samman Tahhan A, Vaduganathan M, Kumar S, Okafor M, **Greene SJ**, Butler J. Design Elements and Enrollment Patterns of Contemporary Trials in Heart Failure With Preserved Ejection Fraction: A Systematic Review. *JACC Heart Fail.* 2018 Aug;6(8):714-717. doi: 10.1016/j.jchf.2018.04.014. Epub 2018 Jul 11. PMID: 30007553; PMCID: PMC7473468.
29. Tahhan AS, Vaduganathan M, **Greene SJ**, Fonarow GC, Fiuzat M, Jessup M, Lindenfeld J, O'Connor CM, Butler J. Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials: A Systematic Review. *JAMA Cardiol.* 2018 Oct 1;3(10):1011-1019. doi: 10.1001/jamacardio.2018.2559. PMID: 30140928.
30. **Greene SJ**, Mentz RJ, Fiuzat M, Butler J, Solomon SD, Ambrosy AP, Mehta C, Teerlink JR, Zannad F, O'Connor CM. Reassessing the Role of Surrogate End Points in Drug Development

for Heart Failure. *Circulation*. 2018 Sep 4;138(10):1039-1053. doi: 10.1161/CIRCULATIONAHA.118.034668. PMID: 30354535; PMCID: PMC6205720.

31. Bhagat AA, **Greene SJ**, Vaduganathan M, Fonarow GC, Butler J. Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization. *JACC Heart Fail*. 2019 Jan;7(1):1-12. doi: 10.1016/j.jchf.2018.06.011. Epub 2018 Nov 7. PMID: 30414818; PMCID: PMC8053043.
32. Marti CN, Fonarow GC, Anker SD, Yancy C, Vaduganathan M, **Greene SJ**, Ahmed A, Januzzi JL, Gheorghiade M, Filippatos G, Butler J. Medication dosing for heart failure with reduced ejection fraction - opportunities and challenges. *Eur J Heart Fail*. 2019 Mar;21(3):286-296. doi: 10.1002/ejhf.1351. Epub 2018 Dec 10. PMID: 30537163; PMCID: PMC6528811.
33. Eisenstein EL, Prather K, **Greene SJ**, Harding T, Harrington A, Gabriel D, Jones I, Mentz RJ, Velazquez EJ, Anstrom KJ. Death: The Simple Clinical Trial Endpoint. *Stud Health Technol Inform*. 2019;257:86-91. PMID: 30741178; PMCID: PMC8228236.
34. Butler J, Packer M, **Greene SJ**, Fiuzat M, Anker SD, Anstrom KJ, Carson PE, Cooper LB, Fonarow GC, Hernandez AF, Januzzi JL Jr, Jessup M, Kalyani RR, Kaul S, Kosiborod M, Lindenfeld J, McGuire DK, Sabatine MS, Solomon SD, Teerlink JR, Vaduganathan M, Yancy CW, Stockbridge N, O'Connor CM. Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues. *Circulation*. 2019 Dec 17;140(25):2108-2118. doi: 10.1161/CIRCULATIONAHA.119.042155. Epub 2019 Dec 16. PMID: 31841369; PMCID: PMC7027964.
35. Brooksbank JA, **Greene SJ**, DeWald TA, Mentz RJ. Body surface area and medication dosing in patients with heart failure with reduced ejection fraction. *Trends Cardiovasc Med*. 2021 Feb;31(2):111-116. doi: 10.1016/j.tcm.2019.12.011. Epub 2020 Jan 15. PMID: 32008834.
36. Tahhan AS, Vaduganathan M, **Greene SJ**, Alrohaibani A, Raad M, Gafeer M, Mehran R, Fonarow GC, Douglas PS, Bhatt DL, Butler J. Enrollment of Older Patients, Women, and Racial/Ethnic Minority Groups in Contemporary Acute Coronary Syndrome Clinical Trials: A Systematic Review. *JAMA Cardiol*. 2020 Jun 1;5(6):714-722. doi: 10.1001/jamacardio.2020.0359. PMID: 32211813.
37. Cosiano MF, Tobin R, Mentz RJ, **Greene SJ**. Physical Functioning in Heart Failure With Preserved Ejection Fraction. *J Card Fail*. 2021 Sep;27(9):1002-1016. doi: 10.1016/j.cardfail.2021.04.013. Epub 2021 May 12. PMID: 33991684.
38. Grubb AF, **Greene SJ**, Fudim M, Dewald T, Mentz RJ. Drugs of Abuse and Heart Failure. *J Card Fail*. 2021 Nov;27(11):1260-1275. doi: 10.1016/j.cardfail.2021.05.023. Epub 2021 Jun 13. PMID: 34133967.
39. Khan MS, Khan F, Fonarow GC, Sreenivasan J, **Greene SJ**, Khan SU, Usman MS, Vaduganathan M, Fudim M, Anker SD, Butler J. Dietary interventions and nutritional supplements for heart failure: a systematic appraisal and evidence map. *Eur J Heart Fail*. 2021 Sep;23(9):1468-1476. doi: 10.1002/ejhf.2278. Epub 2021 Jul 8. PMID: 34173307.
40. Rao VN, Murray E, Butler J, Cooper LB, Cox ZL, Fiuzat M, Green JB, Lindenfeld J, McGuire DK, Nassif ME, O'Brien C, Pagidipati N, Sharma K, Vaduganathan M, Vardeny O, Fonarow

- GC, Mentz RJ, **Greene SJ**. In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction. *J Am Coll Cardiol*. 2021 Nov 16;78(20):2004-2012. doi: 10.1016/j.jacc.2021.08.064. PMID: 34763778; PMCID: PMC9766421.
41. Tomasoni D, Fonarow GC, Adamo M, Anker SD, Butler J, Coats AJS, Filippatos G, **Greene SJ**, McDonagh TA, Ponikowski P, Rosano G, Seferovic P, Vaduganathan M, Voors AA, Metra M. Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction. *Eur J Heart Fail*. 2022 Mar;24(3):431-441. doi: 10.1002/ejhf.2397. Epub 2022 Jan 17. PMID: 34894038; PMCID: PMC9303969.
 42. Peters AE, Mentz RJ, DeWald TA, **Greene SJ**. An evaluation of torsemide in patients with heart failure and renal disease. *Expert Rev Cardiovasc Ther*. 2022 Jan;20(1):5-11. doi: 10.1080/14779072.2022.2022474. Epub 2022 Jan 3. PMID: 34936522; PMCID: PMC8887994.
 43. Usman MS, Van Spall HGC, **Greene SJ**, Pandey A, McGuire DK, Ali ZA, Mentz RJ, Fonarow GC, Spertus JA, Anker SD, Butler J, James SK, Khan MS. The need for increased pragmatism in cardiovascular clinical trials. *Nat Rev Cardiol*. 2022 Nov;19(11):737-750. doi: 10.1038/s41569-022-00705-w. Epub 2022 May 17. PMID: 35581337; PMCID: PMC9112643.
 44. Gautam N, Ghanta SN, Clausen A, Saluja P, Sivakumar K, Dhar G, Chang Q, DeMazumder D, Rabbat MG, **Greene SJ**, Fudim M, Al'Aref SJ. Contemporary Applications of Machine Learning for Device Therapy in Heart Failure. *JACC Heart Fail*. 2022 Sep;10(9):603-622. doi: 10.1016/j.jchf.2022.06.011. PMID: 36049812.
 45. Khan MS, Ahmed A, **Greene SJ**, Fiuzat M, Kittleson MM, Butler J, Bakris GL, Fonarow GC. Managing Heart Failure in Patients on Dialysis: State-of-the-Art Review. *J Card Fail*. 2023 Jan;29(1):87-107. doi: 10.1016/j.cardfail.2022.09.013. Epub 2022 Oct 13. PMID: 36243339.
 46. Khan MS, Shahid I, **Greene SJ**, Mentz RJ, DeVore AD, Butler J. Mechanisms of current therapeutic strategies for heart failure: more questions than answers? *Cardiovasc Res*. 2023 Feb 3;118(18):3467-3481. doi: 10.1093/cvr/cvac187. PMID: 36536991.
 47. **Greene SJ**, Bauersachs J, Brugts JJ, Ezekowitz JA, Lam CSP, Lund LH, Ponikowski P, Voors AA, Zannad F, Zieroth S, Butler J. Worsening Heart Failure: Nomenclature, Epidemiology, and Future Directions: JACC Review Topic of the Week. *J Am Coll Cardiol*. 2023 Jan 31;81(4):413-424. doi: 10.1016/j.jacc.2022.11.023. PMID: 36697141.
 48. Siddiqi AK, **Greene SJ**, Fudim M, Mentz RJ, Butler J, Khan MS. Vericiguat for the treatment of heart failure with reduced ejection fraction. *Expert Rev Cardiovasc Ther*. 2023 Mar 7. doi: 10.1080/14779072.2023.2189101. Epub ahead of print. PMID: 36881733.
 49. Khan MS, Usman MS, Talha KM, Van Spall HGC, **Greene SJ**, Vaduganathan M, Khan SS, Mills NL, Ali ZA, Mentz RJ, Fonarow GC, Rao SV, Spertus JA, Roe MT, Anker SD, James SK, Butler J, McGuire DK. Leveraging electronic health records to streamline the conduct of cardiovascular clinical trials. *Eur Heart J*. 2023 Jun 1;44(21):1890-1909. doi: 10.1093/eurheartj/ehad171. PMID: 37098746.

50. Patolia H, Khan MS, Fonarow GC, Butler J, **Greene SJ**. Implementing Guideline-Directed Medical Therapy for Heart Failure: JACC Focus Seminar 1/3. *J Am Coll Cardiol*. 2023 Aug 8;82(6):529-543. doi: 10.1016/j.jacc.2023.03.430. PMID: 37532424.
51. **Greene SJ**, Bauersachs J, Brugts JJ, Ezekowitz JA, Filippatos G, Gustafsson F, Lam CSP, Lund LH, Mentz RJ, Pieske B, Ponikowski P, Senni M, Skopicki N, Voors AA, Zannad F, Zieroth S, Butler J. Management of Worsening Heart Failure With Reduced Ejection Fraction: JACC Focus Seminar 3/3. *J Am Coll Cardiol*. 2023 Aug 8;82(6):559-571. doi: 10.1016/j.jacc.2023.04.057. PMID: 37532426.
52. Khan MS, Arshad MS, **Greene SJ**, Van Spall HGC, Pandey A, Vemulapalli S, Perakslis E, Butler J. Artificial Intelligence and Heart Failure: A State-of-the-Art Review. *Eur J Heart Fail*. 2023 Aug 10. doi: 10.1002/ejhf.2994. Epub ahead of print. PMID: 37560778.
53. Haywood HB, Fonarow GC, Khan MS, Van Spall HGC, Morris AA, Nassif ME, Kittleson MM, Butler J, **Greene SJ**. Hospital at Home as a Treatment Strategy for Worsening Heart Failure. *Circ Heart Fail*. 2023 Aug 30:e010456. doi: 10.1161/CIRCHEARTFAILURE.122.010456. Epub ahead of print. PMID: 37646170.
54. Talha KM, **Greene SJ**, Butler J, Khan MS. Frailty and Its Implications in Heart Failure with Reduced Ejection Fraction: Impact on Prognosis and Treatment. *Cardiol Clin*. 2023 Nov;41(4):525-536. doi: 10.1016/j.ccl.2023.06.002. Epub 2023 Jul 14. PMID: 37743075.
55. Khan MS, Usman MS, Van Spall HGC, **Greene SJ**, Baqal O, Felker GM, Bhatt DL, Januzzi JL, Butler J. Endpoint adjudication in cardiovascular clinical trials. *Eur Heart J*. 2023 Dec 7;44(46):4835-4846. doi: 10.1093/eurheartj/ehad718. PMID: 37935635.
56. Clephas PRD, Malgie J, Schaap J, Koudstaal S, Emans M, Linssen GCM, de Boer GA, van Heerebeek L, Borleffs CJW, Manintveld OC, van Empel V, van Wijk S, van den Heuvel M, da Fonseca C, Damman K, van Ramshorst J, van Kimmenade R, van de Ven ART, Tio RA, van Veghel D, Asselbergs FW, de Boer RA, van der Meer P, **Greene SJ**, Brunner-La Rocca HP, Brugts JJ. Guideline implementation, drug sequencing, and quality of care in heart failure: design and rationale of TITRATE-HF. *ESC Heart Fail*. 2023 Dec 8. doi: 10.1002/ehf2.14604. Epub ahead of print. PMID: 38064176.
57. **Greene SJ**, Butler J, Kosiborod MN. Chapter 3: Clinical Trials of Sodium-Glucose Co-Transporter-2 Inhibitors for Treatment of Heart Failure. *Am J Med*. 2024 Feb;137(2S):S25-S34. doi: 10.1016/j.amjmed.2023.04.019. PMID: 38184323.
58. Shahid I, Khan MS, Fonarow GC, Butler J, **Greene SJ**. Bridging gaps and optimizing implementation of guideline-directed medical therapy for heart failure. *Prog Cardiovasc Dis*. 2024 Jan-Feb;82:61-69. doi: 10.1016/j.pcad.2024.01.008. Epub 2024 Jan 18. PMID: 38244825.
59. Shariq K, Siddiqi TJ, Van Spall H, **Greene SJ**, Fudim M, DeVore AD, Pandey A, Butler J, Khan MS. Role of telemedicine in the management of obesity: State-of-the-art review. *Obes Rev*. 2024 Mar 26:e13734. doi: 10.1111/obr.13734. Epub ahead of print. PMID: 38528833.
60. Hamid A, **Greene SJ**, Mehta A, Butler J, Khan MS. Estimated Glomerular Filtration Rate Slope as an Endpoint in Cardiovascular Trials. *Curr Heart Fail Rep*. 2024 May 25. doi: 10.1007/s11897-024-00668-8. Epub ahead of print. PMID: 38795231.

61. Khan LA, Khan MS, Ambrosy AP, **Greene SJ**. Selective aldose reductase inhibition as a treatment for diabetic cardiomyopathy: summary of the ARISE-HF trial. *Heart Fail Rev*. 2024 Sep;29(5):1157-1160. doi: 10.1007/s10741-024-10427-5. Epub 2024 Jul 25. PMID: 39052147.
62. Oskouie S, Pandey A, Sauer AJ, **Greene SJ**, Mullens W, Khan MS, Quinn KL, Ho JE, Albert NM, Van Spall HG. From Hospital to Home: Evidence-Based Care for Worsening Heart Failure. *JACC Adv*. 2024 Jul 31;3(9):101131. doi: 10.1016/j.jacadv.2024.101131. PMID: 39184855
63. Shoji S, **Greene SJ**, Mentz RJ. Embracing an era of targeted combination therapy for heart failure with preserved ejection fraction. *Heart Fail Rev*. 2024 Aug 27. doi: 10.1007/s10741-024-10432-8. Epub ahead of print. PMID: 39187605
64. Talha KM, **Greene SJ**, Butler J, Khan MS. Frailty and Its Implications in Heart Failure with Reduced Ejection Fraction: Impact on Prognosis and Treatment. *Heart Fail Clin*. 2024 Oct;20(4):387-398. doi: 10.1016/j.hfc.2024.06.005. PMID: 39216924
65. Arshad MS, Jamil A, **Greene SJ**, Van Spall HGC, Fonarow GC, Butler J, Khan MS. In-hospital initiation of sodium-glucose co-transporter-2 inhibitors in patients with acute heart failure. *Heart Fail Rev*. 2025 Jan;30(1):89-101. doi: 10.1007/s10741-024-10446-2. Epub 2024 Oct 15. PMID: 39404914.
66. Chang AJ, Liang Y, Girouard MP, Bhatt AS, Sandhu AT, Sauer AJ, **Greene SJ**, Harrington J, Go AS, Ambrosy AP. Changing the paradigm in heart failure: shifting from treatment to prevention. *Heart Fail Rev*. 2025 Jan;30(1):177-189. doi: 10.1007/s10741-024-10454-2. Epub 2024 Oct 23. PMID: 39441333.
67. Siddiqi TJ, Packer M, Ezekowitz JA, Fonarow GC, **Greene SJ**, Kittleson M, Khan MS, Mentz RJ, Testani J, Voors AA, Butler J. Diuretic Potentiation Strategies in Acute Heart Failure. *JACC Heart Fail*. 2025 Jan;13(1):14-27. doi: 10.1016/j.jchf.2024.09.017. PMID: 39779178.
68. Shahid I, Khan MS, Butler J, Fonarow GC, **Greene SJ**. Initiation and sequencing of guideline-directed medical therapy for heart failure across the ejection fraction spectrum. *Heart Fail Rev*. 2025 May;30(3):515-523. doi: 10.1007/s10741-025-10481-7. Epub 2025 Jan 15. PMID: 39815071.
69. Khan LA, Jamil A, **Greene SJ**, Khan MS, Butler J. Aldosterone and Potassium in Heart Failure: Overcoming This Major Impediment in Clinical Practice. *Card Fail Rev*. 2024 Dec 20;10:e18. doi: 10.15420/cfr.2024.09. PMID: 39872850; PMCID: PMC11770538.
70. Kittipibul V, Ambrosy AP, **Greene SJ**. Myeloperoxidase inhibition in the landscape of anti-inflammatory therapies for heart failure with preserved ejection fraction: the ENDEAVOR trial. *Heart Fail Rev*. 2025 Feb 25. doi: 10.1007/s10741-025-10498-y. Epub ahead of print. PMID: 39998729.
71. Halaseh R, Sun GK, Bhatt AS, Chang AJ, Svetlichnaya J, Adatya S, Fudim M, **Greene SJ**, Bensimhon DR, Adler ED, Alexy T, Biegus J, Sauer AJ, Pang PS, Collins SP, Pandey A, Butler J, Ambrosy AP. Outpatient worsening heart failure: innovative decongestion strategies and health equity implications. *Heart Fail Rev*. 2025 Apr 5. doi: 10.1007/s10741-025-10509-y. Epub ahead of print. PMID: 40188318.

72. Khan MS, Rashid AM, Van Spall HGC, **Greene SJ**, Bhatt AS, Pandey A, Keshvani N, Mentz RJ, Ambrosy AP, DiMaio JM, Butler J. Integrating cardiovascular implementation science research within healthcare systems. *Prog Cardiovasc Dis*. 2025 Apr 15:S0033-0620(25)00059-3. doi: 10.1016/j.pcad.2025.04.005. Epub ahead of print. PMID: 40246187.
73. Tang AB, Lewsey SC, Yancy CW, Heidenreich PA, **Greene SJ**, Allen LA, Jessup M, Bolles M, Rutan C, Navar N, Thomas K, Fonarow GC. Get With the Guidelines-Heart Failure: Twenty Years in Review, Lessons Learned, and the Road Ahead. *Circ Heart Fail*. 2025 May 12:e012936. doi: 10.1161/CIRCHEARTFAILURE.125.012936. Epub ahead of print. PMID: 40351187.
74. Taub PR, **Greene SJ**, Fudim M. The role of finerenone in the concomitant management of chronic kidney disease-type 2 diabetes and the implication for heart failure prevention and treatment. *Heart Fail Rev*. 2025 Sep;30(5):971-984. doi: 10.1007/s10741-025-10520-3. Epub 2025 May 31. PMID: 40448875; PMCID: PMC12296780.
75. Beavers CJ, **Greene SJ**. Hyperkalemia in Heart Failure with Reduced Ejection Fraction: Implications and Management. *Heart Fail Rev*. 2025 Aug 22. doi: 10.1007/s10741-025-10549-4. Epub ahead of print. PMID: 40841869.
76. Keramida K, Musella F, Abdelhamid M, Sato N, **Greene SJ**, Farmakis D, Harrington J, Ambrosy AP. Victoria and Victor: event-driven lessons for integrating vericiguat into practice and reducing residual risk in HFrEF. *Heart Fail Rev*. 2025 Dec 11;31(1):13. doi: 10.1007/s10741-025-10587-y. PMID: 41379379.
77. Mansoor T, Ismayl M, Virani SS, Nambi V, Misra A, Jia X, Fudim M, **Greene SJ**, Sperling L, Parikh S, Rifai MA, Koshy SK, Abramov D, Minhas AMK. Lipid-lowering therapies to target cardiac allograft vasculopathy after heart transplantation: Current evidence and future directions. *J Clin Lipidol*. 2025 Dec 4:S1933-2874(25)00526-4. doi: 10.1016/j.jacl.2025.12.001. Epub ahead of print. PMID: 41494936.

C. Editorials, and Peer-Reviewed Position and Background Papers:

1. Vaduganathan M, **Greene SJ**, Butler J, Gheorghiade M. Endpoints for diuresis: are we there yet? *J Am Coll Cardiol*. 2014 Mar 4;63(8):838-9. doi: 10.1016/j.jacc.2013.04.108. Epub 2013 Dec 4. PMID: 24315896.
2. Vaduganathan M, **Greene SJ**, Ambrosy AP, Gheorghiade M. Lipids, statins, and clinical outcomes in heart failure: rethinking the data. *Heart Fail Rev*. 2014 Nov;19(6):695-8. doi: 10.1007/s10741-014-9423-1. PMID: 24509934.
3. Vaduganathan M, **Greene SJ**, Fonarow GC, Bonow RO, Butler J, Gheorghiade M. Coronary artery disease in patients with heart failure: incidental, coincidental, or a target for therapy? *Am J Med*. 2014 Jul;127(7):574-8. doi: 10.1016/j.amjmed.2014.01.041. Epub 2014 Feb 19. PMID: 24561111.
4. **Greene SJ**, Alkhwam L, Vaduganathan M. Dual antiplatelet therapy after stent implantation. *JAMA*. 2014 Apr 9;311(14):1446. doi: 10.1001/jama.2014.2092. PMID: 24715081.

5. Vaduganathan M, **Greene SJ**, Fonarow GC, Voors AA, Butler J, Gheorghiade M. Hemoconcentration-guided diuresis in heart failure. *Am J Med*. 2014 Dec;127(12):1154-9. doi: 10.1016/j.amjmed.2014.06.009. Epub 2014 Jun 14. PMID: 24937157.
6. Vaduganathan M, **Greene SJ**. Influence of chronic kidney disease on warfarin therapy for atrial fibrillation. *JAMA*. 2014 Jun 25;311(24):2541-2. doi: 10.1001/jama.2014.5576. PMID: 25058089.
7. **Greene SJ**, Shah AN, Butler J, Ambrosy AP, Anker SD, Chioncel O, Collins SP, Dinh W, Dunnmon PM, Fonarow GC, Lam CS, Mentz RJ, Pieske B, Roessig L, Rosano GM, Sato N, Vaduganathan M, Gheorghiade M. Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries. *Am Heart J*. 2014 Aug;168(2):142-9. doi: 10.1016/j.ahj.2014.05.009. Epub 2014 May 24. PMID: 25066552; PMCID: PMC4160662.
8. **Greene SJ**, Gheorghiade M. Matching mechanism of death with mechanism of action: considerations for drug development for hospitalized heart failure. *J Am Coll Cardiol*. 2014 Oct 14;64(15):1599-601. doi: 10.1016/j.jacc.2014.06.1199. PMID: 25301464.
9. **Greene SJ**, Gheorghiade M. Reply: considerations for drug development for heart failure. *J Am Coll Cardiol*. 2015 Mar 17;65(10):1061-2. doi: 10.1016/j.jacc.2014.11.064. PMID: 25766958.
10. **Greene SJ**, Fonarow GC, Butler J. REPORT-HF: the unique blend of global heart failure registry and longitudinal cohort study. *Eur J Heart Fail*. 2015 May;17(5):472-4. doi: 10.1002/ejhf.264. Epub 2015 Apr 8. PMID: 25851696.
11. **Greene SJ**, Gheorghiade M. Same protocol, different continents, different patients: should we continue to conduct global heart failure trials? *Eur J Heart Fail*. 2015 Sep;17(9):875-8. doi: 10.1002/ejhf.335. Epub 2015 Aug 20. PMID: 26289544.
12. **Greene SJ**, Fonarow GC. Insulin resistance in heart failure: widening the divide between reduced and preserved ejection fraction? *Eur J Heart Fail*. 2015 Oct;17(10):991-3. doi: 10.1002/ejhf.337. Epub 2015 Sep 16. PMID: 26377227.
13. **Greene SJ**, Epstein SE, Kim RJ, Quyyumi AA, Cole RT, Anderson AS, Wilcox JE, Skopicki HA, Sikora S, Verkh L, Tankovich NI, Gheorghiade M, Butler J. Rationale and design of a randomized controlled trial of allogeneic mesenchymal stem cells in patients with nonischemic cardiomyopathy. *J Cardiovasc Med (Hagerstown)*. 2017 Apr;18(4):283-290. doi: 10.2459/JCM.0000000000000303. PMID: 26479144.
14. Gheorghiade M, Larson CJ, Shah SJ, **Greene SJ**, Cleland JG, Colucci WS, Dunnmon P, Epstein SE, Kim RJ, Parsey RV, Stockbridge N, Carr J, Dinh W, Krahn T, Kramer F, Wahlander K, Deckelbaum LI, Crandall D, Okada S, Senni M, Sikora S, Sabbah HN, Butler J. Developing New Treatments for Heart Failure: Focus on the Heart. *Circ Heart Fail*. 2016 May;9(5):e002727. doi: 10.1161/CIRCHEARTFAILURE.115.002727. PMID: 27166246.
15. Vaduganathan M, Patel RB, **Greene SJ**, Gheorghiade M. Targeting the vulnerable phase of heart failure: initiate novel therapies in stable patients prior to hospitalization. *Eur J Heart Fail*. 2016 Sep;18(9):1190-2. doi: 10.1002/ejhf.598. Epub 2016 Jun 23. PMID: 27339077.

16. Temporelli PL, Buda S, **Greene SJ**. Ruolo degli acidi grassi polinsaturi n-3 dopo sindrome coronarica acuta [Role of omega-3 polyunsaturated fatty acids after acute coronary syndrome]. *G Ital Cardiol (Rome)*. 2016 Jul-Aug;17(7 Suppl 1):3-10. Italian. doi: 10.1714/2336.25080. PMID: 27729661.
17. Brown DA, Perry JB, Allen ME, Sabbah HN, Stauffer BL, Shaikh SR, Cleland JG, Colucci WS, Butler J, Voors AA, Anker SD, Pitt B, Pieske B, Filippatos G, **Greene SJ**, Gheorghiade M. Expert consensus document: Mitochondrial function as a therapeutic target in heart failure. *Nat Rev Cardiol*. 2017 Apr;14(4):238-250. doi: 10.1038/nrcardio.2016.203. Epub 2016 Dec 22. PMID: 28004807; PMCID: PMC5350035.
18. **Greene SJ**, Vaduganathan M, Gheorghiade M. Finding the road to recovery: therapeutic and clinical trial implications of dysfunctional viable myocardium in heart failure with reduced ejection fraction. *Eur J Heart Fail*. 2017 Jul;19(7):870-872. doi: 10.1002/ejhf.842. Epub 2017 May 2. PMID: 28464398.
19. Cheema BS, Sabbah HN, **Greene SJ**, Gheorghiade M. Protein turnover in the failing heart: an ever-changing landscape. *Eur J Heart Fail*. 2017 Oct;19(10):1218-1221. doi: 10.1002/ejhf.905. Epub 2017 Aug 14. PMID: 28805968.
20. **Greene SJ**, Mentz RJ. Potential advantages of torsemide in patients with heart failure: more than just a 'water pill'? *Eur J Heart Fail*. 2018 Mar;20(3):471-473. doi: 10.1002/ejhf.1024. Epub 2017 Oct 29. PMID: 29082584; PMCID: PMC6457240.
21. **Greene SJ**, Felker GM. Considering the duration of heart failure: using the past to predict the future. *Eur J Heart Fail*. 2018 Feb;20(2):382-384. doi: 10.1002/ejhf.1064. Epub 2017 Nov 21. PMID: 29164734; PMCID: PMC6436553.
22. Patel RB, Vaduganathan M, **Greene SJ**, Butler J. Nomenclature in heart failure: a call for objective, reproducible, and biologically-driven terminology. *Eur J Heart Fail*. 2018 Oct;20(10):1379-1381. doi: 10.1002/ejhf.1231. Epub 2018 Jun 26. PMID: 29943879; PMCID: PMC6179933.
23. Mentz RJ, **Greene SJ**. Adding Troponin to the Puzzle of Heart Failure With Preserved Ejection Fraction: Marker or Mediator? *J Am Coll Cardiol*. 2018 Jul 3;72(1):41-44. doi: 10.1016/j.jacc.2018.04.038. PMID: 29957230; PMCID: PMC6726113.
24. **Greene SJ**, Felker GM. Innovation in Diuretic Therapy: The Missing Ingredient for Treating Worsening Heart Failure Outside the Hospital? *JACC Basic Transl Sci*. 2018 Mar 1;3(1):35-37. doi: 10.1016/j.jacbts.2018.01.002. PMID: 30062192; PMCID: PMC6058943.
25. **Greene SJ**, Felker GM, Butler J. Outpatient versus inpatient worsening heart failure: distinguishing biology and risk from location of care. *Eur J Heart Fail*. 2019 Jan;21(1):121-124. doi: 10.1002/ejhf.1341. Epub 2018 Nov 5. PMID: 30394644; PMCID: PMC6333499.
26. **Greene SJ**, Felker GM. The Urgency of Doing: Addressing Gaps in Use of Evidence-Based Medical Therapy for Heart Failure. *JACC Heart Fail*. 2019 Jan;7(1):22-24. doi: 10.1016/j.jchf.2018.11.006. PMID: 30606483.

27. **Greene SJ**, Butler J. Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus. *Circulation*. 2019 Jan 8;139(2):152-154. doi: 10.1161/CIRCULATIONAHA.118.037599. PMID: 30615507; PMCID: PMC6834062.
28. **Greene SJ**, Califf RM. Reframing Global Variation in Heart Failure Trials: Thinking Beyond Location on the Map. *JACC Heart Fail*. 2019 Apr;7(4):347-349. doi: 10.1016/j.jchf.2018.12.012. Epub 2019 Feb 6. PMID: 30738979; PMCID: PMC7437717.
29. **Greene SJ**, Fonarow GC, Butler J. Reply: Titration of Guideline-Directed Medical Therapy Improves Patient-Centered Outcomes in Heart Failure With Reduced Ejection Fraction. *J Am Coll Cardiol*. 2019 Sep 10;74(10):1426-1427. doi: 10.1016/j.jacc.2019.06.061. PMID: 31488284.
30. O'Brien EC, **Greene SJ**. Real-World Evidence for Medication Safety: Causal, Confounded, or Capable? *JACC Heart Fail*. 2019 Oct;7(10):846-848. doi: 10.1016/j.jchf.2019.05.003. Epub 2019 Sep 11. PMID: 31521681; PMCID: PMC7350085.
31. Myhre PL, Vaduganathan M, **Greene SJ**. Diagnosing heart failure with preserved ejection fraction in 2019: the search for a gold standard. *Eur J Heart Fail*. 2020 Mar;22(3):422-424. doi: 10.1002/ejhf.1638. Epub 2019 Dec 21. PMID: 31863672.
32. Khan MS, Butler J, **Greene SJ**. Patient-reported outcomes for heart failure with preserved ejection fraction: conducting quality studies on quality of life. *Eur J Heart Fail*. 2020 Jun;22(6):1019-1021. doi: 10.1002/ejhf.1762. Epub 2020 Mar 10. PMID: 32154649.
33. Khan MS, Butler J, **Greene SJ**. The real world of de novo heart failure: the next frontier for heart failure clinical trials? *Eur J Heart Fail*. 2020 Oct;22(10):1786-1789. doi: 10.1002/ejhf.1844. Epub 2020 May 6. PMID: 32374051.
34. **Greene SJ**, Fonarow GC, Butler J. Risk Profiles in Heart Failure: Baseline, Residual, Worsening, and Advanced Heart Failure Risk. *Circ Heart Fail*. 2020 Jun;13(6):e007132. doi: 10.1161/CIRCHEARTFAILURE.120.007132. Epub 2020 Jun 2. PMID: 32482088.
35. Mann DL, **Greene SJ**, Givertz MM, Vader JM, Starling RC, Ambrosy AP, Shah P, McNulty SE, Mahr C, Gupta D, Redfield MM, Lala A, Lewis GD, Mohammed SF, Giotra NA, DeVore AD, Gorodeski EZ, Desvigne-Nickens P, Hernandez AF, Braunwald E; LIFE Investigators. Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial. *JACC Heart Fail*. 2020 Oct;8(10):789-799. doi: 10.1016/j.jchf.2020.05.005. Epub 2020 Jun 10. Erratum in: *JACC Heart Fail*. 2020 Dec;8(12):1059. PMID: 32641226; PMCID: PMC7286640.
36. Khan MS, Butler J, **Greene SJ**. Recognizing the Significance of Outpatient Worsening Heart Failure. *J Am Heart Assoc*. 2020 Jul 21;9(14):e017485. doi: 10.1161/JAHA.120.017485. Epub 2020 Jul 14. PMID: 32662304; PMCID: PMC7660711.
37. **Greene SJ**, DeVore AD. The Maximally Tolerated Dose: The Key Context for Interpreting Subtarget Medication Dosing for Heart Failure. *JACC Heart Fail*. 2020 Sep;8(9):739-741. doi: 10.1016/j.jchf.2020.05.011. Epub 2020 Aug 12. PMID: 32800507.
38. Khan MS, Butler J, **Greene SJ**. The Time Is Now for Sodium Glucose Co-Transporter 2 Inhibitors for Heart Failure: A Call to Overcome Clinical Inertia. *Circ Heart Fail*. 2020

Dec;13(12):e008030. doi: 10.1161/CIRCHEARTFAILURE.120.008030. Epub 2020 Nov 9. PMID: 33161728.

39. **Greene SJ**, Adusumalli S, Albert NM, Hauptman PJ, Rich MW, Heidenreich PA, Butler J; Heart Failure Society of America Quality of Care Committee. Building a Heart Failure Clinic: A Practical Guide from the Heart Failure Society of America. *J Card Fail.* 2021 Jan;27(1):2-19. doi: 10.1016/j.cardfail.2020.10.008. Epub 2020 Oct 24. PMID: 33289664.
40. Bhatt AS, Abraham WT, Lindenfeld J, Bristow M, Carson PE, Felker GM, Fonarow GC, **Greene SJ**, Psofka MA, Solomon SD, Stockbridge N, Teerlink JR, Vaduganathan M, Wittes J, Fiuzat M, O'Connor CM, Butler J. Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory. *JACC Heart Fail.* 2021 Jan;9(1):1-12. doi: 10.1016/j.jchf.2020.10.014. Epub 2020 Dec 9. PMID: 33309582.
41. Felker GM, **Greene SJ**. Improving In-Hospital Diuretic Therapy for Heart Failure: The Need for High-Quality Evidence. *J Am Coll Cardiol.* 2021 Feb 16;77(6):709-712. doi: 10.1016/j.jacc.2020.12.018. PMID: 33573740.
42. **Greene SJ**, Velazquez EJ, Anstrom KJ, Eisenstein EL, Sapp S, Morgan S, Harding T, Sachdev V, Ketema F, Kim DY, Desvigne-Nickens P, Pitt B, Mentz RJ; TRANSFORM-HF Investigators. Pragmatic Design of Randomized Clinical Trials for Heart Failure: Rationale and Design of the TRANSFORM-HF Trial. *JACC Heart Fail.* 2021 May;9(5):325-335. doi: 10.1016/j.jchf.2021.01.013. Epub 2021 Mar 10. PMID: 33714745; PMCID: PMC8087639.
43. **Greene SJ**, Khan MS. Quadruple Medical Therapy for Heart Failure: Medications Working Together to Provide the Best Care. *J Am Coll Cardiol.* 2021 Mar 23;77(11):1408-1411. doi: 10.1016/j.jacc.2021.02.006. PMID: 33736822.
44. Khan MS, Fonarow GC, **Greene SJ**. Sodium-glucose co-transporter 2 inhibitors for heart failure: clinical trial efficacy and clinical practice effectiveness. *Eur J Heart Fail.* 2021 Jun;23(6):1023-1025. doi: 10.1002/ejhf.2170. Epub 2021 Apr 7. PMID: 33779013.
45. **Greene SJ**, Butler J, Fonarow GC. Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for Heart Failure-Optimizing Therapy With the Need for Speed. *JAMA Cardiol.* 2021 Jul 1;6(7):743-744. doi: 10.1001/jamacardio.2021.0496. PMID: 33787823.
46. **Greene SJ**, Fonarow GC. Clinical inertia and medical therapy for heart failure: the unintended harms of 'first, do no harm'. *Eur J Heart Fail.* 2021 Aug;23(8):1343-1345. doi: 10.1002/ejhf.2283. Epub 2021 Jul 6. PMID: 34184376.
47. **Greene SJ**, Khan MS. Practical and Evidence-Based Approaches to In-Hospital Decongestion for Heart Failure: Are We There Yet? *JACC Heart Fail.* 2021 Sep;9(9):649-652. doi: 10.1016/j.jchf.2021.06.002. Epub 2021 Jul 7. PMID: 34246608.
48. **Greene SJ**, Butler J, Metra M. Another reason to embrace quadruple medical therapy for heart failure: medications enabling tolerance of each other. *Eur J Heart Fail.* 2021 Sep;23(9):1525-1528. doi: 10.1002/ejhf.2301. Epub 2021 Jul 29. PMID: 34263507.
49. Khan MS, Butler J, **Greene SJ**. Simultaneous or rapid sequence initiation of medical therapies for heart failure: seeking to avoid the case of 'too little, too late'. *Eur J Heart Fail.* 2021 Sep;23(9):1514-1517. doi: 10.1002/ejhf.2311. Epub 2021 Aug 4. PMID: 34286897.

50. **Greene SJ**, Velazquez EJ, Anstrom KJ, Eisenstein EL, Mentz RJ. Reply: Pragmatic Clinical Trials: The Big Picture. *JACC Heart Fail.* 2021 Aug;9(8):606-608. doi: 10.1016/j.jchf.2021.05.018. PMID: 34325892.
51. **Greene SJ**, Butler J. Investigator-Reported Versus Adjudicated Clinical Events: 2 Versions of the Truth? *J Am Coll Cardiol.* 2021 Oct 12;78(15):1538-1540. doi: 10.1016/j.jacc.2021.08.023. PMID: 34620411.
52. **Greene SJ**, Butler J, Fonarow GC. In-hospital initiation of quadruple medical therapy for heart failure: making the post-discharge vulnerable phase far less vulnerable. *Eur J Heart Fail.* 2022 Jan;24(1):227-229. doi: 10.1002/ejhf.2382. Epub 2021 Nov 23. PMID: 34779112.
53. **Greene SJ**, Butler J, Fonarow GC. Contextualizing Risk Among Patients With Heart Failure. *JAMA.* 2021 Dec 14;326(22):2261-2262. doi: 10.1001/jama.2021.20739. PMID: 34779819.
54. Rao VN, **Greene SJ**. Breaking Clinical Inertia in Heart Failure Management. *Jt Comm J Qual Patient Saf.* 2022 Jan;48(1):3-4. doi: 10.1016/j.jcjq.2021.11.002. Epub 2021 Nov 11. PMID: 34840128.
55. Khan MS, Shahid I, Fonarow GC, **Greene SJ**. Classifying heart failure based on ejection fraction: imperfect but enduring. *Eur J Heart Fail.* 2022 Jul;24(7):1154-1157. doi: 10.1002/ejhf.2470. Epub 2022 Mar 20. PMID: 35239210.
56. Khan MS, DeVore AD, Felker GM, Butler J, Fonarow GC, **Greene SJ**. Reply: Revisited Metformin Therapy in Heart Failure With Preserved Ejection Fraction. *JACC Heart Fail.* 2022 May;10(5):366-367. doi: 10.1016/j.jchf.2022.02.013. PMID: 35483801.
57. **Greene SJ**, Lautsch D, Gaggin HK, Djatche LM, Zhou M, Song Y, Signorovitch J, Stevenson AS, Blaustein RO, Butler J. Contemporary outpatient management of patients with worsening heart failure with reduced ejection fraction: Rationale and design of the CHART-HF study. *Am Heart J.* 2022 Sep;251:127-136. doi: 10.1016/j.ahj.2022.05.016. Epub 2022 May 29. PMID: 35640728.
58. Khan MS, Butler J, Vaduganathan M, **Greene SJ**. Heart Failure Specific Versus All-cause End Points in Heart Failure Clinical Trials. *J Card Fail.* 2022 Sep;28(9):1398-1400. doi: 10.1016/j.cardfail.2022.07.001. Epub 2022 Jul 14. PMID: 35843491.
59. Khouri MG, **Greene SJ**. Sodium-Glucose Co-Transporter-2 Inhibitor Therapy During Anthracycline Treatment: Is There a Role for Cardioprotection? *JACC Heart Fail.* 2022 Aug;10(8):568-570. doi: 10.1016/j.jchf.2022.04.014. Epub 2022 Jul 6. PMID: 35902160.
60. Bhatt AS, Fonarow GC, **Greene SJ**. Prioritizing prevention of de novo and worsening chronic heart failure. *Eur J Heart Fail.* 2022 Apr;24(4):653-656. doi: 10.1002/ejhf.2464. Epub 2022 Mar 15. PMID: 35218135; PMCID: PMC9106859.
61. **Greene SJ**, Fonarow GC, Butler J. Sodium-glucose cotransporter 2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: time to deliver implementation. *Eur J Heart Fail.* 2022 Oct;24(10):1902-1905. doi: 10.1002/ejhf.2688. Epub 2022 Sep 26. PMID: 36097872.

62. Peters AE, Mentz R, **Greene SJ**. Advancing the Evidence for Diuretic Therapy for Heart Failure: Implications of the ADVOR and TRANSFORM-HF Trials. *Eur Heart J Cardiovasc Pharmacother*. 2023 Jan 13:pvad002. doi: 10.1093/ehjcvp/pvad002. Epub ahead of print. PMID: 36639123.
63. **Greene SJ**, Felker GM. Considering Addition of Acetazolamide to Loop Diuretics as Treatment for Acute Heart Failure: ADVOR Reappraisal. *JACC Heart Fail*. 2023 Mar;11(3):365-367. doi: 10.1016/j.jchf.2023.01.011. PMID: 36889884.
64. Haywood HB, Fonarow GC, Khan MS, Nassif ME, Butler J, **Greene SJ**. Hospital at Home as a Novel Care Strategy for Worsening Heart Failure. *JACC Heart Fail*. 2023 Apr 6:S2213-1779(23)00127-0. doi: 10.1016/j.jchf.2023.02.013. Epub ahead of print. PMID: 37115128.
65. Yeung AM, Huang J, Pandey A, Hashim IA, Kerr D, Pop-Busui R, Rhee CM, Shah VN, Bally L, Bayes-Genis A, Bee YM, Bergenstal R, Butler J, Fleming GA, Gilbert G, **Greene SJ**, Kosiborod MN, Leiter LA, Mankovsky B, Martens TW, Mathieu C, Mohan V, Patel KV, Peters A, Rhee EJ, Rosano GMC, Sacks DB, Sandoval Y, Seley JJ, Schnell O, Umpierrez G, Waki K, Wright EE Jr, Wu AHB, Klonoff DC. Biomarkers for the Diagnosis of Heart Failure in People with Diabetes: A Consensus Report from Diabetes Technology Society. *Prog Cardiovasc Dis*. 2023 May 11:S0033-0620(23)00050-6. doi: 10.1016/j.pcad.2023.05.002. Epub ahead of print. PMID: 37178991.
66. Shahid I, Fonarow GC, **Greene SJ**. Time to Quadruple Guideline-Directed Medical Therapy as a Key Performance Measure for Heart Failure. *J Card Fail*. 2023 May;29(5):730-733. doi: 10.1016/j.cardfail.2023.02.012. Epub 2023 Mar 15. PMID: 36925046.
67. Fonarow GC, **Greene SJ**. Rapid and Intensive Guideline-Directed Medical Therapy for Heart Failure: Strong Impact Across Ejection Fraction Spectrum. *J Am Coll Cardiol*. 2023 Jun 6;81(22):2145-2148. doi: 10.1016/j.jacc.2023.04.006. PMID: 37257949.
68. **Greene SJ**, Pierce JB. Overcoming Barriers to Use of SGLT2 Inhibitor Therapy: The Battle Against Clinical Inertia. *JACC Heart Fail*. 2023 Jun 5:S2213-1779(23)00238-X. doi: 10.1016/j.jchf.2023.05.006. Epub ahead of print. PMID: 37318416.
69. **Greene SJ**, Fonarow GC. Targeting sacubitril/valsartan for heart failure with mildly reduced or preserved ejection fraction. *Eur Heart J*. 2023 Aug 14;44(31):2994-2997. doi: 10.1093/eurheartj/ehad427. PMID: 37403607.
70. Pierce JB, Butler J, **Greene SJ**. Implementation of sodium-glucose cotransporter 2 inhibitors for heart failure with reduced ejection fraction: Where we are versus where we need to be. *Eur J Heart Fail*. 2023 Aug 15. doi: 10.1002/ejhf.2999. Epub ahead of print. PMID: 37581237.
71. Averbuch T, **Greene SJ**, Van Spall HGC. Guideline-Recommended Therapy Following Hospitalization for Heart Failure: Understanding the Gaps, Navigating the Barriers. *JACC Heart Fail*. 2023 Oct;11(10):1333-1336. doi: 10.1016/j.jchf.2023.07.022. PMID: 37793736.
72. **Greene SJ**, Butler J. Expanding the Definition of Worsening Heart Failure and Recognizing the Importance of Outpatient Escalation of Oral Diuretics. *Circulation*. 2023 Nov 28;148(22):1746-1749. doi: 10.1161/CIRCULATIONAHA.123.066915. Epub 2023 Nov 27. PMID: 38011247.

73. Clephas PRD, Malgie J, Schaap J, Koudstaal S, Emans M, Linssen GCM, de Boer GA, van Heerebeek L, Borleffs CJW, Manintveld OC, van Empel V, van Wijk S, van den Heuvel M, da Fonseca C, Damman K, van Ramshorst J, van Kimmenade R, van de Ven ART, Tio RA, van Veghel D, Asselbergs FW, de Boer RA, van der Meer P, **Greene SJ**, Brunner-La Rocca HP, Brugts JJ. Guideline implementation, drug sequencing, and quality of care in heart failure: design and rationale of TITRATE-HF. *ESC Heart Fail.* 2024 Feb;11(1):550-559. doi: 10.1002/ehf2.14604. Epub 2023 Dec 8. PMID: 38064176
74. **Greene SJ**, Fonarow GC, Butler J. SGLT2 Inhibitors for Heart Failure with Preserved Ejection Fraction: What Hospitalists Need to Know. *Am J Cardiovasc Drugs.* 2024 Jan;24(1):1-4. doi: 10.1007/s40256-023-00624-2. Epub 2023 Dec 29. PMID: 38157160.
75. **Greene SJ**, Khan MS, Butler J. Why do clinicians not prescribe quadruple medical therapy for heart failure with reduced ejection fraction? *Eur J Heart Fail.* 2024 Feb;26(2):338-341. doi: 10.1002/ejhf.3133. Epub 2024 Jan 18. PMID: 38235943.
76. Khan MS, Fonarow GC, **Greene SJ**. Guideline-directed medical therapy for heart failure: The key ingredient for successful in-hospital and post-discharge care. *Eur J Heart Fail.* 2024 Feb;26(2):355-358. doi: 10.1002/ejhf.3152. Epub 2024 Jan 30. PMID: 38291014.
77. Khan MS, **Greene SJ**, DeVore AD. Serial NT-proBNP Measurements and Implementation of Guideline-Directed Medical Therapy. *JACC Heart Fail.* 2024 Mar;12(3):488-491. doi: 10.1016/j.jchf.2024.01.003. PMID: 38448150.
78. Handelsman Y, Anderson JE, Bakris GL, Ballantyne CM, Bhatt DL, Bloomgarden ZT, Bozkurt B, Budoff MJ, Butler J, Cherney DZI, DeFronzo RA, Del Prato S, Eckel RH, Filippatos G, Fonarow GC, Fonseca VA, Garvey WT, Giorgino F, Grant PJ, Green JB, **Greene SJ**, Groop PH, Grunberger G, Jastreboff AM, Jellinger PS, Khunti K, Klein S, Kosiborod MN, Kushner P, Leiter LA, Lepor NE, Mantzoros CS, Mathieu C, Mende CW, Michos ED, Morales J, Plutzky J, Pratley RE, Ray KK, Rossing P, Sattar N, Schwarz PEH, Standl E, Steg PG, Tokgözoğlu L, Tuomilehto J, Umpierrez GE, Valensi P, Weir MR, Wilding J, Wright EE Jr. DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases. *Metabolism.* 2024 Jun 4:155931. doi: 10.1016/j.metabol.2024.155931. Epub ahead of print. PMID: 38852020.
79. Bayes-Genis A, **Greene SJ**. Bio-adrenomedullin: A weak biomarker for a STRONG patient. *Eur J Heart Fail.* 2024 Jun 14. doi: 10.1002/ejhf.3351. Epub ahead of print. PMID: 38874279.
80. **Greene SJ**, Butler J, Fonarow GC. Rapid and Intensive Guideline-Directed Medical Therapy for Heart Failure: 5 Core Principles. *Circulation.* 2024 Aug 6;150(6):422-424. doi: 10.1161/CIRCULATIONAHA.124.070228. Epub 2024 Aug 5. PMID: 39102475.
81. **Greene SJ**, Böhm M, Bozkurt B, Butler J, Cleland JG, Coats AJ, Desai NR, Grobbee DE, Kelepouris E, Pinto F, Rosano G, Morin I, Szecsödy P, Fabien S, Waechter S, Crespo-Leiro MG, Hülsmann M, Kempf T, Pfister O, Pouleur AC, Sauer AJ, Saxena M, Schulz M, Volterrani M, Anker SD, Kosiborod MN. Cardiovascular and Renal Treatment in Heart Failure Patients with Hyperkalemia or High Risk of Hyperkalemia: Rationale and Design of the CARE-HK in HF Registry. *J Card Fail.* 2024 Sep 4:S1071-9164(24)00368-3. doi: 10.1016/j.cardfail.2024.08.048. Epub ahead of print. PMID: 39277029.

82. **Greene SJ**, Spahillari A, Shahzeb Khan M. Enabling Medical Therapy for Heart Failure: New Tools Bring a New Reality for Hyperkalemia. *J Am Coll Cardiol*. 2024 Oct 1;84(14):1309-1312. doi: 10.1016/j.jacc.2024.05.080. PMID: 39322324.
83. Bozkurt B, Ahmad T, Alexander K, Baker WL, Bosak K, Breathett K, Carter S, Drazner MH, Dunlay SM, Fonarow GC, **Greene SJ**, Heidenreich P, Ho JE, Hsich E, Ibrahim NE, Jones LM, Khan SS, Khazanie P, Koelling T, Lee CS, Morris AA, Page RL 2nd, Pandey A, Piano MR, Sandhu AT, Stehlik J, Stevenson LW, Teerlink J, Vest AR, Yancy C, Ziaeeian B; WRITING COMMITTEE MEMBERS. HF STATS 2024: Heart Failure Epidemiology and Outcomes Statistics An Updated 2024 Report from the Heart Failure Society of America. *J Card Fail*. 2024 Sep 14:S1071-9164(24)00232-X. doi: 10.1016/j.cardfail.2024.07.001. Epub ahead of print. PMID: 39322534.
84. Biegus J, Palazzuoli A, **Greene SJ**. Effect of finerenone across the stages of heart failure: From prevention to treatment. *Eur J Heart Fail*. 2025 Feb 17. doi: 10.1002/ejhf.3606. Epub ahead of print. PMID: 39957404.
85. **Greene SJ**, Butler J, Fonarow GC. Simultaneous or Rapid Initiation of Combination Therapy for Heart Failure With Preserved Ejection Fraction. *JAMA Cardiol*. 2025 May 1;10(5):407-408. doi: 10.1001/jamacardio.2025.0038. PMID: 40042835.
86. Laufs U, **Greene SJ**, Schulz M. Time for a new perspective on polypharmacy in heart failure. *Eur J Heart Fail*. 2025 Mar 27. doi: 10.1002/ejhf.3650. Epub ahead of print. PMID: 40148117.
87. **Greene SJ**, Kittipibul V, Dunlay SM. Overcoming the Risk-Treatment Paradox: Prescribing GDMT for Severe Heart Failure. *JACC Heart Fail*. 2025 Apr;13(4):628-630. doi: 10.1016/j.jchf.2025.01.014. PMID: 40204387.
88. Lopez-Jimenez F, Alger HM, Attia ZI, Barry B, Chatterjee R, Dolor R, Friedman PA, **Greene SJ**, Greenwood J, Gundurao V, Hackett S, Jain P, Kinaszczuk A, Mehta K, O'Grady J, Pandey A, Pullins C, Puranik AR, Ranganathan MK, Rushlow D, Stampehl M, Subramanian V, Vassor K, Zhu X, Awasthi S. A multicenter pragmatic implementation study of AI-ECG-based clinical decision support software to identify low LVEF: Clinical trial design and methods. *Am Heart J Plus*. 2025 Mar 21;54:100528. doi: 10.1016/j.ahjo.2025.100528. PMID: 40276542; PMCID: PMC12017965.
89. Shoji S, Fonarow GC, **Greene SJ**. Simultaneous or Rapid Sequence Optimization of Medical Therapy for Heart Failure: Time to Keep Score. *Circ Heart Fail*. 2025 Sep;18(9):e013417. doi: 10.1161/CIRCHEARTFAILURE.125.013417. Epub 2025 Aug 13. PMID: 40799134.
90. Fonarow GC, Ahmad FS, Ahmad T, Albert NM, Alexander KM, Baker WL, Bozkurt B, Breathett K, Carter S, Cheng RK, Deswal A, Drazner MH, Dunlay S, Gorodeski EZ, **Greene SJ**, Heidenreich P, Hsich E, Jones L, Kanwar M, Khazanie P, Khush K, Koelling T, Lee CS, Page R, Pandey A, Reza N, Sandhu AT, Shah P, Stehlik J, Tedford RJ, Teerlink JR, Vest AR, Yancy C, Ziaeeian B; WRITING COMMITTEE MEMBERS. HF STATS 2025: Heart Failure Epidemiology and Outcomes Statistics An Updated 2025 Report from the Heart Failure Society of America. *J Card Fail*. 2025 Aug 29:S1071-9164(25)00326-4. doi: 10.1016/j.cardfail.2025.07.007. Epub ahead of print. PMID: 40987671.
91. Palazzuoli A, Del Buono MG, La Vecchia G, **Greene SJ**, Ambrosy AP, Chioncel O, Gustafsson F, Krim SR, Lavie CJ, Adamo M, Gal TB, Geavlete O, Antohi L, Rosano G, Collins S, Crea F.

Worsening versus advanced heart failure: Management and challenges. *ESC Heart Fail.* 2025 Oct 4. doi: 10.1002/ehf2.15437. Epub ahead of print. PMID: 41045229.

92. Lopez-Jimenez F, Alger HM, Hackett SP, Gundurao V, Mehta K, Jain P, Kumar-M P, Padhye C, Puranik A, Vassor K, Ravi SK, Barry B, Chatterjee R, Chow C, Dolor R, **Greene SJ**, Lin G, Rushlow D, Stampehl M, Zhu X, Awasthi S. A Pragmatic Trial Evaluating the Impact of the Anumana Clinical Decision Support Tool for Guideline-Directed Management of Heart Failure (ACT-HF): Clinical trial design and methods. *Am Heart J Plus.* 2025 Nov 15;61:100675. doi: 10.1016/j.ahjo.2025.100675. PMID: 41377035; PMCID: PMC12689177.
93. **Greene SJ**, Butler J, Fonarow GC. Beyond Quadruple Therapy for Heart Failure with Reduced Ejection Fraction: Where Do Additional Medical Therapies Fit? *Eur J Heart Fail.* 2026 Feb 26:xuag053. doi: 10.1093/ehf/xuag053. Epub ahead of print. PMID: 41755454.

D. Non-refereed publications:

1. Ambrosy AP, Mentz RJ, Krishnamoorthy A, **Greene SJ**, Severance HW. Identifying Barriers and Practical Solutions to Conducting Site-Based Research in North America: Exploring Acute Heart Failure Trials As a Case Study. *Heart Fail Clin.* 2015 Oct;11(4):581-9. doi: 10.1016/j.hfc.2015.07.002. Epub 2015 Aug 4. PMID: 26462098.
2. **Greene SJ**, AlKhawam L, Ambrosy AP, Vaduganathan M, Mentz RJ. Hospitalized Heart Failure in the United States: Lessons Learned from Clinical Trial Populations. *Heart Fail Clin.* 2015 Oct;11(4):591-601. doi: 10.1016/j.hfc.2015.07.003. Epub 2015 Aug 4. PMID: 26462099.
3. Samman Tahhan A, Vaduganathan M, **Greene SJ**, Okafor M, Kumar S, Butler J. Evolving Landscape of Clinical Trials in Heart Failure: Patient Populations, Endpoint Selection, and Regions of Enrollment. *Curr Heart Fail Rep.* 2018 Feb;15(1):10-16. doi: 10.1007/s11897-018-0374-z. PMID: 29350324.
4. Chow C, Mentz RJ, **Greene SJ**. Update on the Impact of Comorbidities on the Efficacy and Safety of Heart Failure Medications. *Curr Heart Fail Rep.* 2021 Jun;18(3):132-143. doi: 10.1007/s11897-021-00512-3. Epub 2021 Apr 9. PMID: 33835396.
5. Marx N, Cheng AYY, Agarwal R, **Greene SJ**, Abuhantash H. Heart failure with reduced ejection fraction and the intersection of cardio-renal-metabolic medicine #CaReMe. *Eur Heart J Suppl.* 2022 Dec 19;24(Suppl L):L29-L37. doi: 10.1093/eurheartjsupp/suac114. PMID: 36545231; PMCID: PMC9762887.

Appointments and Recognition:

A. Scientific reviewer:

Editorial Roles:

2016 – Present Editorial Board Member, *European Journal of Heart Failure*

2022 – Present Editorial Board Member, *JACC: Heart Failure*

2022 – Present Guest Associate Editor, *Journal of the American College of Cardiology*

2022 – Present Guest Associate Editor, *JACC: Heart Failure*
2024 – Present Associate Editor, *Heart Failure Reviews*
2024 – Present Guest Editor, *European Journal of Heart Failure*

Peer Reviewer:

- *American Heart Journal*
- *American Journal of Cardiology*
- *Circulation*
- *Circulation: Heart Failure*
- *European Heart Journal*
- *European Journal of Heart Failure*
- *International Journal of Cardiology*
- *JAMA Cardiology*
- *Journal of the American College of Cardiology*
- *Journal of Cardiac Failure*
- *JACC: Heart Failure*
- *Lancet*

B. Professional societies, service organizations

2007 – Present Member, American Medical Association
2010 – Present Member and Specialty Certification, American Board of Internal Medicine
2015 – Present Member, American College of Cardiology
2015 – Present Member, American Heart Association
2016 – Present Member, Heart Failure Society of America
2020 – Present Fellow, American College of Cardiology (FACC)
2022 – Present Fellow, Heart Failure Society of America (FHFA)
2022 – Present Member, European Society of Cardiology
2024 – Present Fellow, Heart Failure Association of the European Society of Cardiology

National and International Committees:

2017 – 2020 Member, Heart Failure Society of America Research Network Task Force
2020 – 2021 Member, Heart Failure Society of America Quality of Care Committee
2021 – Present Member, American Heart Association's Get With The Guidelines Heart Failure Systems of Care Advisory Group
2022 – Present Chapter Lead within Heart Failure Section, ACC-SAP, American College of Cardiology

- 2023 – Present Member, Heart in Diabetes Conference Scientific Committee
- 2023 Judge, American College of Cardiology Young Investigator Award Committee
- 2024 – Present Member, Heart Failure Society of America Epidemiology and Outcomes Statistics Writing Group
- 2024 – Present Member, Heart Failure Society of America Optimal Medical Therapy Committee
- 2024 – Present Member, Heart Failure Society of America HF STATS Writing Group
- 2025 – Present Member, Heart Failure Society of America Annual Scientific Meeting Working Group
- 2025 – Present Co-chair, Heart in Diabetes Annual Meeting

C. Scholarly societies:

- 2007 Phi Beta Kappa National Honor Society, Brown University
- 2020 Alpha Omega Alpha Medical Honor Society, Duke University

D. Professional awards and recognition:

- 2007 Member, Phi Beta Kappa National Honor Society, Brown University
- 2013 Recipient, Best Poster Award, American College of Cardiology 2013 Scientific Sessions (2 awards)
- 2014 Recipient, Northwestern Internal Medicine Program Teaching Award
- 2015 Recipient, Northwestern Department of Medicine Gerald M. Grumet Teaching Award
- 2015 Recipient, Northwestern Department of Medicine Jameson Research Prize
- 2016 Recipient, Top 5 senior reviewer for the *European Journal of Heart Failure*
- 2017 Recipient, Top 10 senior reviewer for the *European Journal of Heart Failure*
- 2017 Recipient, Heart Failure Society of America Future Leaders in Heart Failure Award
- 2017 Recipient, Heart Failure Society of American Acute Heart Failure Young Investigator Award
- 2019 Recipient, Duke Division of Cardiology Joseph C. Greenfield Scholar in Cardiology Award
- 2020 Member, Alpha Omega Alpha Medical Honor Society, Duke University School of Medicine
- 2020 Recipient, Top reviewer for *JACC Heart Failure*
- 2021 Duke Department of Medicine Chair's Research Award
- 2023 Recipient, Top reviewer for the *European Journal of Heart Failure*

2025 Recipient, Top reviewer for the *European Journal of Heart Failure*

Professional Development

2020 Recipient, Duke Department of Medicine Faculty Development Academy

2022 Selected Investigator, Duke University School of Medicine LEADER Program – LEADership DEvelopment for Researchers

Research Support:

Current:

Project title: REFOCUS-HTN US

Grant number: Duke SPS Proposal #308122

PI: Stephen Greene

Your role: PI

Your % effort: 12%

Funding source: AstraZeneca Pharmaceuticals, LP

Funding amount: \$2,022,948

Duration: 12/16/25-2/28/27

Project synopsis: To evaluate the epidemiology and treatment patterns of adults with hypertension in the United States

Project title: Post-hoc Analysis of the TRANSFORM-HF Trial

Grant number: Duke SPS Proposal #298118

PI: Stephen Greene

Your role: PI

Your % effort: 1%

Funding source: University of Texas Southwestern

Funding amount: \$38,000

Duration: 07/01/25-12/31/26

Project synopsis: To evaluate the effect of torsemide versus furosemide in patients with heart failure by baseline diuretic resistance

Project title: MARITIME-HF

Grant number: Duke SPS Proposal #301766

PI: Stephen Greene

Your role: PI

Your % effort: 10%

Funding source: Amgen, Inc

Funding amount: \$2,239,615

Duration: 07/08/21-06/31/26

Project synopsis: To evaluate the effect of maritide vs placebo on cardiovascular outcomes in patients with heart failure with preserved ejection fraction

Project title: PARACOR-19

Grant number: Duke SPS Proposal #268046

PI: Stephen Greene

Your role: PI

Your % effort: 1.5%

Funding source: Novartis Pharmaceuticals Corp.

Funding amount: \$671,667

Duration: 07/08/21-06/31/26

Project synopsis: To evaluate the effect of sacubitril/valsartan vs placebo following COVID-19 infection

Project title: Outpatient Intravenous Diuretic Therapy for Worsening Heart Failure

Grant number: Duke SPS Proposal #271858

PI: Stephen Greene

Your role: PI

Your % effort: 15%

Funding source: American Heart Association

Funding amount: \$230,932

Duration: 04/01/22-03/31/26

Project synopsis: To evaluate the use and effectiveness of outpatient IV diuretics for worsening heart failure

Project title: GWTG-HF Registry

Grant number: AHA CONTRACT ID #100623-S22 PARENT

PI: Jonathan Piccini

Your role: Co-Investigator

Your % effort: 5%

Funding source: American Heart Association

Funding amount: \$1,558,658

Duration: 07/01/25-06/30/26

Project synopsis: To evaluate quality of care and outcomes of patients hospitalized for heart failure in the GWTG-HF registry

Project title: GWTG-HF Registry

Grant number: AHA CONTRACT ID # 100623-M-123736 PARENT

PI: Jonathan Piccini

Your role: Co-Investigator

Your % effort: 2.5%

Funding source: American Heart Association

Funding amount: \$430,633

Duration: 07/01/25-06/30/26

Project synopsis: Industry sponsor collaborations with the GWTG-HF registry

Project title: Identifying barriers to and optimizing in-hospital use of evidenced-based Medical therapies for patients with Cardio-Renal-Metabolic Disease (IMPLEMENT-CRM)

Grant number: NCT05781334

PI: Stephen Greene

Your role: PI

Your % effort: 2%

Funding source: Duke University, Boehringer Ingelheim

Funding amount: \$117,683

Duration: 05/03/23-04/30/26

Project synopsis: To evaluate effect of an inpatient virtual consult team on medical therapy for patients with cardio-renal-metabolic disease

Completed:**Project title:** GOALS-HF**Grant number:** Duke SPS Proposal #281832**PI:** Stephen Greene**Your role:** PI**Your % effort:** 2%**Funding source:** Tricog Health Inc.**Funding amount:** \$299,120**Duration:** 05/03/23-04/30/25**Project synopsis:** To evaluate the feasibility of using home wearable and medical devices to monitor patients with heart failure and titrate medical therapy**Project title:** ANUMANA #DOC-244**Grant number:** Duke SPS Proposal #287120**PI:** Ranee Chatterjee Montgomery**Your role:** Co-Investigator**Your % effort:** 2.5%**Funding source:** Anumana, Inc.**Funding amount:** \$202,089**Duration:** 09/05/2023-ongoing**Project synopsis:** A multicenter study of artificial intelligence ECG-based clinical decision support tool to identify low ejection fraction (AIM-ECG)**Project title:** ANUMANA #DOC-245**Grant number:** Duke SPS Proposal #287121**PI:** Ranee Chatterjee Montgomery**Your role:** Co-Investigator**Your % effort:** 2.5%**Funding source:** Anumana, Inc.**Funding amount:** \$157,169**Duration:** 09/01/2023 - 08/31/2024**Project synopsis:** Pragmatic trial of a clinical decision support tool for medical therapy for heart failure (ACT-HF)**Project title:** Duke Department of Medicine Chair's Research Award**Grant number:** Internal Grant**PI:** Stephen Greene**Your role:** PI**Your % effort:** 60%**Funding source:** Duke University Department of Medicine**Funding amount:** \$95,000**Duration:** 07/01/21-06/30/22**Project synopsis:** Generate real-world evidence regarding outpatient IV diuretics as a treatment for heart failure**Project title:** TRANSFORM-HF CCC (Subcontract with Yale)**Grant number:** Duke SPS Proposal #267951**PIs:** Robert Mentz / Eric Velazquez**Your role:** Co-Investigator**Your % effort:** 1%**Funding source:** NIH (GR107794 (CON-800001968))

Funding amount: \$385,282

Duration: 08/01/21-07/31/24

Project synopsis: Pragmatic trial to assess effectiveness of torsemide vs furosemide for heart failure

Project title: Comparison of Dyspnea Measurement Instruments in Acute Heart Failure

Grant number: Duke SPS Proposal # 232374

PI: Stephen Greene

Your role: PI

Your % effort: N/A

Funding source: Heart Failure Society of America Young Investigator Award

Funding amount: \$80,000

Duration: 07/01/17-06/30/19

Project synopsis: Compare standard dyspnea measurement instruments in acute heart failure

Project title: HEORUSV201208

Grant number: N/A

PI: Emily O'Brien

Your role: Co-Investigator

Your % effort: 5%

Funding source: Novartis Pharmaceuticals Corporation

Funding amount: \$944,401

Duration: 08/15/17-01/31/23

Project synopsis: Identify patterns of post-discharge adherence to sacubitril/valsartan, variation in these patterns by initiation time period, and the association between post-discharge adherence

Clinical Trial and National Registry Involvement

Principal Investigator: Served as overall trial principal investigator for the following studies:

- FOCUS-WHF: OPC-131461 for worsening heart failure
- PARACOR-19: Sacubitril/valsartan following COVID-19 infection (completed; *Eur J Heart Fail.* 2024;26:1393-1398)
- IMPLEMENT-CRM: In-hospital virtual consult for patients with cardio-renal-metabolic disease
- VELOCITY: Safety and tolerability of initiating vericiguat at a starting dose of 5 mg daily

Executive Committee: Serve(d) on the executive committee overseeing study execution and dissemination for the following trials (in addition to those noted above for overall PI and Clinical Lead

- GWTG-HF: American Heart Association's national quality improvement registry to improve care for patients hospitalized with heart failure (ongoing, several publications)

National Leader: Served as trial national leader for the following study:

- CARE-HK in HF Registry: Cardiovascular and renal treatment in heart failure patients with hyperkalemia or at high risk of hyperkalemia (recruitment ongoing)
- MARITIME-HF: Cardiovascular outcomes trial assessing the effect of a novel incretin-based therapy on cardiovascular outcomes in patients with heart failure and ejection fraction >40%

Co-Investigator: Lead co-investigator for the following trials. Assisted in writing the grants, obtaining funding, conducting the trial and disseminating the results.

- TRANSFORM-HF: Torsemide vs. furosemide in heart failure (recruitment ongoing)
- VICTORIA Registry: Registry in parallel to the VICTORIA randomized clinical trial (completed; published *J Card Fail.* 2022;28:1063-1077).
- CHAMP-HF Registry: outpatient registry to assess quality of care and outcomes for patients with heart failure (completed; published *J Am Coll Cardiol* 2018;72:351-366)
- SOCRATES-Reduced: vericiguat vs placebo in heart failure (completed; published *JAMA* 2015;314:2251-2262)
- ASTRONAUT: aliskiren vs placebo in heart failure (completed; published *JAMA* 2013;309:1125-1135.)
- Allogeneic Mesenchymal Stem Cells vs placebo in heart failure (completed; published *Circ Res* 2017;120:332-340)
- Human stresscopin (JNJ-39588146) vs placebo in heart failure (completed; published *Eur J Heart Fail.* 2013;15:679-689)
- COMPOSE Programme: cinaciguat vs placebo in heart failure (completed; published *Eur J Heart Fail.* 2012;14:1056-1066)

Medical Monitor: Served as medical monitor and reviewed safety cases for the following trials:

- GALACTIC-HF: omecamtiv mecarbil vs placebo in heart failure
- LIFE: sacubitril/valsartan in patients with advanced heart failure
- COMET-HF: omecamtiv mecarbil vs placebo in severe heart failure

Clinical Events Committee: Served on the clinical events committee and adjudicated clinical event cases for the following trials.

- VICTORIA: vericiguat vs placebo in heart failure
- SCORED: sotagliflozin in patients with diabetic kidney disease
- HEART-FID: ferric carboxymaltose in heart failure
- HARMONY: albiglutide and cardiovascular outcomes in type 2 diabetes
- AMPLITUDE-O: efpeglenatide and cardiovascular outcomes in type 2 diabetes
- CONTEMP-ICD: primary prevention ICD for heart failure with reduced ejection in the era of contemporary medical therapy

Mentoring activities:

From 2018 to the present, I have served as a mentor for Duke Medical Students, Internal Medicine Residents and Duke Cardiology Fellows. Selected publications are annotated.

1. Christine Chow, MD
 - Current Duke Medical Student
 - Training Period: 2020 -2022
 - Research Project: Sex differences in mode of death for patients with HF and comorbidities in HF
 - Manuscripts: refereed manuscript #102, non-refereed manuscript #4 (Greene as senior)
2. Ankeet Bhatt, MD
 - Former Duke Medicine Resident, Current attending cardiologist at Kaiser Permanente Northern California
 - Training Period: 2015-2018
 - Research Project: hemodilution post-discharge for HF, prevention of worsening HF
 - Manuscripts: refereed manuscript #67 (Greene as senior); review manuscript #40; editorial #60 (Greene as senior)
3. Michael Cosiano, MD
 - Former Duke Medicine Resident, Current Duke Cardiology Fellow
 - Training Period: 2020 – Present
 - Research Project: physical function in patients with HFpEF, NYHA Class and Patient-Reported Outcomes
 - Manuscripts: refereed manuscript #146 (Greene as senior), review manuscript #37 (Greene as senior)
4. Vanessa Blumer, MD
 - Former Duke Cardiology Fellow, Current Cleveland Clinic Heart Failure Fellow
 - Training Period 2019-2022
 - Research Project: sex differences in HF, prior hospitalizations for HF
 - Manuscripts: refereed manuscripts #62, #70, #80, #95, #97 (Greene as senior), #103, #110, #116 (Greene as senior)
5. Muhammad Shahzeb Khan, MD MSc
 - Former Cook County Medicine Resident, Current Duke Cardiology Fellow
 - Training Period: 2017-present
 - Research Project: clinical trial design and execution, temporal trends in HF outcomes
 - Manuscripts: refereed manuscripts #38, #39, #69, # 71, #74, #83, #86, #98, #101, #111, #114 (Greene as senior), #130, #159 (Greene as senior), #170; review manuscripts #39, #45, #46, #49, #50, #52, #53 (Greene as senior); position piece/editorial #32, #33, #36, #38, #43, #44, #49, #55, #56, #58 (Greene as senior on all)
6. Jacob B. Pierce, MD MPH
 - Current Duke Medicine Resident

- Training Period: 2021-present
 - Research Project: real-world adoption of guideline-directed medical therapy for HF
 - Manuscripts: refereed manuscripts #135, #146, #151, #159, #165 (Greene as senior on all); referred manuscript #174, position piece/editorial #67, #69
7. Vishal N. Rao, MD MPH
 - Current Duke Cardiology Fellow
 - Training Period: 2018-present
 - Research Project: implementation of guideline-directed medical therapy for HF
 - Manuscripts: refereed manuscript #145; review manuscript #40 (Greene as senior); editorial #54 (Greene as senior)
 8. Anthony E. Peters, MD
 - Current Duke Cardiology Fellow
 - Training Period: 2019-present
 - Research Project: patient-reported outcomes, amyloid cardiomyopathy
 - Manuscripts: refereed manuscript #137, #171 (Greene as senior on all); review manuscript #42 (Greene as senior); editorial #61 (Greene as senior)
 9. Josephine Harrington, MD
 - Current Duke Cardiology Fellow
 - Training Period: 2019-present
 - Research Project: medication related attributable events in HF, severely reduced ejection fraction heart failure
 - Manuscripts: refereed manuscripts #160, #164 (Greene as senior)
 10. Nijat Aliyev, MD
 - Current Duke Medicine Resident
 - Training Period: 2020-present
 - Research Project: household income level and HF readmissions
 - Manuscripts: refereed manuscripts #152, #167 (Greene as senior on all)
 11. Hubert Haywood, MD
 - Current Duke Medicine Resident
 - Training Period: 2020-present
 - Research Project: hospital at home for worsening heart failure
 - Manuscripts: review manuscript #53 (Greene as senior), position piece/editorial #64 (Greene as senior)
 12. Harsh Patolia, MD
 - Current Duke Medicine Resident
 - Training Period: 2020-present
 - Research Project: strategies to improve implementation of guideline-directed medical therapy for HF
 - Manuscripts: review manuscript #50

Education / teaching activities (residents, fellows, medical students, CME):

2019 Apr 30	Clinical trials for patients hospitalized for heart failure: where have we been? where can we go? <i>Duke Cardiology Grand Rounds</i> .
2020 Sept 22	Review of Recent Heart Failure Trials lecture. Duke Cardiology Fellowship Didactic Lecture. Core Lecture Series.
2020 - present	Acute Heart Failure. Duke Cardiology Fellowship Annual Didactic Lecture. Core Lecture Series.
2021 - present	Core teaching faculty member for the Duke Advanced Heart Failure and Transplantation fellowship.
2023 – present	Mentor for the Duke Clinical Research Institute T32 Postdoctoral Training Grant in Cardiovascular Clinical Research

Invited lectures and presentations (do not list abstract presentations):

2018

- Invited Presenter. Comparison of dyspnea measurement instruments in acute heart failure: interim results from the DYSPNEA-AHF pilot study. *Heart Failure Society of America 2018 Annual Meeting*. September 15, 2018
- Invited Presenter. Comparison of dyspnea measurement instruments in acute heart failure: interim results from the DYSPNEA-AHF pilot study. *American College of Emergency Physicians 2018 Annual Meeting*. October 1, 2018

2019

- Invited Presenter. Relationship between timing of trial randomization, protocol completion, and clinical outcomes among patients hospitalized for heart failure: from the ASTRONAUT trial. *Duke Clinical Research Institute Research Forum*. January 8, 2019.
- Invited Presenter. Gaps in guideline directed therapy for heart failure with reduced ejection fraction. *Heart Failure Society of America 2019 Annual Meeting*. September 14, 2019.
- Invited Presenter. Clinical effectiveness of sacubitril/valsartan among patients hospitalized for heart failure with reduced ejection fraction. *Late-breaking clinical trial session at the Heart Failure Society of America 2019 Annual Meeting*. September 16, 2019.
- Invited Presenter. Clinical trials for patients hospitalized for heart failure: where have we been? where can we go? *Saint Luke's Mid-America Heart Institute Cardiovascular Grand Rounds*. December 12, 2019.
- Invited Presenter. Guideline Directed Therapy for Heart Failure in the United States: Where Do We Stand? Where Can We Go? *Yale Cardiology Noon Conference*. December 18, 2019.

2020

- Invited Presenter. Acute Heart Failure. *Duke Cardiology Fellow Didactic Lecture*. July 27, 2020
- Invited Presenter. Review of Recent Heart Failure Trials. *Duke Cardiology Fellow Didactic Lecture*. September 22, 2020
- Invited Presenter. EMPEROR-Reduced and Clinical Practice: Can We Implement? *Heart Failure Society of America 2020 Annual Meeting*. October 3, 2020.
- Invited Presenter. Overcoming Clinical Inertia in Use and Dosing of GDMT. *Heart Failure Society of America 2020 Annual Meeting*. October 4, 2020.
- Social Media Moderator. Late-breaking Clinical Trials for Heart Failure. *American Heart Association 2020 Scientific Sessions*. November 2020.
- Invited Presenter. New York Heart Association Class and Patient-Reported Outcomes for HFrEF: From the CHAMP-HF Registry. *American Heart Association 2020 Scientific Sessions*. November 2020.

2021

- Invited Presenter. Acute Heart Failure. *Duke Cardiology Fellow Didactic Lecture*. July 19, 2021
- Invited Presenter. Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for HFrEF. *Duke Heart Failure Symposium 2021*. October 8, 2021.
- Invited Presenter. New Treatments in HFrEF. *Duke Heart Failure Symposium 2021*. October 8, 2021.
- Invited Presenter. Guideline Directed Medical Therapy for Heart Failure in the United States. Where Do We Stand? Where Can We Go? *University of Pennsylvania Cardiology Grand Rounds*. October 20, 2021
- Moderator. Featured Science in Heart Failure. *American Heart Association 2021 Scientific Sessions*. November 2021.

2022

- Invited Presenter. SGLT2i in Heart Failure: HFrEF, HFpEF, Class Effect? *American College of Cardiology 2022 Scientific Sessions*. April 3, 2022.
- Invited Presenter. Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for HFrEF. *Quality of Care and Outcomes Research 2022 Conference*. May 13, 2022.
- Invited Presenter. Contemporary Approach to the Management of CKD and Heart Failure. *Heart in Diabetes 2022 Annual Meeting*. June 24, 2022.
- Invited Presenter. Acute Heart Failure. *Duke Cardiology Fellow Didactic Lecture*. August 2, 2022

- Invited Presenter. Heart Failure Across the Range of Preserved Ejection Fraction in the United States. *European Society of Cardiology 2022 Annual Meeting*. August 28, 2022.
- Invited Presenter. Rapid sequencing and up-titrating of the four pillars. *Heart Failure Seoul 2022 Congress by the Korean Society of Heart Failure*. September 16, 2022.
- Invited Presenter. GDMT Initiation & Titration: Barriers and Potential Solutions. *Duke New Advances in HFrEF Learning Lab*. October 11, 2022.
- Invited Presenter. Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for HFrEF. *Duke New Advances in HFrEF Learning Lab*. October 11, 2022.
- Moderator. Managing the HF patient with valvular heart disease. *E-Space Heart Failure 2022*. October 15, 2022
- Invited Presenter. Implementation of evidence-based heart failure treatments. *E-Space Heart Failure 2022*. October 15, 2022
- Invited Presenter. Medication Changes and Reasons for No Medication Change Among Outpatients with Heart Failure with Reduced Ejection Fraction: Results from CHART-HF. *American Heart Association 2022 Scientific Sessions*. November 5, 2022.
- Moderator. *Biomarkers of the Future 2022 Conference*. November 15, 2022
- Invited Presenter. Heart Failure Across the Broad Range of Ejection Fraction. *Middle East Heart Failure Academy*. November 25, 2022.
- Invited Presenter. Managing Patients with Acute HF. *Middle East Heart Failure Academy*. November 25, 2022.
- Invited Presenter. The Intersection of CKD and Heart Failure. *World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease 2022 Meeting*. December 1, 2022

2023

- Invited Presenter. Diuretic Therapy for Heart Failure in 2023. *Rochester Heart Failure Symposium*. February 16, 2023
- Invited Presenter. Improving Patient Outcomes with Rapid Optimization of GDMT for Heart Failure: Insights from the STRONG-HF Trial. *American College of Cardiology 2023 Scientific Sessions*. March 6, 2023
- Invited Presenter. Quad Therapy vs. Avoiding Polypharmacy: Titration of GDMT in Elderly Patients with HF and Comorbidities. *American College of Cardiology 2023 Scientific Sessions*. March 6, 2023.
- Invited Presenter. New Evidence in Worsening Heart Failure: Examining Implications for Managed Care. *Academy of Managed Care Pharmacy 2023 Annual Meeting*. March 23, 2023

- Invited Presenter. SGLT2i Inhibitors for Heart Failure Across the Spectrum of Ejection Fraction. *28th Annual Current Concepts in Cardiovascular Disease by New Mexico Heart Institute*. April 22, 2023
- Invited Presenter. Management of Acute Heart Failure. *Advocate Christ Medical Center and Heart Institute*. April 27, 2023
- Invited Presenter. Medical Therapy for Patients Hospitalized for Heart Failure. *59th Annual Jeresaty Cardiovascular Symposium, Trinity Heath of New England Saint Francis Hospital*. May 4, 2023
- Invited Presenter. First intermediate analysis of the CARE-HK in heart failure registry. *European Society of Cardiology Heart Failure 2023 Annual Meeting*. May 20, 2023
- Invited Presenter. US Population Burden of Acute Heart Failure Events and Hospitalization Among Patients with Worsening Heart Failure and Left Ventricular Ejection Fraction $\leq 30\%$. *European Society of Cardiology Heart Failure 2023 Annual Meeting*. May 20, 2023
- Invited Presenter. Contemporary Use of SGLT2i Therapy Among Patients Hospitalized for Heart Failure with Reduced Ejection Fraction in the United States. *European Society of Cardiology Heart Failure 2023 Annual Meeting*. May 22, 2023
- Invited Presenter. Effect of Torsemide vs Furosemide on Symptoms and Quality of Life in Heart Failure: The TRANSFORM-HF Trial. *Late Breaking Clinical Trial Session of the European Society of Cardiology Heart Failure 2023 Annual Meeting*. May 22, 2023
- Invited Presenter. Diuretics and Heart Failure. *Heart in Diabetes 2023 Annual Meeting*. June 10, 2023
- Invited Presenter. Heart Failure and the Intersection of Cardio-Renal-Metabolic Medicine. *Heart in Diabetes 2023 Annual Meeting*. June 10, 2023
- Invited Presenter. Heart Failure and the Intersection of Cardio-Renal-Metabolic Medicine. *Heart in Diabetes 2023 Annual Meeting*. June 10, 2023
- Invited Presenter. Optimizing Polypharmacy – Latest Strategies to Resolve Treatment Gaps in HFrEF. *Amelia Island Heart Failure Management 2023 Annual Meeting*. July 13, 2023
- Invited Presenter. Vericiguat: Insights Concerning Clinical Application. *Amelia Island Heart Failure Management 2023 Annual Meeting*. July 15, 2023
- Invited Presenter. Harnessing the Power of SGLT Inhibition in Heart Failure. *American Society of Preventive Cardiology 2023 Annual Meeting*. July 19, 2023
- Invited Presenter. Rapid Sequence or Simultaneous Initiation of GDMT for HFrEF: Optimizing Therapy with a Need for Speed. *Cardiac Society of Australia and New Zealand 2023 Annual Meeting*. August 4, 2023
- Invited Presenter. The Intersection of Chronic Kidney Disease and Heart Failure. *Cardiac Society of Australia and New Zealand 2023 Annual Meeting*. August 4, 2023

- Invited Presenter. Guideline Directed Medical Therapy for Heart Failure. *Duke Cardiology Fellow Didactic Lecture*. August 9, 2023
- Invited Presenter. Going Beyond Foundational Therapy for HFrEF: What is the Role of sGC Stimulators? *European Society of Cardiology 2023 Annual Meeting*. August 26, 2023
- Invited Presenter. Implementing Heart Failure Guidelines with Collaborative Care. *European Society of Cardiology Congress 2023 Congress*. August 27, 2023
- Invited Presenter. Clinical Perceptions and Reasons for Non-Use of Guideline-Directed Medical Therapy for Heart Failure with Reduced Ejection Fraction in the United States. *European Society of Cardiology Congress 2023*. August 27, 2023
- Invited Presenter. Implementing Quadruple Medical Therapy for Heart Failure with Reduced Ejection Fraction. *American Heart Association Webinar*. August 31, 2023
- Invited Presenter. Improving Patient Outcomes with Rapid Optimization of GDMT for Heart Failure: Insights from the STRONG-HF Trial. *Mexican Heart Failure Association Annual Summit*. October 5, 2023
- Invited Presenter. Where Are We With GDMT for HFrEF/HFmrEF in 2023? *Heart Failure Society of American 2023 Annual Meeting*. October 8, 2023
- Invited Presenter. How to Bring the GDMT Ideals to the Real World. *Heart Failure Society of American 2023 Annual Meeting*. October 9, 2023
- Invited Presenter. Rapid Sequence or Simultaneous Initiation of GDMT for HFrEF: Optimizing Therapy with a Need for Speed. *Duke Cardiology Grand Rounds*. October 24, 2023
- Invited Presenter. Late-breaking Clinical Trial Discussant: Determining What is Best of Patients with Heart Failure: Novel Clinical Trial Designs? *American Heart Association 2023 Scientific Sessions*. November 11, 2023
- Invited Presenter. Pro: Every Patient Should Have Rapid Titration of Quadruple Therapy. *American Heart Association 2023 Scientific Sessions*. November 13, 2023
- Invited Presenter. Contemporary Approach to Management of Heart Failure. *World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease 2023 Meeting*. December 8, 2023
- Invited Presenter. The Role of Diuretics in Heart Failure. *World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease 2023 Meeting*. December 9, 2023

2024

- Invited Presenter. A Strategy to Improve Adherence to GDMT & The Role of Multidisciplinary Heart Failure Program. *Arab Health Symposium 2024*. January 30, 2024

- Invited Presenter. Guideline-Directed Medical Therapy for Heart Failure with Reduced Ejection Fraction: Optimizing Therapy with a Need for Speed. *Sovah Health Grand Rounds*. February 8, 2024
- Invited Presenter. Strategies and Tips for GDMT Optimization for Heart Failure. *American Heart Association's Heart Failure A.S.I.A. Program Webinar*. February 15, 2024
- Invited Presenter. Medical Therapies Across the Heart Failure Spectrum. *Cardiovascular Research Technologies 2024 Annual Meeting*. March 11, 2024.
- Invited Presenter. What Are You Waiting For? In-hospital Initiation of GDMT. *American College of Cardiology 2024 Scientific Sessions*. April 6, 2024.
- Invited Presenter. Contemporary Approach to Medical Therapy for Heart Failure. *29th Annual Current Concepts in Cardiovascular Disease by New Mexico Heart Institute*. April 20, 2024
- Invited Presenter. Contemporary Principles for the Management of Heart Failure. *2024 Duke Heart Failure Symposium*. May 4, 2024
- Invited Presenter. Implications of Delayed Diagnosis and Sub-Optimal GDMT. *European Society of Cardiology Heart Failure 2024 Annual Meeting*. May 13, 2024
- Invited Presenter. Implementation Across a Continuum of Ejection Fraction. *Canadian Heart Failure Society 11th Annual Heart Failure Update 2024*. May 24, 2024
- Invited Presenter. Rapid Sequence or Simultaneous Initiation of GDMT for HFrEF: Optimizing Therapy with a Need for Speed. *Duke Regional Hospital Medicine Grand Rounds*. June 4, 2024
- Invited Presenter. The Proper Management of Heart Failure Circa 2024. *Heart in Diabetes 2024 Annual Meeting*. June 9, 2024
- Invited Presenter. Case Presentation – SGLT2i for Heart Failure in Practice. *American Association of Heart Failure Nurses 2024 Annual Meeting*. June 20, 2024
- Invited Presenter. Quad Therapy vs. Avoiding Polypharmacy: Titration of GDMT in Elderly Patients with HF and Comorbidities. *Amelia Island Heart Failure Management 2024 Annual Meeting*. July 18, 2024
- Invited Presenter. Worsening Heart Failure in Patients with HFrEF: Examining the Impact, Contextualizing the Risk, and Facing the Challenges of Optimizing GDMT. *Amelia Island Heart Failure Management 2024 Annual Meeting*. July 19, 2024
- Invited Presenter. Latest Approaches to the Treatment of Worsening Heart Failure. *Amelia Island Heart Failure Management 2024 Annual Meeting*. July 20, 2024
- Invited Presenter. The Risks of Omission in Heart Failure Management. *European Society of Cardiology Congress 2024*. August 31, 2024

- Invited Presenter. Clinical and Financial Implications of Inpatient and Outpatient Management Strategies for Worsening Heart Failure. *European Society of Cardiology Congress 2024*. September 2, 2024
- Invited Presenter. Current State of GDMT Implementation in HF: Clinical and Organizational Barriers. *E-SPACE Heart Failure 2024*. October 16, 2024
- Invited Presenter. Medical Management of Patients Hospitalized for Heart Failure. *Southeastern Regional Medical Center Grand Rounds*. October 23, 2024
- Invited Presenter. Worsening Heart Failure: Nomenclature, Epidemiology, and Future Directions. *World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease 2024 Meeting*. December 12, 2024

2025

- Invited Presenter. Worsening Heart Failure. *University Hospitals Cleveland Medical Center Advanced Heart Failure Grand Rounds*. February 12, 2025
- Invited Presenter. Worsening Heart Failure – Stage C Transitioning to Stage D. *American Association of Heart Failure Nurses Advanced Heart Failure Symposium*. February 28, 2025
- Invited Presenter. Worsening Heart Failure and Management Strategies with Vericiguat. *Heart Failure Association of India 2025 Annual Meeting*. February 9, 2025
- Invited Presenter. Medical Management of Patients Hospitalized for Heart Failure. *Sovah Health Grand Rounds*. March 6, 2025
- Invited Presenter. Current guideline recommendations for the management of chronic heart failure. *SciArc Live Global Live Webinar: The changing landscape in the management of chronic heart failure*. April 2, 2025
- Invited Presenter. Hyperkalemia in Patients with Heart Failure. *Access to Pharmacy AXS 2025*. April 30, 2025
- Invited Presenter. Contemporary Approaches to the Management of Heart Failure. *30th Annual Current Concepts in Cardiovascular Disease by New Mexico Heart Institute*. May 3, 2025
- Invited Presenter. The power of now: a focus on SGLT2 inhibitors for heart failure in the hospital. *European Society of Cardiology Heart Failure 2024 Annual Meeting*. May 17, 2025
- Invited Presenter. Safety and Tolerability of a 5 mg Starting Dose of Vericiguat Among Patients with Heart Failure: The VELOCITY Study. *European Society of Cardiology Heart Failure 2024 Annual Meeting*. May 18, 2025
- Invited Presenter. Finerenone Across the Stages of Heart Failure: From Prevention to Treatment. *Heart in Diabetes 2025 Annual Meeting*. June 7, 2025

- Invited Presenter. Proper Medical Management of HFpEF in 2025. *Heart in Diabetes 2025 Annual Meeting*. June 7, 2025
- Invited Presenter. Setting the Stage: Latest Clinical Trial Data and Real-world Evidence Supporting SGLT2 Inhibitors in Heart Failure GDMT. *American Association of Heart Failure Nurses 2025 Annual Meeting*. June 12, 2025.
- Invited Presenter. Treating Hyperkalemia in Patients with Heart Failure. *American Association of Heart Failure Nurses 2025 Annual Meeting*. June 12, 2025.
- Invited Presenter. Titration of GDMT in Older Patients with HF and Comorbidities. *Amelia Island Heart Failure Management 2025 Annual Meeting*. July 17, 2025
- Invited Presenter. Hyperkalemia and Risk in HF: Recognizing the Impact of RAASi Therapy Discontinuation/ Dose-Reduction. *Amelia Island Heart Failure Management 2025 Annual Meeting*. July 18, 2025
- Invited Moderator. Aldosterone: New Insights and Emerging Perspectives for Cardiologists. *SciArc Live Global Live Webinar*. July 21, 2025
- Invited Presenter. GDMT for Heart Failure: Optimizing Therapy with a Need for Speed. *Duke Cardiology Fellows Conference*. July 23, 2025
- Invited Presenter. Pathophysiology and Risk Staging of CKM Syndrome. *Korean Heart Failure Society 2025 Meeting*. September 11, 2025
- Invited Presenter. Treatment of Advanced CKM Syndrome: Present and Future. *Korean Heart Failure Society 2025 Meeting*. September 11, 2025
- Invited Presenter. For Patients Hospitalized for Heart Failure, the #1 Priority is Rapid In-Hospital Initiation of GDMT. *Heart Failure Society of America 2025 Annual Meeting*. September 27, 2025
- Invited Presenter. Arm-in-Arm With Heart Failure Experts: A Master Class in Optimizing Heart Failure Treatment With SGLT2 Inhibitors. *Heart Failure Society of America 2025 Annual Meeting*. September 27, 2025
- Invited Presenter. Residual Risk of Hyperkalemia Among Patients with Heart Failure Treated with SGLT2i and ARNI Instead of ACEI/ARB. *Heart Failure Society of America 2025 Annual Meeting*. September 27, 2025
- Invited Presenter. Clinical Outcomes for Patients with Heart Failure at High Risk of Hyperkalemia According to Optimization of Agents Targeting the Renin-Angiotensin-Aldosterone System. *Heart Failure Society of America 2025 Annual Meeting*. September 27, 2025
- Invited Presenter. Management of Worsening Heart Failure. *World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease 2025 Meeting*. December 3, 2026
- Invited Presenter. Management of Worsening Heart Failure. *Providence Little Company of*

Mary of Torrance Grand Rounds. December 11, 2026

- Invited Presenter. Simultaneous or Rapid Sequence GDMT for Heart Failure Optimizing Therapy with a Need for Speed. *University Hospitals Cleveland Medical Center Cardiology Grand Rounds. December 18, 2026*

2026

- Invited Presenter. Treating Hyperkalemia in Patients with Heart Failure. *American Heart Association Heart Failure Awareness Week Webinar. February 13, 2026*
- Invited Presenter. Management of Worsening Heart Failure. *McMaster University Cardiology Grand Rounds. February 17, 2026*

Clinical activity

- Clinical commitment is 50% effort
- Clinical activities are devoted to the care of patients with general and advanced heart failure.
- Round on the inpatient advanced and general heart failure services approximately 10 weeks per year.
- Serve in the outpatient clinic one morning per week.
- Practice in the left ventricular assist device outpatient clinic approximately one afternoon per week.

Academic, leadership and administrative activities – School of Medicine (list roles / responsibilities, include dates): N/A

Leadership and administrative activities – hospital / DUHS (list roles / responsibilities, include dates):

- 2023 - present Co-Director, Heart Failure Medical Therapy Titration Clinic. Collaborate with pharmacists for the safe and timely optimization of medical therapy for patients with heart failure.